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ABSTRACT
M. Sue McManus
ILLNESS REPRESENTATIONS AND MEDICATION ADHERENCE
OF PATIENTS WITH CHRONIC KIDNEY DISEASE
Chronic kidney disease (CKD) places a high personal and economic burden
globally on individuals, families, and society.  Although kidney protective medications
slow the progression of CKD to end stage kidney disease, adherence to these medications
is inadequate.  The primary purposes of this study are to: 1) describe the illness and
treatment beliefs of CKD patients in stage 3 guided by the Common Sense M model
(CSM); and 2) examine the relationship of those beliefs with adherence to renal
protective medications, ACE-I.  Secondary purposes of this study include determining
adherence levels of ACE-I among patients with CKD stage 3; examining relationships
between individual and clinical characteristics with patient beliefs and medication
adherence with ACE-I; and examining the relationship between the Medication
Adherence Report Scale (MARS) and the Medication Possession Ratio (MPR).
Using a descriptive cross-sectional design, a convenience sample of 92
individuals with Stage 3 CKD was obtained from a Midwestern VA medical center. Data
were collected through self-administered mailed surveys and medical record reviews.
Data analyses were performed using descriptive statistics, correlation, t-tests and
ANOVA. Seventeen symptoms experienced were perceived as related to CKD by at least
one respondent with most reporting legs/feet swelling (n=31).  Top perceived cause of
CKD was aging (60%). Revised Illness Perception Questionnaire (IPQ-R) items were
scored from 1 to 5 with higher scores indicating perceptions of higher personal and
vtreatment control of chronic, cyclical illness with serious consequences and negative
emotional reactions. In this study, the CKD timeline was perceived as a long-term
chronic rather than short-term acute condition (M = 3.8), with minimal cyclical
exacerbations (M = 2.7), and moderate severity of consequences (M = 3.1).  Respondents
perceived having both, but more personal control than treatment control of CKD (M = 3.5
v 3.2).  Participants did not perceive CKD as related to a great negative emotional
response (M = 2.8).  Illness Representations were not found to be significantly correlated
with self-reported medication adherence. Medication adherence levels by self-report (M
= 4.8 [5 = perfect adherence]) and pharmacy refill records (73% had perfect refill ratio of
1:1) reveal highly adherent levels among this sample.
Janet L. Welch, PhD, RN, FAAN, Chair
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1CHAPTER 1
Background
Chronic kidney disease (CKD) has become recognized as a national and
international public health problem since it was defined and staged in 2002 (Amaresan &
Geetha, 2008).  This devastating disease is estimated to affect 16 % or 31 million U.S.
citizens (U.S. Renal Data System (USRDS), 2008a).  CKD is a progressive disease
moving from asymptomatic, early stages with indications of kidney damage (i.e. albumin
in the urine) to overt, later stages with indications of whole organ damage and symptoms
from failing filtering capacity (i.e. insufficient glomerular filtration rate).  The
progression of CKD is not an isolated event; it is accompanied by a decreased quality of
life, multiple co-morbid conditions, and premature mortality, all of which impose huge
personal and economic burdens on patients, families, society, and health care systems
worldwide (National Institutes of Health & National Institute of Diabetes and Digestive
and Kidney Diseases, 2007; National Kidney Foundation, 2007; Tonelli et al., 2006;
USRDS, 2008a).  The final stage of CKD, recognized as end stage renal disease (ESRD)
requires life-long, life-sustaining treatments which carry even higher human and
economic burdens than the earlier stages (U.S. Renal Data System (USRDS), 2008b).
Kidney protective medications such as Angiotensin Converting Enzyme Inhibitors
(ACE-I) have been shown to slow progression of CKD through reduction of proteinuria,
yet the overall estimated prevalence of CKD is still increasing at an alarming rate (Coresh
et al., 2007; de Zeeuw et al., 2006; Kopyt, 2005; USRDS, 2008a).  Research indicates
that although these medications are increasingly prescribed to those with early stage renal
disease (Cooke & Fatodu, 2006; Philipneri et al., 2008; Schmieder, 2005), adherence to
2these medications is not adequate and non-adherence may be associated with the
continued progression of CKD to ESRD (Bailie et al., 2005; National Kidney
Foundation, 2004; Williams, Manias, & Walker, 2008).  The renal protective effects of
ACE-I medications are dependent on CKD patients’ adherence to taking them as
prescribed over an extended period of time.
There is an abundance of literature on predictors of medication adherence in
chronically ill populations indicating non-adherence rates of approximately 50%
(National Counsel on Patient Information and Education, 2007; National Quality Forum,
2005; Peterson, Takiya, & Finley, 2003; World Health Organization, 2003).  No
empirical evidence is available, at this time that identifies predictors of medication
adherence among early stage CKD patients.  Given the vast size of the CKD population
and heavy burden of the disease progression, it is imperative that studies be designed to
examine predictors of medication adherence to ACE-I in patients with pre-ESRD stages
of CKD.  CKD stage 3 is an ideal stage in which to study renal protective medication
adherence because it is most often accompanied by proteinuria and a continuous decline
in renal function (Garcia-Donaire, Segura, & Ruilope, 2005).  Unless this progression is
halted, the patient with stage 3 CKD will either progress through the CKD stages to
ESRD (stage 5) requiring dialysis or transplantation to sustain life or die prematurely
from cardiovascular events (Coresh etal., 2007; Keith, Nichols, Gullion, Brown, & Smith,
2004).
There is an expanse of medication adherence research available with no consistent
reliable and valid empirical support for specific antecedents of long-term medication
3adherence.  There is growing evidence that medication adherence is affected by patients’
beliefs about their illness and treatments (DiMatteo, Haskard, & Williams, 2007; Haynes,
Ackloo, Sahota, McDonald, & Yao, 2008; Peterson et al., 2003; Vermeire, Hearnshaw,
Van Royen, & Denekens, 2001).  Patient beliefs about the nature of their illness and
treatment have been shown to be predictive of long-term medication adherence (Horne,
Weinman, Barber, Elliott, & Morgan, 2005; National Counsel on Patient Information and
Education, 2007; World Health Organization, 2003).  Leventhal’s self-regulatory
common sense model (CSM) (Leventhal, Brissette, & Leventhal, 2003; Leventhal,
Diefenbach, & Leventhal, 1992) is an appropriate theoretical framework in which to
study the relationship between CKD stage 3 patients’ beliefs about their illness and
treatment and adherence to renal protective medications, ACE-I.  The CSM is a health
specific model that examines the cognitive and emotional activities that take place
throughout the chronic illness experience.  As such, the CSM captures vital health and
illness aspects unique to individual experiences and provides beneficial information to
healthcare providers.  The model may be used to help clinicians develop appropriate
interventions by gaining understanding of human efforts to protect health and reduce the
threat caused by chronic illness (Leventhal et al., 2003; Leventhal, Leventhal, &
Cameron, 2001).
Statement of the Problem
Chronic kidney disease is a progressive disease leading to ESRD or premature
death from cardiovascular events.  CKD places a high personal and economic burden on
individuals, families, and society, as well as national and international healthcare
systems.  Research indicates less than adequate adherence to medications that have been
4shown to slow progression of CKD to ESRD and help prevent cardiovascular events.
There are no studies examining predictors of adherence to ACE-I, renal protective
medications, in CKD stage 3 patients.  Descriptive and correlation studies of medication
adherence are needed with this population as a basis for future prospective and
interventional studies aimed at slowing the progression of this destructive disease.  The
findings from this and future research will provide evidence-based guidance to support
nurses working with CKD patients.  Understanding how patients’ perspectives of CKD
and its treatment affect their decisions to take their renal protective medications as
prescribed will enable nurses to build a more therapeutically effective patient-nurse
relationship.  Nurses will be better equipped to help CKD patients understand the value
of medication adherence when they understand patients’ perspectives of their illness and
treatments.
Purpose
The primary purposes of this study are to: 1) describe the illness and treatment
beliefs of CKD patients in stage 3 guided by the CSM; and 2) examine the relationship of
those beliefs with adherence to renal protective medications, ACE-I.  Secondary purposes
of this study include determining adherence levels of ACE-I among patients with CKD
stage 3; examining relationships between individual and clinical characteristics with
patient beliefs and medication adherence with ACE-Is; and examining the relationship
between the Medication Adherence Report Scale (MARS) and the Medication Possession
Ratio (MPR).
5Conceptual Model
According to Leventhal’s CSM, when individuals are faced with a threat to their
health, they build a cognitive and emotional representation (mental model) and this
representation determines how they will respond to the health threat (Leventhal et al.,
1997; Leventhal et al., 2003).  These representations of illness, unique to the individual,
are based on the individual’s demographics, knowledge, and personal and familial
experiences (Petrie & Weinman, 2006).  The illness representation leads the patient to
reduce the threat of illness or symptoms by guiding their choices of coping strategies
(e.g., to take medication, stop smoking, lose weight) directed at reducing the threat
(Leventhal et al. 2003).
Figure 1.  Proposed model based on Leventhal’s Common Sense Model
Chronic Kidney Disease
Demographics:
Individual Characteristics
Age
Gender
Race
Education
Financial status
Marital status
Clinical Characteristics
Co-morbidity
Lgth of time CKD dx
Fmly hx ESRD/dialysis
Total number of medications
Illness representation:
Cognitive representation
Identity
Cause
Timeline
Control/cure
Consequences
Emotional representation
Coping Strategy:
ACE-I medication
adherence
6In the proposed model (Figure 1), a diagnosis of CKD stimulates an individual’s
unique view of himself or herself experiencing kidney disease and its complications.  The
CKD patient, drawing from personal background, knowledge, life events, experiences
and familial experiences, develops a cognitive and emotional illness representation of
CKD and its treatments. The person is an active participant using common-sense coping
strategies to manage the life changing challenges that CKD presents. Renal protective
medication adherence is considered a coping strategy that a CKD patient might choose to
take in order to reduce the threat of the disease progression.  The patient’s decision to
take his or her medication as prescribed is affected by his or her illness representation of
CKD.  Thus, the patient’s common-sense illness representations guide his or her
adherence decisions (Horne, 1997; Leventhal et al., 2003).
Research Questions
The research questions posed in this study include:
1. What are the illness representations (cognitive representation [identity, cause,
timeline, control/cure, consequences] and emotional representation) of patients
with CKD stage 3?
2. What are the medication adherence levels of ACE-I among patients in CKD stage
3 as measured by self-report MARS?
3. Does illness representation (cognitive representation [identity, cause, timeline,
control/cure, consequences] and emotional representation) of patients with CKD
stage 3 predict self-reported adherence to ACE-I as measured with the MARS?
4. What are the relationships among each of the Individual Characteristics (age,
gender, race, education, financial status, and living with a partner status) with the
7individual Cognitive Representation dimensions (identity, cause, timeline,
control/cure, consequences) and self-reported medication adherence with ACE-I?
5. What are the relationships among each of the Individual Characteristics (age,
gender, race, education, financial status, and living with a partner status) with the
Emotional Representation construct?
6. What are the relationships among each of the clinical characteristics (Co-
morbidity, Length of time CKD diagnosis, Family history of ESRD/dialysis and Number
of medications) with the individual Cognitive Representation dimensions (identity,
cause, timeline, control/cure, consequences) and self-reported medication
adherence with ACE-I?
7. What are the relationships among each of the clinical characteristics (Co-
morbidity, Length of time CKD diagnosis, Family history of ESRD/dialysis and Number
of medications) with the Emotional Representation construct?
8. What is the relationship between the Medication Adherence Report Scale
(MARS) and the Medication Possession Ratio (MPR)?
Conceptual Definitions
Illness Representation
In the proposed model, illness representation is the subject’s view of the status of
his or her CKD created within two domains: cognitive representation and emotional
representation.
Cognitive representation. The cognitive representation is composed of five
content dimensions:  identity, timeline, consequences, cause, and control/cure. Identity is
the label assigned to the illness by the patient, often associated with symptoms they
8perceive to be related to their illness. Cause is the patient’s ideas of disease etiology (i.e.
environmental pollution, personal behaviors, genetics). Timeline is the patient’s
perception of duration and pattern of illness. Control/Cure is the patient’s perception of
how effective he or she can be in controlling or curing the illness and how well a
treatment can control or cure the condition. Consequences are the negative effects or
outcomes the patient associates with the illness (Leventhal et al., 1997; Leventhal et al.,
1992).
Emotional representation. Emotional representations are internal emotional
responses to the mental image of possible dangers imposed by the illness threat, such as
depression, fear, anger, or anxiety. Depression is the patient’s perspective of feeling
depressed (e.g. feeling blue or sad, losing interest) when thinking of their kidney disease.
Fear is the patient’s expression of feeling afraid when thinking of their illness; fear
provoked by the threat of the kidney disease. Anger is the patient’s strong sense of
displeasure in response to their kidney disease. Anxiety is the patient’s expression of
uneasiness, worry, or apprehension when thinking of their kidney disease (Barsevick,
Whitmer, and Walker, 2001; Leventhal et al., 1997; J. F. Johnson, 1999; Leventhal et al.,
2001; Moss-Morris et al., 2002). As opposed to general emotional responses, emotional
representations are emotional responses related to the experience of living with kidney
disease.
Coping Strategy
Coping strategy (action plan) is the subject’s plans and tactics for the control of
the illness threat.  Coping strategies are created in order to reduce the cognitive and
emotional threats posed by the illness (Leventhal et al., 1997; Leventhal et al., 2001;
9Leventhal et al., 2003). The current study examines the specific coping strategy of
medication adherence, which is conceptually defined as the patient intentionally taking
his medication as prescribed.
Summary
CKD is a progressive disease that is a growing global burden to individuals and
society as a whole.  The cost and complexity of CKD and accompanying co-morbidities,
premature mortality, and costly treatments demand attention to methods to prevent
progression of this debilitating illness.
There are renal protective medications shown to reduce proteinuria, a
predominant cause of kidney disease progression.  The most prescribed renal protective
medications currently are ACE-I. They are being prescribed for patients with renal
involvement, however, evidence indicates that patients may not be adherent in taking
these medications as prescribed.  There is a vast amount of medication adherence
research spanning decades, with agreement that an unacceptably high percentage of non-
adherence exists, but little consistency in specific predictors of adherence.  Evidence is
growing that medication adherence is affected by patients’ beliefs about their illness and
treatments and these beliefs are predictive factors associated with long-term medication
adherence.  At this time, there are no studies examining beliefs and perceptions, of
patients with CKD stage 3, about their illness and treatments (illness representations), nor
their adherence to renal protective medications.
The current study, guided by the CSM addresses this gap by examining illness
representations of patients with CKD stage 3 and the relationships between those illness
representations and medication adherence with renal protective medications.  The
10
examination of illness representations, of patients with CKD stage 3, and their
associations with adherence to ACE-I, is an imperative first step to halting progression of
this devastating condition.  The findings will help nurses build client-centered
participatory partnerships needed to foster adherence with renal protective treatments and
will serve as a foundation for future research.
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CHAPTER 2
Empirical and Theoretical Literature Review
This chapter includes a review of the literature defining, staging, and examining
the progressive course of chronic kidney disease (CKD) and renal protective medications
shown to prevent or delay progression. General medication adherence research as well as
clinical trials evaluating disease and medication specific adherence behaviors is included
in this section. An overview is provided of health behavior and self-regulation theories
with emphasis on Leventhal’s Common Sense Model (CSM) as a guiding framework for
the proposed study (Leventhal, Brissette, & Leventhal, 2003). Individual and clinical
characteristics are examined in relationship to the CSM model and medication adherence.
The chapter concludes with a summary of research findings from studies examining the
illness representations and their relationships with medication adherence behaviors drawn
from samples of patients with chronic disease, such as end-stage renal disease, diabetes
mellitus, and hypertension. Lastly, how the proposed study will address the gaps found
in the existing research is also discussed.
Chronic Kidney Disease
To describe CKD, one must start from the end – end stage renal disease (ESRD),
also known as kidney failure (National Kidney Foundation, 2003). The definition of
ESRD is an administrative term derived from the conditions set by the Medicare ESRD
Program (HR-1 bill) responsible for coverage of dialysis and transplantation expenses for
ESRD patients. Payment for ESRD health services requires a glomerular filtration rate
(GFR) of less than 15 mL/min/1.73m2, with exceptions made before that point for
12
patients at increased risk of mortality and morbidity (Hoffart, 1995). In the time since
passage of HR-1 bill by the U.S. Congress in 1972 which made treatment for ESRD
reimbursable under the Medicare program regardless of age, millions of lives have been
extended (U.S. Renal Data System (USRDS), 2006). However as of 2004, the annual
cost of the ESRD program soared to nearly 19 billion Medicare dollars, 1.1 billion Health
Maintenance Organizations (HMO) dollars, 9 billion non-Medicare dollars, and 390
million Employee Group Health Plan dollars (USRDS, 2006). Chronic kidney disease
and ESRD patients constitute a small proportion of the Medicare population (6.6 and 1.2
percent, respectively) yet consume a large portion of the entire Medicare budget (19.4
and 6.4 percent, respectively) (U.S. Renal Data System (USRD), 2007). The high burden
CKD places on the American population and economy make it an important public health
issue requiring a major public health initiative and redirection of the national focus from
ESRD to CKD (NKF, 2002; Schoolwerth, et al., 2006; USRDS, 2006).
Little attention was paid to earlier stages of CKD until 2002 when the National
Kidney Foundation (NKF) published the Chronic Kidney Disease Guidelines to define
and classify stages of the disease (NKF, 2002 ).  CKD is defined as meeting at least one
of two criteria: structural or functional kidney damage for at least three months and/or
glomerular filtration rate (GFR) less than 60 mL/min/1.73m2 for at least three months.
Structural or functional kidney damage is determined by abnormalities in blood or urine
tests or imaging studies. A GFR of less than 60 mL/min/1.73m2 represents a loss of at
least one half of normal adult kidney functioning. A CKD classification system was
established using five stages to describe the degree of kidney damage. The stages of
CKD are determined by the level of GFR with the lower stages representing higher GFR
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levels (less kidney damage) and the higher stages representing lower GFR levels (more
kidney damage). Level 5 is classified as ESRD which requires dialysis or transplantation
to sustain life (NKF, 2002; USRDS, 2006). When this classification system was applied
to the most recent National Health and Nutrition Examination Survey (NHANES) 1988-
1994 and 1999-2006 data, an estimated 31 million American citizens fell into one of the
five CKD stages (USRDS, 2008). This is an ominous sign of an impending surge on the
health care system and Medicare budget.
Stage 3 CKD has been chosen for this study for two reasons. First, of the five
stages of CKD, there are more Americans (2.5 million) estimated to have stage 3 CKD
(Coresh et al., 2007; USRDS, 2008). Second, stage 3 is a critical stage to examine since
it is most often accompanied by proteinuria (a marker for progression to kidney failure),
complications of organ dysfunction and a continuous decline in renal function leading to
diagnosis and patient awareness of renal disease (Garcia-Donaire, Segura, & Ruilope,
2005; NKF, 2004). Research is needed to examine ways to interrupt the progression of
CKD. Unless the progression of kidney disease is halted, this large number of patients
with stage 3 CKD will either progress to kidney failure, requiring dialysis or
transplantation to sustain life, or die prematurely from cardiovascular events (Coresh et
al., 2007; Go, Chertow, Fan, McCulloch, & Hsu, 2004; Keith, Nichols, Gullion, Brown,
& Smith, 2004).
The clinical factor that has repeatedly emerged as a major link to progression of
CKD to ESRD and increased risk of cardiovascular disease leading to premature death, is
proteinuria.  Proteinuria is most often associated with elevated blood pressure levels and
inadequate glycemic control among patients with diabetes (Coresh et al., 2007; de Zeeuw
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et al., 2004b; Keith et al., 2004; Lakkis & Weir, 2004; Praga et al., 1995). It is now
recognized that proteinuria is not only a marker of kidney damage, but also has  toxic
effects on the kidney contributing to the progression of renal disease (Remuzzi, Benigni,
& Remuzzi, 2006; Schieppati & Remuzzi, 2003). The degree of proteinuria has been
shown to be an independent factor contributing to the rate of functional decline, the need
for dialysis and transplantation, as well as renal and all-cause mortality, irrespective of
the primary etiology of the renal disease (Campbell, Ruggenenti, & Remuzzi, 2002;
Keane, 2000; Velde et al., 2009; Wolf, Butzmann, & Wenzel, 2003). Angiotensin II
(ANG II), part of the renin-angiotensin system (RAS), has been shown to increase
proteinuria by altering glomerular capillary permselectivity leading to podocyte injury,
glomerulosclerosis, and interstitial fibrosis (Abbate et al., 2002; Kshirsagar, Joy, Hogan,
Falk, & Colindres, 2000; Yoshioka, Rennke, Salant, Deen, & Ichikawa, 1987). In
addition, studies have shown that ANG II contributes to an inflammatory process that
contributes to chronic renal injury (Keane, 2000; Schieppati & Remuzzi, 2003).
The classical known systemic hemodynamic effects of ANG II, to maintain
extracellular volume and blood pressure to compensate for volume depletion, have been
expanded in recent years suggesting local tissue generation of ANG II through a RAS in
several organ tissues including the kidney tubular cells. Micropuncture animal studies
indicate the local tissue RAS may function independently from the systemic RAS.  Two
main ANG II receptors, AT1 and AT2 are implicated in the locally activated RAS.  AT1
receptors are associated with ANG II functions such as vasoconstriction, release of
aldosterone, tubular transport, pro-inflammatory, pro-fibrogenic activities and growth
stimulation effects.  Activities associated with AT2 receptors are thought to antagonize
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AT1 receptor effects by reduction of blood pressure through release of nitric oxide (NO)
and bradykinin release, inhibition of  proliferation inducing differentiation, and may even
mediate apoptosis in some cells (Abbate et al., 2002; Bader et al., 2001; Wolf et al.,
2003).
The intracellular involvement of ANG II in podocyte foot process effacement and
cytoskeleton reorganization leading to increased proteinuria was the focus of several
recent animal studies (Macconi et al., 2006; Ronco, 2007; Sever et al., 2007).  The
common denominator in all of these studies was that ANG II plays a major role in
proteinuria which is a marker of and contributor to kidney damage and progression to
renal failure.
There are renal protective medications shown to interfere with the RAS and to
reduce proteinuria in CKD patients, including diabetic, non-diabetic and hypertensive
patients (de Zeeuw et al., 2006; Hovind, Tarnow, Rossing, Carstensen, & Parving, 2004;
Kopyt, 2005; Matsuda, Hayashi, & Saruta, 2003). Currently the most effective
antiproteinuric agents are angiotensin-converting enzyme inhibitors (ACE-I) and
angiotensin receptor blockers (ARB), which inhibit and block the damaging effects of
ANG II, thereby preventing or delaying progression of renal dysfunction (de Zeeuw et
al., 2004a, 2004b; Remuzzi, Ruggenenti, & Perico, 2002; Ronco, 2007).
The Reduction in Endpoints in Non-Insulin Dependent Diabetes Mellitus with the
Angiotensin II Antagonist Losartan Study (RENAAL), a multinational randomized,
double-blind study of 1,513 participants with diabetic nephropathy, compared the effects
of an ARB (Losartan) and placebo on renal and cardiovascular outcomes (Brenner et al.,
2001). The ARB resulted in a significant 35% reduction in proteinuria (p = .001) and
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reduced incidence of ESRD (28% risk reduction, p = .002).  In a secondary analysis, data
from the RENAAL study were analyzed by de Zeeuw et al. (2004a, 2004b) to examine
albuminuria as a marker of renal disease and as a monitor of the renoprotective efficacy
of an ARB in diabetic nephropathy. High albuminuria levels at baseline were associated
with a higher risk for progression to ESRD.  There was significant reduction in
albuminuria by the ARB with related renal protection short and long term.
Two smaller studies found significant renal protective benefits of ACE-Is and
ARBs.  Praga et al. (1995) studied the influence of weight loss and ACE-I treatment in 17
obese patients with proteinuria.  Both weight loss and ACE-I use without weight loss
were associated with a significant decrease in proteinuria and stable renal function (Praga
et al., 1995).  In a study by Matsuda et al. (2003), monotherapy using ACE-I and ARB
treatment groups in 52 hypertensive patients with proteinuria revealed a significant
reduction in proteinuria in both groups, however there was a time difference in onset of
effects.  The ACE-I reduction occurred at 12 weeks while the ARB reduction became
significant at 48 weeks (Matsuda et al., 2003).  A summary of reviews and meta-analysis
examining the relationship between ACE-I, ARB monotherapy or combination therapy in
21 studies with 18,418 diabetic and non-diabetic hypertensive subjects found significant
antiproteinuric effects independent of the blood pressure lowering effects (Bakris,
Ferdinand, Douglas, & Sowers, 2002; Hunsicker, 2004; Kopyt, 2005). These renal
protective effects were found in monotherapy and combination therapy.  Cardiovascular
function improvement also was found independent of blood pressure effects.  These
studies attest to the antiproteinuric affect of ACE-I and ARB medications.
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Prescribing patterns of renal protective medications are increasing, especially with
diabetic renal disease patients (78.6%) and hypertensive patients with renal involvement
(85%) (Cooke & Fatodu, 2006; Schmieder, 2005).  However, medication adherence is
less than adequate among the general chronic disease population and across medications,
with an average estimated rate of 50% (Balkrishnan, 2005; Gossec, Tubach, Dougados, &
Ravaud, 2007; Svarstad, Chewning, Sleath, & Claesson, 1999; Williams, Rodin, Ryan,
Grolnick, & Deci, 1998). Some studies have shown that adherence to blood pressure
medications and more specifically, ACE-I and ARBs is higher than average at 60.4%
(Cooke & Fatodu, 2006) and 77% (Pladevall et al., 2004). If applied to CKD patients,
this would indicate that approximately 23 to 39.6 % of the estimated 2.5 million patients
with stage 3 CKD (Coresh et al., 2007; USRDS, 2008) are not taking renal protective
medications as prescribed to slow progression of their renal disease.
Medication Adherence
Although there is a lack of literature on the medication adherence practices of
early stage chronic kidney disease patients, there are studies that indicate a less than
desirable medication adherence pattern among people with diabetes and hypertension,
which comprise the majority of CKD patients (Carter, 2006; NKF, 2004; Shenolikar,
Balkrishnan, Camacho, Whitmire, & Anderson, 2006; USRDS, 2006).  The concept of
medication adherence is complex; adherence problems are common where self-
administration of long term medication is required, such as those prescribed for chronic
illnesses; and many patient-related factors are involved in patient adherence to long-term
medications.
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Patient-related factors involved in non-adherence to medication are often divided
into two categories: unintentional and intentional.  Unintentional factors related to
medication non-adherence include forgetfulness, being unable to understand instructions
(e.g. low health literacy, language barriers, etc), and unable to follow instructions for
taking medications (e.g. costs of medications, lack of transportation to pharmacy, unable
to physically open medication container, etc).  Intentional factors related to medication
non-adherence include patients’ beliefs and attitudes about the nature and severity of their
illness (duration and course of illness, etc.); about the value and effectiveness of the
medications; associated social concerns and stigmas attached to medications; fear of side
effects, dependency, self-injections; and lack of self-efficacy and positive motivations to
make medication adherence behavior changes (Horne, Weinman, Barber,
Elliott, & Morgan, 2005; National Counsel on Patient Information and Education, 2007;
World Health Organization, 2003).
Horne et al. (2005) proposes that unintentional factors affecting medication
adherence stem from limitations in patient capacity and resources that prevent them from
following the treatment plan they decided upon.  Examples provided include memory and
dexterity limitations, problems obtaining prescriptions, and competing work, family or
social demands.  He also describes intentional factors affecting medication adherence as
those stemming from “beliefs, attitudes, and expectations that influence patients’
motivation to begin and persist with the treatment regimen” (p. 14). The World Health
Organization (2003) does not divide factors affecting patients’ adherence to medication
into unintentional and intentional, but do support the same antecedents described by
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Horne by stating that “patient-related factors represent the resources, knowledge,
attitudes, beliefs, perceptions and expectations of the patient” (p. 30).
Systematic reviews and meta-analyses of medication adherence research conclude
there is support for general, but no consistent reliable and valid empirical support for
specific factors predicting long-term medication adherence or nonadherence (DiMatteo,
Haskard, & Williams, 2007; Haynes, Ackloo, Sahota, McDonald, & Yao, 2008; Peterson,
Takiya, & Finley, 2003; Vermeire, Hearnshaw, Van Royen, & Denekens, 2001). Some
of the general factors cited include: a) medication-related factors such as complexity of
the prescribed medication regimen; b) prescriber-related factors such as clinicians’ skill
in basic adherence management principles, trust of provider-patient relationship, and
quality of communication with patient; c) pharmacy-related factors such as access to
community-based pharmacists and formal pharmacy care programs tailoring education
and counseling to patient needs; and d) system- and government-related factors such as
lack of consensus and interrelation of various healthcare clinician roles, interpretation of
federal and state laws, and funding for adherence research (Horne et.al, 2005; National
Counsel on Patient Information and Education, 2007; National Quality Forum, 2005;
World Health Organization, 2003).
Patient-related factors are most often the focus in literature regarding adherence to
medication. Vermeire and colleagues (2001) reported that medication adherence was
affected by patients’ beliefs about medications. Adherence is also affected by patients’,
as well as family and friends’ knowledge, ideas, and experiences with medications
(Vermeire et al., 2001).  Although Haynes et al. (2005) agrees there is little consistency
in findings regarding medication adherence antecedents, he also recognizes limited
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education, lack of understanding of medication instructions, and forgetfulness as
contributing factors of medication non-adherence (Haynes et al., 2005).
In a meta-analysis of intervention studies designed to improve medication
adherence, the inability to achieve positive results has been attributed to the multitude of
variables affecting a patient’s decision to take a medication.  The patient’s “deeply
ingrained values and beliefs” regarding illness and medications are sometimes powerful
barriers to medication adherence (Peterson et al., 2003, p. 662).  DiMatteo et al. (2007)
stated that despite more than 60 years of patient adherence research, findings are still
conflicting and answers remain elusive.  However, in a meta-analysis examining patient
adherence in relation to health beliefs and disease severity, a significantly positive
correlation was found between patients’ beliefs about their illness severity and treatment
adherence.  An interesting finding in this meta-analysis was that for patients with a less
serious illness, poorer health was a predictor of adherence, whereas for a more serious
illness, poorer health was a predictor of non-adherence (DiMatteo et al., 2007).  There is
consensus among these reviews and meta-analyses that intentional factors related to
medication adherence include patients’ beliefs and attitudes about the nature and severity
of their illness.
Results of individual studies of medication adherence support the findings of
national and international work groups, meta-analyses and systematic reviews, that
adherence to medications is problematic where self-administration is required.  This has
been found true regardless of disease type and severity, accessibility to resources, age,
and gender (George, Kong, Thoman, & Stewart, 2005; Hedenrud, Jonsson, & Linde,
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2008; Roe, Motheral, Teitelbaum, & Rich, 2000; Thier et al., 2008; World Health
Organization, 2003).
Studies acknowledge that patients make their own decisions regarding how they
manage their medications.  These decisions are often seen as a rational choice based on
their beliefs and understanding, taking into account physical, economic, psychological,
and social considerations (George et al., 2005; Hedenrud et al., 2008; Kidd & Altman,
2000; N. H. Miller, 1997).  In medication adherence research with chronic obstructive
pulmonary disease patients, George et al. (2005), found that patients’ beliefs,
experiences, and behaviors regarding disease and treatment were stronger predictors of
adherence to medications than sociodemographic and clinical factors.  A large
retrospective analysis of a national insurer’s claims data reveals that knowledge and
access to medication are important predictive factors in medication adherence.  They also
found medication non-adherence is evident in those covered by commercial insurance,
Medicaid and Medicare, as well as those without any form of insurance coverage –
adherence issues cut across socioeconomic status and level of insurance coverage (Thier
et al., 2008). Shalansky and Levy (2002) also found no difference between adherent and
non-adherent patients based on whether or not they had insurance coverage. These
individual studies supported previous findings of studies that examined over 200 factors
in relation to medication adherence; characteristics like age, gender, education,
occupation, financial status, race, and ethnic background have not been consistently
associated with adherence. In contrast, illness-related cognition, patient perceptions of
illness and beliefs about treatment have shown consistently strong relationships with
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adherence (Haynes, McKibbon, & Kanani, 1996; Wetzels et al., 2006; World Health
Organization, 2003).
Renal protective medication treatments require a patient-medical team
partnership, but success depends a great deal on the patient’s ability to successfully self
manage his or her illness (Lorig, 2001; J. F. Miller, 2000). Current clinical interventions
are not working with a large portion of the CKD population (Coresh et al., 2007; National
Institutes of Health & National Institute of Diabetes and Digestive and Kidney Diseases,
2007; USRDS, 2006).  To examine why CKD patients are not adherent with renal
protective medications, the literature suggests that researchers and healthcare providers
need to go to the patients themselves to look at individual human perspectives that might
lead to promoting behavior change in a context unique to patients diagnosed with CKD.
What are CKD patients’ perceptions, beliefs, and emotional responses to his or her
disease process and prescribed treatments and do they predict medication adherence
behavior?  Knowing this may lead to more successful interventions to improve adherence
to medications and curb the burden of kidney disease progression in this unique group of
patients.
Theoretical Framework
There has been a growing body of research guided by health behavior theories
and models over the past two decades (Cameron & Leventhal, 2003a; Glanz, Rimer, &
Lewis, 2002).  Some of the most prominent health-related behavioral theories and models
cited in the literature are the Health Belief Model (Rosenstock, Strecher, & Becker,
1988), Social Cognitive Theory (Bandura, 1989), and the Transtheoretical Model
(Prochaska, DiClemente, & Norcross, 1992).  Each of the above models have been
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examined and tested by researchers and have developed over time as valid and reliable
theoretical frameworks for health behavior research (Glanz et al., 2002).  However,  Noar
and Zimmerman point out in their critique of health behavior theories, initiation of
behavior change is the focus in most of the current theories, and there is a lack of
theoretical models that also address maintenance of behavior change as a separate process
(Noar & Zimmerman, 2005).  The focus of studies on behaviors to promote health has
left a gap with a need for theoretical frameworks with emphasis on behaviors to adapt to
and manage chronic illness over the long-term. The theory of self-regulation fills this
gap in health-related behavior research (Cameron & Leventhal, 2003b; Vohs &
Baumeister, 2004).
The complexity of studying CKD patients’ health beliefs and medication
adherence behaviors requires a theoretical framework that addresses the dynamic nature
of living with and managing a chronic illness and its complex treatments.  According to
self-regulation theory, health behavior in the context of chronic illness is a dynamic
process requiring feedback, motivation, and goal pursuit to initiate and maintain optimal
outcomes (Cameron & Leventhal, 2003b).  The theory proposes that illness threatens all
aspects of an individual’s personal and social self, requiring short- and long-term self-
regulation of critical aspects of living, including emotional and physical states (Cameron
& Leventhal, 2003b; Vohs & Baumeister, 2004). According to Leventhal’s self-
regulation CSM, when individuals are faced with threats to their health, they build
cognitive and emotional representations (mental models) and these representations
determine how they will respond to the threat (Leventhal et al., 1997; Leventhal et al.,
2003).  These representations of illness, unique to the individual, are influenced by the
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individual’s demographics, knowledge, and personal and familial experiences (Petrie &
Weinman, 2006).  The illness representations lead the patient to reduce the threat of
illness or symptoms by guiding their choices of coping strategies (e.g., to take
medication, stop smoking, lose weight) directed at reducing the threat.  The patient then
analyzes the outcomes of his coping strategies.  If the patient deems them satisfactory, he
or she is motivated to continue the strategies, if less than satisfactory a feedback loop is
redirected back to representations and coping strategies (Leventhal et al., 2003).
The content of a person’s “problem-solving system” (Leventhal et al., 2001, p 20)
is composed of both cognitive and emotional representations of the health threat.  Health
threats are processed as two interacting, but independent dimensions.  The cognitive
dimension processes information for controlling the danger of the health threat while the
emotional dimension processes information for controlling the emotional responses
triggered by the health threat.  The dual dimensions of the problem-solving system
became evident in Leventhal’s early work that revealed the emotional response to disease
threat messages triggered fear, anxiety, depression and anger, attitude change and
sometimes influenced behavior.  The emotional response was temporary, facilitated
disease prevention behavior, inhibited illness detection behavior, and did not lead to
health protective changes required for long term behavior change.  This indicated that
there was something else, besides the emotional response in play to drive health behavior
change for the long term.  He found health protective actions for the longer term were
taken when participants were exposed to health threat messages combined with action
plans requiring a cognitive response.  Therefore, a cognitive response, in addition to an
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emotional response, was needed to recognize the health threat and move plans into action
for the long term (Leventhal et al., 2001).
Emotional distress in the face of illness threats is not static – it varies between
persons and within the same person over time.  Illness specific rather than general
emotional responses predict health behavior responses. The cognitive-emotional
representation links are complex and dynamic.  Health threats ignite bi-directional
movement between cognition and emotional representations.  The emotional response
and ability to regulate the response will affect the cognitive response.  On the other hand,
emotional reactions depend greatly on the cognitive meaning a person assigns to them.
In effect, “…the affective tail is wagged by the cognitive dog” (Leventhal et al., 2001, p
25; Leventhal, Weinman, Leventhal, & Phillips, 2008).
The cognitive-emotional link is described in work by Millar and Millar (1993;
1996) in their experimental studies examining the relationship between health attitudes
and health behavior.  Health attitudes are described as being composed of both cognition
and affect components.  Positive health behaviors are described as being composed of
disease detection and health promotion behaviors.  Millar and Millar found that disease
detection behaviors were significantly associated with the affective component of health
attitudes (p = .002), and health promotion behaviors were significantly associated with
cognitive components of health attitudes (p = .001).  Overall, however, significantly more
cognitive than affective responses were used to describe participants’ reactions to both
detection and health promotion behaviors.  These findings are in line with Leventhal’s
theory of cognitive-emotional representations driving health behavior actions.
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The CSM has remained constant in its focus of the individual’s self-regulating
belief system of illness representation, coping and appraisal across cultures, disciplines
and illnesses (Hagger & Orbell, 2003).  In a meta-analysis of 45 empirical studies derived
from psychology that were guided by the CSM and encompassed 23 illnesses (including
diabetes mellitus and hypertension) and conditions, Hagger and Orbell (2003) examined
the convergence and discriminant validity of the CSM model.  They also examined the
relationship between the CSM variables of illness representation, coping behaviors and
illness outcomes across the studies.  Most of the studies were cross-sectional designs
followed by prospective or mixed cross-sectional and longitudinal study designs. A
variety of measures were used across the studies to examine illness representations,
coping behaviors and outcomes.  The measures used in this meta-analysis showed a
collective congruence in measuring and scoring the illness representation dimensions of
cause, consequences, cure/control, identity and timeline.  Using the average corrected
intercorrelation matrix, the CSM illness representation dimensions of consequences,
control/cure, identity, and timeline were shown to follow a logical pattern across studies,
thus supporting construct validity across illness types.  Perceived controllability of the
illness was significantly associated with both general and specific problem-focused
coping strategies (rc = 0.27, p < .05 and rc = 0.12, p < .05) such as diabetes management
behavior and treatment adherence as well as cognitive reappraisal (rc = .20, p < .05).   The
Hagger and Orbell meta-analysis also supported evidence for “theoretically predictable
relations” (p. 141) of a major CSM tenet that a causal relationship exists between illness
cognitions and outcomes that are mediated by coping behaviors.  In the meta-analysis, a
stronger, more significant relationship between illness representations and outcomes was
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revealed than between illness representations and coping behaviors.  This suggests that
the relationship between illness representation and outcomes is mediated by coping
behaviors.   A limitation given as an explanation of the low-to-moderate correlation
between illness representation and coping behaviors is the generality of the coping
measures in this meta-analysis drawn from psychological research.  A recommendation
for future research was to use more objective, specific problem-focused coping measures,
such as treatment and medication adherence (Hagger & Orbell, 2003).
Illness Representation
A search was conducted to examine empirical literature guided by the CSM
examining illness representations of patients with chronic illness and in the relationships
with problem-focused coping strategies.  The search revealed 26 studies guided by self-
regulation theory or CSM drawn from populations of patients with chronic illness.
However, the search exposed a paucity of research guided by self-regulation theory or
CSM examining the relationship between illness representation and objective, specific
problem-focused coping strategies such as medication adherence.  More importantly,
there were no CSM-guided studies of CKD patients in earlier stages of the disease
process, before end-stage renal disease and dialysis.  There were a limited number of
studies of dialysis patients and these will be discussed.  However, since the focus of the
current study is the examination of the illness representation of CKD patients and the
relationship of illness representation with renal protective medication adherence in CKD
patients before end-stage renal disease; and since the two major causes of CKD are
diabetes mellitus and hypertension (NKF, 2002 ; USRDS, 2006), the literature review is
drawn mainly from CKD proxy chronic illness populations of diabetes mellitus and
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hypertension. The illness representation of these chronic illness groups are examined
with a special emphasis placed on CSM-guided studies as they relate illness
representation to the specific problem-focused coping of medication adherence.
End stage renal disease. There were four CSM-guided studies conducted with
the end-stage renal disease patient population, with only one addressing medication
adherence.  Two quantitative cross-sectional studies examined illness representation in
relationship to quality of life (Covic, Seica, Gusbeth-Tatomir, Gavrilovici, & Goldsmith,
2004; Fowler & Baas, 2006).  One qualitative study using narrative methodology in face-
to-face interviews used the CSM, termed the theory of representations in this study, to
examine the lived experience of hemodialysis patients and how they reinterpret living
with illness by identifying their own beliefs about symptoms, causes, consequences and
ability to control their treatment (Velez & Ramasco, 2006).  The fourth study, a
prospective cross-sectional study of 73 hemodialysis patients, examined the utility of
CSM to predict specific problem-focused coping strategies of diet, fluid regimen and
medication adherence (O'Connor, Jardine, & Millar, 2008).  Indirect physiological
measures were used for diet (serum potassium levels), fluid intake (mean and standard
deviation of interdialytic weight gain), and medication adherence (serum phosphate
levels).  Serum potassium levels of greater than or equal to 5.5 mEq/l indicated
nonadherence to diet, and an interdialytic weight gain of greater than or equal to 2 kg
indicated nonadherence to fluid restrictions in this study.  Oral phosphate-binding
medications are prescribed to dialysis patients to manage serum phosphate levels.  Serum
phosphate levels greater than or equal to 1.8mmol/l were an indirect measure of
medication nonadherence in this study.  The results indicated that 70% (M = 2.4, S.D.
29
0.87, range 0.8 - 5.31) of patients were non-adherent to fluid restrictions, 55% (M = 1.8,
S.D. 0.49, range 0.85 - 2.91) were nonadherent to medication, and 16% (M = 4.7, S.D.
0.75, range 0.24 - 1.78) were nonadherent to diet. Illness representations, as measured by
the mean Revised Illness Perception Questionnaire (IPQ-R) scores, suggested that the
strongest beliefs of these dialysis participants were about the timeline (M = 25.81, S.D. =
4.35) and the consequences (M = 23.19, S.D. = 4.39) of their illness.  This implies that
the participants perceived their illness to be chronic (rather than acute) and to have severe
negative effects on their physical, economic, and social life.  A relative strong personal
cure/control belief (M = 18.16, S.D. = 5.26), as well as coherence belief (M = 18.73, S.D.
= 4.99), indicated a belief in the self-efficacy of their own actions, and understanding of
their illness to manage the disease process.  Participants had a less strong belief in their
treatment control/cure ability (M = 14.05, S.D. = 3.97).  Most of the participants
perceived that they experienced emotional distress as a result of their illness (M = 17.25,
S.D. = 5.74).  Hierarchical regression analysis showed that as a block of variables, illness
representation was a predictor of fluid adherence only, (p = .04). While of individual
illness representation variables predicted diet and medication adherence coping strategies,
(p < .05) specifically, emotional representations predicted diet adherence (β = .443, p =
.01) and medication adherence (β = .362, p = .048) and timeline predicted medication
adherence (β = –.324, p = .024).
These findings indicated that the perception of emotional distress from their
illness predicted diet and medication nonadherent behavior and the perception of their
illness being chronic rather than acute predicted medication nonadherence. An
interesting finding is that the participants’ emotional representation of ESRD predicted
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medication and diet adherence over and above general psychological distress as measured
by the Hospital Anxiety and Depression Scale (HADs).  This finding is supported in an
immunosuppressant medication adherence study of renal transplant patients where
emotional distress about the transplant was significantly related to medication
nonadherence, while general emotional distress as measured by SF36 scale was not
significantly related to medication adherence behavior (Butler et al., 2004).  O’Connor et
al. (2008) posit that medication adherence prediction may be based on illness-specific
rather than general emotional responses.
The lack of CSM-guided ESRD studies examining the ability of illness
representations to predict treatment adherence as a coping strategy is apparent in this
review of literature.  The O’Connor et al. (2008) study did support the ability of illness
representation to predict the coping behaviors of diet and medication adherence, was a
prospective designed study, and reported an adequately powered sample size for
appropriate analysis.  Stronger support for the prediction ability of the illness
representation of the participants may have been gained with the use of self-report, pill
counts, or refill records as measures of adherence in addition to the proxy physiological
measures.  Treatment control beliefs were not significant predictors of treatment
adherence, including medication adherence in this study.  It is postulated that a measure
more specific to the type of treatment being studied rather than treatments in general
would add to the validity of the study of treatment adherence and illness representation
(Horne & Weinman, 2002; O'Connor et al., 2008).
Diabetes Mellitus. There were 16 CSM or similar self-regulation model guided
studies identified that focused on the diabetes mellitus (DM) patient population.  All of
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the studies contributed to the growing body of evidence indicating that illness
representation is an important factor in the study of chronic illness health behavior across
multiple patient populations and illnesses. Among studies that used the CSM in the
diabetic population, few examined the relationship between illness representations and
the objective, specific problem-focused coping strategy of medication adherence.  Of the
16 studies, 6 examined illness representation in DM patients focusing on family
interactions, physiological complications, psychological outcomes and emotional-focused
coping strategies (Edgar & Skinner, 2003; Eiser, Riazi, Eiser, Hammersley, & Tooke,
2001; Keogh et al., 2007; Paschalides et al., 2004; Scollan-Koliopoulos, O'Connell, &
Walker, 2005; Searle et al., 2008).  One study examined predictors of illness
representation as opposed to the ability of illness representation to predict coping
strategies or outcomes (Lawson, Bundy, & Harvey, 2007).  Nine of the 16 studies
examined illness representation in DM patients as it related to health behaviors and
specific, problem-focused coping strategies. The specific, problem-focused coping
strategy most often studied was dietary behaviors. None of the DM studies focused on
medication adherence alone, but seven of the problem-focused studies included
medication adherence, two of which dropped medication adherence from the model
before final analysis.  Glascow, Hampson, Strycker, and Ruggiero (1997) excluded
medication use secondary to extremely high compliance reporting resulting in heavy
skewing.  Heterogeneity of medication regimens was the reason given for Hampson,
Glasgow, and Foster (1995) excluding medication use, citing that some participants were
on insulin injections, others taking pills and some on both or neither.  Only 5 of the 16
DM studies included medication adherence in the final analysis (Barnes, Moss-Morris, &
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Kaufusi, 2004; Griva, Myers, & Newman, 2000; Kart, Kinney, Subedi, Basnyat, &
Vadakkan, 2007; Scollan-Koliopoulosm O’Connell, & Walker, 2007; Searle et al., 2007).
Scollan-Kiliopoulos et al. (2005) used the Theory of Illness Representation and
the Family-systems-illness-disability Model to examine the multigenerational legacy of
Type 2 diabetes in a review of the literature from 1984-2004.  The implications from the
findings in this review are that having a family history of diabetes has an affect on the
health behavior of the next generation of family members with diabetes.  Each individual
diabetes patient has his or her own illness representation, but this study indicates that the
individual’s representations are shaped by multigenerational legacies – the illness
representation of diabetes exemplified by family members who have experienced living
with the disease.  Another study of illness representations among DM patients and family
members was submitted in the form of a proposal of a randomized controlled trial of a
family-based intervention as part of an ongoing study of patient and family members’
illness perceptions (Keogh et al., 2007). Studies examining multigenerational legacies of
DM are relevant to kidney disease, also a multigenerational legacy disease which may
influence the CKD patient’s illness representation and health behavior coping strategies
(National Institutes of Health & National Institute of Diabetes and Digestive and Kidney
Diseases, 2002; NKF, 2004; USRDS, 2008).
Searle et al. (2008) examined three matched groups of DM patients’ self-reported
illness beliefs in relation to DM complications in a cross-sectional study.  General
findings that DM was perceived as a chronic illness having moderately severe
consequences that could be controlled were similar across the three groups of patients -
those without complications, those with retinopathy, and those with active ulceration.
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Significant specific beliefs were found in the ulceration group who perceived a more
cyclical timeline (p = .001), higher personal control (p = .01), poorer treatment control (p
= .006) and had poorer perceived understanding (coherence) of DM than the other two
groups (Searle et al., 2008).  These findings suggest that patients may share general
illness perceptions within a common chronic illness, while having more specific illness
beliefs according to co-morbidities.  Since DM is a co-morbidity of a high percentage of
CKD patients, 46.4% of patients 65 years and older  and 37.8% ages 20 - 64 years,
(USRDS, 2008) the specific illness perceptions of patients experiencing complications of
DM are relevant to this study.
Psychological outcomes and emotional-focused coping strategies were examined
in relation to illness representation in three cross-sectional questionnaire survey studies
(Edgar & Skinner, 2003; Eiser et al., 2001; Paschalides et al., 2004).  Positive and
negative well-being and quality of life dimensions were examined in relation to DM
patients’ illness beliefs.  Significant findings were found across the three studies in three
illness representation dimensions: identity (i.e. labeling of symptoms), consequences (i.e.
degree of disruption caused by DM) and in control (i.e. belief in personal efficacy or
treatment to control DM and complications).  More perceived symptoms and
consequences were related to higher levels of depression, anxiety and poorer physical and
mental functioning.  Greater perceived effectiveness of personal or treatment control of
DM was associated with greater sense of well-being (p < .001), self-efficacy (p = .006),
mental functioning (p < .001), and less pessimistic expectations (p < .001).  One finding
of particular relevance to the current CKD study of illness representation relationships to
the problem-focused coping strategy of medication adherence is that emotion-focused
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coping strategies examined in Edgar and Skinner (2003) did not appear to be robust
mediators between illness representation and outcomes of emotional well-being, thus
supporting the value of examining illness representation in relationship to problem-
focused coping strategies.
An interesting study by Lawson et al. (2007), phase one of a longitudinal
prospective study, examined factors that influence individuals’ personal models of
illness. Along with demographics and clinical factors as predictors of patients’ personal
models of illness, how the health threat was communicated to the patient and personality
traits were also examined as predictors.  Patient’s perceptions of how diabetes was
explained to them were the strongest overall predictors of personal models of DM in this
study.  When health messages were communicated in a more threatening way,
participants perceived more severe consequences and greater emotional responses
associated with DM.  These findings are important since these two dimensions of illness
representation, consequences and emotional response, have been shown to be related to
medication adherence in some studies (Barnes et al., 2004; O'Connor et al., 2008;
Scollan-Koliopoulos et al., 2005).
Nine studies examined illness representation of DM patients in relation to more
specific problem-focused coping self-management strategies such as diet, physical
activity, glucose monitoring, foot care, seeking care, and medication adherence (Barnes
et al., 2004; Glasgow et al., 1997; Griva et al., 2000; Hampson et al., 1995; Hampson,
Glasgow, & Strycker, 2000; Kart et al., 2007; Lawson, Bundy, Lyne, & Harvey, 2004;
Scollan-Koliopoulos et al., 2007; Searle, Norman, Thompson, & Vedhara, 2007).  With
the exception of Lawson et al. (2004), all studies included self-management of diet in
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combination with one or more other self-management coping strategies.  Lawson et al.
examined the association between illness representation and level of care seeking of DM
patients.  This cross-sectional study of 52 DM patients seeking regular follow-up care and
32 patients who were not seeking regular care found no illness representation dimensions
significantly associated with regular care seekers, although perceptions of control almost
reached significance in this group (p = .07).  Four illness representation dimensions
reached statistical significant levels with the group that did not seek regular care:  identity
(reported more symptoms p = .02); timeline chronic (more pessimistic timeline p = .03);
consequences (reported more serious consequences, p = .02); and control (less perceived
control of DM, p = 0.05).
Of the eight remaining problem-focused DM studies that included dietary self-
management, one (Hampson et al., 2000) also included physical activity and two
(Glasgow et al., 1997; Hampson et al., 1995) included physical activity, glucose
monitoring and medication adherence.  However, as previously described, medication
adherence was dropped from the model in both studies. The five remaining DM studies
examined illness representation associations with dietary self-management and
medication adherence (Barnes et al., 2004; Griva et al., 2000; Kart et al., 2007; Scollan-
Koliopoulos et al., 2007; Searle et al., 2007) along with physical activity, glucose
monitoring, and/or foot care which were also included in some.  The illness
representation dimensions found to be associated with problem-focused coping strategies
among the DM participants in these five studies were: timeline (acute/chronic) positive
correlation, (p = < .05 to .05), timeline (cyclical), mixed positive and negative
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correlations (p = .001 to < .05), consequences, all negative correlations (p = .001 to <
.05), control, mixed positive and negative correlations (p = .007 to .065).
Searle et al. (2007) examined 164 patient-partner dyads’ illness representation and
relationship to diet, exercise and medication adherence in a non-randomized prospective
study of illness representation.  Patients’ beliefs about the timeline of their condition
being long-term (chronic) and their perception of having personal control over their
disease were positively and significantly related to dietary (p < .01) and physical activity
self-management coping strategies (p < .01).  Moreover, partners’ illness representations
in these dimensions were positively correlated and partially mediated the relationships
between patients’ illness representation and their self-management of diet and physical
exercise.  High levels of medication adherence were self-reported by participants (range 6
- 30; M = 28.3, S.D. = 5) and no meditational relationships were found suggesting that
the self-management behavior of medication adherence is beyond the partners’ influence.
Barnes et al. (2004) compared 43 Tongan and 39 European patients’ DM self-
management behaviors in a cross-sectional correlation study.  Glycosylated hemoglobin
levels revealed significantly poorer DM control of Tongan patients.  There was also a
significant difference in illness representation between Tongan and European DM
patients.  Tongan patients were more likely to report perceptions of DM as cyclical,
uncontrollable, and caused by external factors. Poor adherence to diet was significantly
associated with cyclical timeline (p < .05) and perceived cause of DM from poor medical
care in the past (p < .01).  Poor adherence to medications was significantly associated
with perceptions of a cyclical nature of DM (rs = -.27, p < .05), more severe consequences
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(rs = -.28, p < .05), and external causes of DM such as God’s will (rs = -.40, p < .001),
environmental pollution (rs = -.33, p < .01), and poor medical care (rs = -.29, p < .05).
A cross sectional correlation study by Griva et al. (2000) examined the respective
and combined role of illness representation and self-efficacy in insulin treatment
adherence and metabolic control, in 64 DM Type 1 adolescents and young adults.
Significant correlations were found between several illness representation dimensions
and self-efficacy in this study.  Self-efficacy beliefs were associated with greater
perceived control (p < .01), fewer diabetes-associated symptoms (p < .01) and the
perception of less serious consequences (p < .001).  Perceived control (t (62) = 2.79, p =
.007) was the only significant difference found between patients reporting good and poor
insulin adherence with higher perceptions of control was related to better adherence with
prescribed insulin regimen.
The Lay explanatory model was used as a guiding framework for a cross sectional
correlation study of 300 Type 2 DM patients in the kingdom of Nepal (Kart et al., 2007).
The purposes of this study were to examine symptoms that patients identified with DM,
and examine the relationship between lay explanations and self-management of DM.
Self-management activities included diet, exercise, glucose testing, foot care, stress
management, taking medications, taking complementary and alternative medicine
(CAM), and stress management.  Lay explanations included patients’ perception of
causes of DM, timeline (acuity/chronicity), timeline (cycle), consequences, personal
control, treatment control, and emotional representation of DM.  There was a high degree
of internal reliability (Cronbach’s alpha of 0.83) in the symptoms response of
participants.  The most frequently reported symptoms believed to be associated with DM
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included fatigue (82.6%), weight loss (80%), and loss of strength (74.5%).  Participants
who believed that alcohol consumption and smoking was a cause of their diabetes were
less likely to adhere to a healthful diet (β = -0.170), but more likely to report greater
medication adherence (β = 0.172).  A significant negative relationship was found
between a belief in psychological causes (poor mental attitude, family concerns,
overwork, and/or negative emotional state) of diabetes and reported medication use (β = -
0.172, p < .05).  A negative relationship was also reported between treatment control and
medication use (β = - 0.346, p < .05).  More confidence in DM treatment was associated
with poorer medication adherence (β = - .346, p < .05), but better adherence to self-
management activities such as, exercise (β = .184, p < .05) , CAM (β = .314, p < .05), and
stress management (β = .309, p < .05).  Stronger beliefs in the cyclicality of DM was
related to more consistent medication usage (β = 0.147, p < .05) and healthful diet (β =
0.169, p < .05).
A cross sectional study drawn from a convenience sample of 123 adults with DM
Type 2 and a family history of diabetes, examined participants recollections of family
members’ DM controllability and social consequences in relation to their own health
beliefs and behaviors (Scollan-Koliopoulos et al., 2007).  A statistically significant
positive relationship was found between recollections of the participant about family
members’ controllability beliefs (p =.03) and perceived social consequences (p = .01) and
the participants own beliefs.  More perceived social consequences of DM were associated
with insulin regimen non-adherence (P = 0.005).  More perceived social consequences (p
= .01) and controllability (p = .01) of DM were negatively associated with adherence to
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pill regimens. There were no statistically significant relationships between consequences
or controllability and diet, exercise, or glucose monitoring.
In summary, the literature review of the illness representation of DM patients
supports the CSM as a guiding framework for examining coping strategies and outcomes
in individuals living with chronic illness.  Every illness representation dimension was
correlated with some aspect of managing life with Type 1 and Type 2 DM among
adolescents and adults, across various cultures, and as complications changed the
dynamics of living with DM.  Multigenerational legacies of living with DM as well as
patient-partner dyads’ illness representations were also found capable of predicting self-
management coping strategies of DM patients.
Many of the findings were relevant to the proposed study of the illness
representation of CKD patients.  The findings that the illness representations of
individuals with DM are shaped by multigenerational legacies may prove to be important
in CKD, an illness that shares the multigenerational legacy phenomenon.  This finding
gives support to adding a family history of kidney disease to the clinical characteristics in
the proposed model.  The findings that patients may share general illness perceptions
within a common chronic illness, but have different specific illness beliefs according to
co-morbidities also lends support to adding co-morbidity to the model.  Another
interesting finding to consider is that the patient’s perception of how diabetes was
explained to them was a strong predictor of their illness representation of DM, which
therefore, according to the CSM, would affect the patient’s health behavior choices such
as medication adherence.
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Also noted in this review of CSM in the diabetic population, is the paucity of
studies examining the relationship between illness representations and the specific
problem-focused coping strategy of medication adherence.  Only 5 of 16 DM studies
(Barnes et al., 2004; Griva et al., 2000; Kart et al., 2007; Scollan-Koliopoulos et al.,
2007; Searle et al., 2007), included medication adherence in the final analysis and in none
of the studies was medication adherence the predominant coping strategy examined.  All
five studies were non-randomized.  Four of the five studies were cross sectional in
design, while one was a prospective repeated measures design.  Sample sizes ranged from
82 to 300 patients with Type 2 DM and 64 patients with Type 1 DM. There were
variations among the studies of DM medication regimens examined with some studies
limited to insulin injections, some to oral medications, and still others with both or just
described as diabetes medications.  Having such variation in the few DM studies
incorporating illness representation and medication adherence makes it difficult to draw
consistent conclusions on which to build more long-term studies to examine medication
adherence in individuals managing life with chronic illness.  The exclusive use of self-
report medication adherence questionnaires was another limitation of these studies
resulting in unusually high adherence rates that sometimes skewed the results to the
extent that medication adherence was excluded from the model. Use of other medication
adherence measurement tools, such as pill counts or pharmacy refill records in addition to
self-report, would add support to the predictability of illness representation in relation to
medication adherence.
Hypertension. Six studies that used the CSM or similar self-regulation model
were conducted with participants from the hypertension (HTN) patient population
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(Blumhagen, 1980; dela Cruz & Galang, 2008; Godoy-Izquierdo, López-Chicheri,
López-Torrecillas, Vélez, & Godoy, 2007; Hekler et al., 2008; Meyer, Leventhal, &
Gutmann, 1985; Ross, Walker, & MacLeod, 2004).  Rich information was captured about
illness perceptions of patients with HTN, however congruent with the ESRD and DM
studies, a minority of the HTN studies examined the relationship between illness
representation and medication adherence.
Two of the six studies were qualitative studies using Kleinman’s explanatory
model of illness, an anthropological model similar to CSM, but focused more on cultural
perceptions, as a guiding framework (Blumhagen, 1980; dela Cruz & Galang, 2008).
Blumhagen (1980) used an exploratory descriptive design to explore illness beliefs of 103
people recruited from an urban Veterans Administration Medical Center HTN clinic.  In
this study, two belief models emerged - the Popular Model and the Professional Model.
The Popular Model was held by 72% of the participants who believed they had ‘Hyper-
Tension’ described as “excessive tenseness” from social stress that led to physical illness
(p. 197).  The remaining 28% of the participants subscribed to the Professional Model
described as a continuing pressure built up in the systemic circulation.  More than half
(68%) felt there was agreement between the Popular Model and the Professional Model
and 32% stated that they knew the difference, but rejected the Professional Model as one
that was generally true, but did not pertain to them personally.  Blumhagen stressed the
importance of clinicians’ understanding of the role of language when caring for patients
with high blood pressure.  He states, “Plain folk say ‘Hyper-Tension’: the experts say
hypertension, and each thinks the other is talking about the same thing” when in reality,
they may be talking about very different illnesses (p. 224). Relationships between illness
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beliefs and illness behaviors were not addressed in this study, but the authors did cite this
as suitable for future studies.
Dela Cruz and Galang (2008) examined illness beliefs and practices of
hypertensive Filipino Americans using the explanatory model, exploring CSM
dimensions of cause, identity, consequences and treatment. This qualitative study used
focus groups segregated by gender, 10 men and 17 women.  The illness beliefs of this
sample corresponded to the biomedical model.  Men reported higher insurance costs and
doctors fees, and sexual-related side effects of medications as reasons for not adhering to
medication regimens.  Women reported forgetfulness and family pressures for not
adhering to healthy lifestyle changes and medication regimens.  This study was aimed at
the participant’s culture, family, and work issues as causes for health behavior choices
rather than the association with particular illness beliefs.
A cross sectional study by Godoy-Izquierdo et al. (2007) sought to establish the
contents of lay illness models of influenza, cancer, and HTN as well as depression and
schizophrenia, based on the CSM (Godoy-Izquierdo et al., 2007).  The illness
representation of healthy participants and those suffering with these diseases, as well as
participants who have and have not coexisted with people suffering with these diseases,
were examined and compared (N = 348).  Similar profiles were found across physical and
mental disease, and the illness representations of healthy and ill participants were
generally in line with the medical model in this study.  However, the cases that were not
in line with the medical model, had beliefs very divergent from the accepted medical
knowledge. Of the participants in this study with physical illness, influenza, cancer, or
HTN, the hypertensive participants’ belief were clearly far from accepted medical
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knowledge.  A significant difference was found in the illness representation of those
participants who experienced disease, either personally or through relatives, and those
who have not (p < 0.05).  Those participants who have experienced or co-existed with
someone experiencing the disease perceived their condition as significantly less chronic
and serious, with a lower impact on day-to-day life and well-being, having more
controllability and curability, and more preventable, stable, and cyclical than participants
who have not experienced or co-existed with someone experiencing the disease.
A cross sectional study of 102 African American hypertensive patients examined
their lay models of HTN and the relationships of those models to medication adherence,
life-style behaviors (diet, exercise, weight loss and getting regular check-ups), stress-
reducing behaviors (including prayer), and blood pressure control (Hekler et al., 2008).
An interview was developed specifically for this study and administered in hour long
sessions by trained African American interviewers.  Rather than soliciting participant’s
beliefs about HTN in general, a 19-item instrument was used to assess participants’
beliefs about their own blood pressure.  Using principal component analysis with varimax
rotation, two main factors (eiganvalues of 3 and 2) were extracted as representing
participants’ beliefs of cause and control dimensions.  Factor 1, drawn from the
cause/control dimensions, endorsed the Medical Belief Model (MBM) with causal beliefs
such as family history and age that could be controlled by medications and diet
(Cronbach  = 0.64).  Factor 2, drawn from cause/control dimensions, endorsed the
Stress Belief Model (SBM) with causal beliefs related to stress that could be controlled
by stress reduction (Cronbach  = 0.63). Other illness representation dimensions
included in the final analysis along with MBM, SMB and demographic variables were
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identity (eigenvalue = 1.9) and consequences (eigenvalue = 2.2).  Medication adherence
was determined by self-report of whether the participants took their medications every
time within the past two weeks.  Medication adherence was dichotomized as adherent and
nonadherent after evaluation of the data indicated a bimodal distribution of 50% self-
report of adherent and 50% non-adherent.  Correlation analyses were conducted to
examine relationships among beliefs, behaviors, and blood pressure.  Medication
adherence was not statistically significantly correlated with illness representation
dimensions (identity, timeline, consequences, cause, and control), demographic variables
(education, marital status, gender), or biomedical variables (body mass index and number
of years with diagnosis) in this analysis.  Multiple regression analyses indicated only one
variable significantly predicted medication adherence, that being age (OR = 1.07, CI 1.01
- 1.13, p < 0.05).  Older age was associated with greater medication adherence (t = -2.4,
df = 100, p < 0.05), endorsement of the Stress Belief Model (r = - 0.22, df = 100, p <
0.05), and consequences (r = - 0.22, df = 100, p < 0.05).
A longitudinal exploratory study was conducted with 230 randomly selected
individuals presenting to a primary care, renal, or HTN clinic for screening or treatment
(Meyer et al., 1985). The participants were entered into one of four groups depending on
their HTN status and clinic history: (1) normotensive group (n = 50) consisted of patients
in a primary care clinic for non-blood pressure reasons; (2) newly treated group (n = 65)
were hypertensive patients attending a clinic for the first visit for treatment of their
elevated blood pressure; (3) continuing treatment group (n = 50) were receiving treatment
for at least three months to 15 years; and (4) re-entry group (n = 65) were patients who
had dropped out and had returned to a clinic for treatment of their HTN.  The purpose of
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this study was to investigate whether people develop illness representations about HTN
and evaluate the impact of their illness representations on medication adherence and
remaining in treatment. Adherence to medications was examined in the continuing
treatment group, as it was felt this was most appropriate since they have remained in
treatment and were less likely to drop out of treatment.  Remaining in treatment was
examined in the newly treated and re-entry groups as these groups are making decisions
about the necessity of treatment.  Findings indicated that people do construct illness
representations of hypertension and there are strong similarities to prior experiences with
illness by the patient or a family member.  All four groups believed symptoms of HTN
were present and one could monitor blood pressure elevations by these symptoms.  An
interesting side note indicating that patients are aware of the medical knowledge that
HTN is asymptomatic was that a majority (63%) of the continuing treatment group
specifically asked that their beliefs about blood pressure symptoms not be communicated
to their provider.  In general, the groups believed that HTN was of limited duration and
related to a variety of causes such as work and family stressors and diet.  Examining the
illness representations by groups of non-hypertensive, newly treated, continuous, and re-
entry hypertensive patients illustrated that their illness representations evolved over time,
in some cases to a closer match with the medical model.  In the continuing treatment
group, 92% of the participants identified symptoms of HTN and 37% of these believed
treatment affected their symptoms.  Of the 37% who believed treatment affected
symptoms, 70% reported taking their medications as prescribed, and of these, 53% had
good blood pressure control. Of those patients who believed treatment affected their
symptoms, but did not take their medication as prescribed, 29% treated their HTN as an
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acute illness, and took their medication only when symptoms were present.  This study
demonstrated that identity of symptoms and timeline beliefs predicted medication
adherence in a group of hypertensive patients who were receiving treatment for their
hypertension on a continuous basis.
Only one of the six hypertensive studies focused specifically on the examination
of illness representations and medication adherence (Ross et al., 2004).  This cross
sectional study of 514 hypertensive patients recruited from secondary clinics in the
United Kingdom found high self-reported medication compliance rates (78%).  In
general, this sample of hypertensive patients’ scores of their illness representation beliefs
(possible range 1-5) indicated a high perception of the chronicity of their disease (M =
3.55, S.D. 0.44), but also that it changes over time (M = 3.21, S.D. 0.79).  The scores also
indicated they did not perceive their illness causing great emotional distress with a
generally low emotional response (M = 2.56, S.D. 0.74) however, outliers scored very
high.  Day-to-day disruption of life (consequences) caused by hypertension was
moderately scored (M = 2.63, S.D. 0.63).  Both control dimensions, treatment (M = 3.53,
S.D. 0.60) and personal (M = 3.49, S.D. 0.66), were scored high indicating that the
participants believed in both personal and treatment efficacy in controlling hypertension.
Participants who held high personal control beliefs were less likely to be adherent with
their medications as opposed to those who believe their treatment could control their
blood pressure, who were more apt to be adherent with their medications.  Analysis of
multiple logistic regression showed statistically significant relationships between
medication adherence and emotional response (OR 0.65, CI 0.47 - 0.90, p < .001) and
personal control (OR 0.59, CI 0.40 - 0.89, p = .012).  Age was the only demographic
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variable that predicted medication adherence (OR 4.82, CI 2.85 - 815), p < .001). The
authors pointed out that illness representation may have mediated the relationship
between age and medication adherence since age was related to both illness
representation dimensions and medication adherence.
Information gleaned from the six studies that were guided by the CSM or similar
self-regulation models and focused on patients with HTN provide useful insight for the
proposed CKD study.  These six studies included 1324 participants drawn from various
community and healthcare settings.  Two of the study designs were qualitative, three
were cross sectional, and one was a longitudinal exploratory study with randomly
selected participants.  Three of the studies were drawn from culturally diverse groups,
including Filipinos, and African Americans.  These studies found that HTN patients
subscribe to two general belief models of HTN, stress-related models and biomedical-
related models which, in turn, predict their choice of coping strategies (Blumhagen, 1980;
dela Cruz & Galang, 2008; Hekler et al., 2008).  Those who identified the stress-related
model described using stress reduction behaviors, including prayer, to reduce the
symptoms of HTN.  Those who identified the biomedical-related model reported
behaviors such as dietary compliance and taking medications as strategies to help reduce
the symptoms of HTN.  According to medical knowledge, HTN is an asymptomatic
condition, as is the early stages of CKD (Blumhagen, 1980; Meyer et al., 1985; Stevens
& Levey, 2009; Stewart et al., 2007) so the findings that patients identify symptoms of
HTN that can be controlled by medically prescribed treatments is an important finding
for the current CKD study.  Meyer et al. (1985) revealed the dynamic nature of illness
representations of HTN and that the longer patients were in treatment for HTN, the more
48
consistent their beliefs were with the biomedical model.  If these findings hold true for
CKD patients, the relationship between illness representations and medication adherence
may be affected by the length of time the patient has been treated for CKD.  Five illness
representation dimensions of HTN were significantly related to medication adherence:
identity, timeline (chronic/acute), personal control, treatment control and emotional
response.
Individual and Clinical Characteristics
A review of the literature regarding the model of CKD patients’ illness
representations in relation to their medication adherence behavior with renal protective
medications reveals conflicting findings. There is a lack of consensus of relationships
among illness representation, medication adherence, demographics and clinical
characteristics in research drawing from the chronic illness population.  The lack of
research examining these variables in CKD patients is evident and the current study adds
to the scientific knowledge base required for further study of this important population
and efforts to slow the progression of CKD.
Age. The relationship of age to illness representation dimensions and medication
adherence varied across studies.  Among the studies examining illness representation of
chronic disease patients and adherence, age was significantly related to four illness
representation dimensions:  identity, consequences, emotion, and control/cure (Lawson et
al., 2007; Ross, 2004; Heckler, 2008; Glasgow, 1997).  In general, older participants
identified fewer symptoms related to their illness, reported less severe consequences and
emotional distress, and higher treatment control beliefs than younger participants.  Age
was not related to any illness representation dimensions in the study by Griva et al.
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(2000). Three studies did not examine the relationship between age and illness
representations (Kart, 2007; Searle, 2007, Meyer, 1985).  Ross et al. (2004) was the only
study to examine the relationship of age with both illness representation and medication
adherence.  Age was significantly related to both illness representation (emotion,
consequence, and control/cure) and medication adherence, thus raising the possibility that
the relationship between age and medication adherence may be mediated by illness
representation.  Most of the studies reviewed, specific to medication adherence among
chronic disease patients, revealed a significant positive relationship between age and
medication adherence (Ross, 2004; Heckler, 2008; Bame, 1993; Caro, Salas, Speckman,
Raggio, & Jackson, 1999; Caro, Speckman, Salas, Raggio, & Jackson, 1999; Shrank et
al., 2006).  However, in a longitudinal study by Caro and Speckman et al. (1999) the
medication adherence gap between the ages closed at 4.5 years into the study with both
young and old becoming less adherent.  In a meta analysis of 596 adherence studies, of
which 238 were medication adherence specific, DiMatteo (2004) reported significant
relationships between age and adherence, but whether the relationship was positive or
negative depended on the measurement tool.  A negative relationship was found with
self-report measures of adherence with older participants reporting less adherence, but a
positive relationship was found with older participants being more adherent when
measures other than self-report were used.  As with illness representation studies, there
were some medication adherence studies of chronic disease patients that found no
significant relationships, such as among DM patients (Griva et al., 2000), hemodialysis
patients (Curtin, Svarstad, & Keller, 1999), and COPD patients (George et al., 2005).
50
Gender. The relationships among gender, illness representations and medication
adherence varied across studies.  Among the studies examining illness representation of
chronic disease patients and adherence, gender was significantly related to three illness
representation dimensions:  cause, consequences, and control/cure (Glasgow et al., 1997;
Heckler et al., 2008; Lawson et al., 2007; Ross et al., 2004).  In general, male participants
exhibited stronger beliefs that their illness was caused by risk factors (i.e. smoking,
dietary indiscretion, alcohol consumption) (p < .001) and reported more severe
consequences resulting from their illness than females (p < .05). Males scored higher on
personal control beliefs than females (p < .01), whereas females reported higher treatment
control beliefs (p = .0000). Four studies did not examine the relationships between
gender and illness representation (Griva et al., 2000; Kart et al., 2007; Searle et al., 2007,
Meyer et al., 1985). Ross et al. (2004) was the only study to examine the relationship of
gender to both illness representation and medication adherence finding a significant
relationship to both, thus raising the possibility that the relationship between gender and
medication adherence may be mediated by illness representation.  The literature specific
to medication adherence was varied with two studies finding females more adherent
(Ross et al., 2004; Caro, Speckman et al., 1999), two studies finding males more adherent
(Shrank et al., 2006; The Boston Consulting Group and Harris Interactive, 2003), and
three studies finding no significant difference in adherence (Bame et al, 1993; Curtin et
al, 1999; DiMatteo, 2004). In a longitudinal study by Caro, Salas et al., (1999) the
medication adherence gap between the genders closed at 4.5 years into the study with
both males and females becoming less adherent (p < .001). In the initial year of diagnosis
of hypertension, women were more persistent in their hypertensive medication use than
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men (80% compared to 77% respectively) with the gap closing at 4.5 years (47%
compared to 46% respectively).
Race. Only one study reported finding a significant relationship between race
and illness representation, that being African Americans reported higher treatment
control beliefs than Caucasians and other races (Glasgow et al., 1997).  No other illness
representation studies reviewed addressed the association of race with illness
representation dimensions.  Two of the studies reviewed, specific to medication
adherence among chronic disease patients, revealed a significant relationship between
race and medication adherence (Curtin et al., 1999; and Shenolikar et al., 2006) and two
studies found no significant differences in race and medication adherence, one of which
was with ESRD participants (Bame et al., 1993; Kressin et al., 2007). In general, the
studies finding significant relationships reported African American participants were less
adherent than Caucasians and other races.  Prescribed medication adherence data was
highly skewed toward perfect adherence in a study of use of prescribed medications and
home remedies among African American and white Americans (Brown & Segal, 1996).
However, it was also found that African American participants were significantly more
likely to admit non-adherence than white American participants. In a large study of race
and medication adherence of DM Type 2 enrollees of Medicare, Caucasians refilled and
consumed a significantly higher total number of oral DM prescriptions, and had higher
rates of medication adherence with oral DM medications than African Americans and
other race groups after adjusting for age, gender, healthcare cost, number of medications,
and co-morbidities (Shenolikar et al., 2006). Six of the medication adherence studies
reviewed did not address race as a variable of study (The Boston Consulting Group,
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2003; Caro, Salas et al., 1999; Caro, Speckman et al., 1999; Shrank et al., 2006; George
et al., 2005; DiMatteo, 2004).
Education. Among the studies examining illness representation of chronic
disease patients and adherence, education was significantly related to two illness
representation dimensions:  identity and control/cure (Glasgow et al., 1997; Heckler et
al., 2008; & Lawson et al., 2007).  Higher education was significantly associated with
lower identity of illness related symptoms and treatment control beliefs, but higher
personal control beliefs.  One study found no significant correlation with education and
illness representation or adherence (Griva et al., 2000) and one found no significant
correlation with adherence (Ross et al., 2004).  Three illness representation studies did
not address relationships between education and illness representation (Kart et al., 2007;
Meyer et al., 1985; & Searle et al., 2007).  Two medication adherence studies found no
significant relationships between education level and medication adherence (Bame et al.,
1993; Curtin et al., 1999) and one study found a significantly positive relationship
between education level and chronic illness treatment regimens, but not acute condition
treatment regimens (DiMatteo, 2004).  Five medication adherence studies did not
examine the variable of education (Caro, Salas et al. 1999; George et al., 2005;
Shenolikar et al., 2006; Shrank et al., 2006; & The Boston Consulting Group, 2003).
Financial status. None of the illness representation studies reviewed addressed
illness representation and income.  Significant associations were found in the medication
adherence studies reviewed, however, how income is measured raises questions of the
usefulness of the findings.  Bame et al. (1993) found a significant association between
medium income ($10,000 - 25,000) participants and medication adherence versus low
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income patients (< $10,000), and no significant association between higher income (>
$25,000) participants and medication adherence.  Shank (2006) found significant
associations between medication adherence with patients residing in higher income zip
codes.  This measurement seems to be an indirect measurement, since a lower income
person may be living with someone in a higher income zip code area.  A meta-analysis of
adherence and demographic studies found a significant and positive correlation when
studies used actual numeric measures of income rather than non-numerical categories
(DiMatteo, 2004).  Two medication adherence studies reviewed did not address income
as a variable (Caro, Salas et al., 1999; & Curtin et al., 1999).
Marital/living with partner status. One study of illness representation and
adherence reported a significant association with illness representations and participants
living with partners (Lawson et al., 2007).  Participants who reported living with a
partner identified fewer illness related symptoms than those living alone (p < .05).  One
study reported significant findings (p < .05) of decreased medication adherence if
participants were married (Kart et al., 2007).  Two studies found no significant difference
in medication adherence behavior between participants married/living with a partner and
those living alone (Bame et al., 1993; Searle et al., 2007).  Searle et al. (2007) posited
that a person’s medication adherence practices are beyond the partner’s influence.
Co-morbidity. Searle et al. (2008) studied the illness representation of patients
with type 2 DM without complications, with retinopathy, and active ulcers.  The illness
representation beliefs of DM were generally consistent across the groups, however there
were significant differences found between the group with active ulcers and those without
complications and with retinopathy.  The group with the co-morbidity of active ulcers
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reported higher scores regarding personal control, lower scores regarding treatment
control, a more cyclical timeline perception and believed that excess weight and lack of
exercise were causes of DM than the other two groups.  None of the studies examining
illness representation of chronic disease patients and adherence addressed illness
representation and co-morbidities and the only medication adherence studies that
addressed it found no significant association between the number of co-morbidities and
medication adherence (Curtin et al., 1999).
Length of time after diagnosis of CKD. The studies do not produce a clear
picture of the effect of the length of time since an illness was diagnosed with illness
representation beliefs or medication adherence.  Two illness representation studies found
no significant correlation between length of time since diagnosis of chronic illness and
illness representations (Griva et al., 2000; and Hekler et al., 2008).  One longitudinal
study of four groups of hypertensive participants, normotensive, new to treatment,
continued treatment and return to treatment found that illness representation beliefs
evolve over time to a closer match with the medical model and more coherent
understanding of hypertension.  Two medication adherence studies found no significant
associations with length of time diagnosis and adherence.  If used as an indirect measure
of time of illness diagnosis, the time from when a medication was first prescribed was
shown to affect adherence rates.  If the prescription was filled upon first being prescribed
(presumably when first diagnosed), adherence rates were highest at 97% in the first six
months and then declined to 78% over the next four years  (Caro, Salas et al., 1999).
Family history of CKD/Dialysis. A family history of CKD is a risk factor for
susceptibility of CKD (NKF, 2004).  Patients’ experiences living with family members
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with CKD and dialysis may affect their own health beliefs and health behaviors.
Diabetes and hypertension studies indicate that living with family members with DM or
HTN significantly affects the health behaviors of the next generation (Godoy-Izquierdo et
al., 2007; Lawson et al., 2007, Scollan-Koliopoulos et al., 2005; Scollan-Koliopoulos et
al., 2007).  Participants with family members having DM complications had perceived
higher emotional distress than those without family members with DM (p < .01) (Lawson
et al., 2007) and HTN participants with family members also having high blood pressure
perceived a less chronic and more cyclical timeline (p < .05), less serious consequences
(p < .01) and more controllability of their disease than those without family members
with HTN (p < .05) (Godoy-Izquierdo et al., 2007) .  Scollan-Koliopoulos et al., (2007)
found significant relationships between participants’ recollections of family members’
experiences and management of DM and their own perceptions of increased
consequences and controllability of their disease which was significantly associated with
a lower rate of medication adherence.
Total number of medications. The total number of medications patients were
prescribed were not included in the illness representation studies reviewed. In the
medication adherence literature, the findings of the impact of the total number of
medications a person is prescribed on medication adherence is conflicting.  Some study
findings indicated that an increased number of medications were associated with a lower
adherence rate (Col, Fanale, & Kronholm, 1990; Monane, Bohn, Gurwitz, Glynn, &
Avorn, 1994) while other studies found the opposite (Ownby, Hertzog, Crocco, & Duara,
2006; Shalansky & Levy, 2002). One of the objectives in a study of 1054 patients at high
risk for drug-related problems, by Billups, Malone, and Carter (2000) was to identify
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indicators of compliance.  In this study patients with a higher number of medications
were significantly more adherent with their medications than those prescribed few
medications (p < 0.001).  Upon further analyses, Billups et al. (2000) suggested that
patients prescribed more chronic medications may perceive they are sicker and become
more attentive to their drug regimen.
Summary
This review of the literature examining the illness representation of patients with
ESRD, DM, and HTN supports the value of unveiling patient perspectives of their illness
and treatment.  It also exposes several gaps that remain to be closed by further research in
patient illness and treatment beliefs leading to choices of strategies to address the threats
their illness poses to their health and well-being.  For the purposes of this study of early
stage CKD patients’ illness representation in relation to medication adherence to preserve
kidney function, the lack of patient illness perception studies in this population is a
glaring gap.  This gap necessitated the use of study samples drawn from chronic illnesses
such as ESRD, DM, and HTN as proxy samples in which to study CSM guided research.
The findings of Hagger and Orbell ‘s (2003) meta-analysis of 45 empirical studies
guided by the CSM of patients living with 23 illnesses (including DM and HTN) attest to
the validity of the CSM as a guiding framework for this study.  This meta-analysis
concluded that the CSM has remained constant in its focus of the individual’s self-
regulating belief system of illness representation, coping and appraisal across cultures,
disciplines and illnesses.  The review of four ESRD, sixteen DM, and six HTN studies
from 1980 to 2008 included 5394 participants drawn from various age groups, cultures,
and settings.  The majority of the study designs were cross sectional (15) with the
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remaining study designs being qualitative (4), random control trials (3), longitudinal (2),
quasi-experimental (1), and review of literature (1).  There was consensus among all of
the studies that understanding patients’ illness representation lends important information
about the experience of living with and self-managing chronic illness.
All illness representation dimensions revealed significant findings in one or more
of the reviewed studies.  Most illness representation correlations were consistent across
the studies.  Some inconsistencies were noted that need further elucidation such as a
higher belief in treatment controllability of symptoms or illness predicting improved
treatment adherence in some studies, and poorer adherence in others.  Considering the
grave consequences of disease progression in CKD patients and the benefits of adherence
with renal protective medications, it is important that several major research limitations
be addressed in the proposed CKD study. This study will (1) rectify the lack of studies
examining CKD patients’ illness representation of this progressive chronic disease; (2)
build on the limited research of the ability of illness representation to predict the
problem-focused coping strategy of medication adherence behaviors; and (3) strengthen
the validity of medication adherence findings in CSM guided studies by using more than
one tool in the measurement of medication adherence.
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CHAPTER 3
Research Design and Method
The purposes of this study were to: (a) describe the illness and treatment beliefs
of CKD patients in stage 3 guided by the CSM, and the relationship of those beliefs to
adherence with renal protective medications, ACE-I, as measured by self-report; (b)
determine the adherence level of ACE-I among CKD stage 3 patients as measured self-
report and retrospectively with pharmacy refill records; (c) examine relationships
between individual and clinical characteristics with patient beliefs and self-reported
medication adherence with ACE-I; and (d) determine the relationship between patient
self-report of adherence with ACE-I and adherence as measured by the MPR. This
chapter includes the description of the study design, sampling, recruitment and setting,
human subject protection, operational definitions and instruments, data collection
procedures and preliminary analysis.
Study Design
A descriptive correlational, cross-sectional design was used to examine the illness
and treatment beliefs of patients with stage 3 CKD and their relationship to renal
protective medication adherence. The cross sectional design allows an examination of
relationships between variables in this understudied population.
Sampling and Setting
The study participants were drawn from a convenience sample of renal clinic
patients seen in a Midwestern Veterans Administration Medical Center (VAMC). Pre-
study it was concluded that there were approximately 580 unique patients with an eGFR
of 30-59 mL/min/1.73m2 (stage 3 CKD) on record at the VAMC study location who had
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appointments in the renal clinic within the last 12 months. If 80-85% of those patients
have been prescribed an ACE-I or ARB by their VAMC providers, as has been suggested
(Cooke & Fatodu, 2006; Schmieder, 2005), this would indicate that there would be
approximately 464-493 patients being seen in the VAMC renal clinic with stage 3 CKD
receiving an ACE-I or ARB. More patients at the VAMC are prescribed an ACE-I as it is
recommended first line as formulary agent over the ARB which is non-formulary.
Therefore, the ACE-I is the class of medication used in this study.
Power was calculated to determine an adequate sample size to perform multiple
regression analyses taking into account effect size and number of possible predictor
variables.  Power analysis was based on the formula:  N> (8/ƒ2) + (M-1), where ƒ2 =
effect size and M = number of independent variables (Tabachnick & Fidell, 2007, p.
123). A medium effect size of 0.15 was proposed based on published research examining
the relationship between illness representations and medication adherence (O'Connor,
Jardine, & Millar, 2008; Scollan-Koliopoulos, O'Connell, & Walker, 2007).  Based on
this information, an estimated sample size of 68 would provide 80% power to detect a
medium effect size of .15 of 16 predictors on the value of ƒ to detect correlations at an
alpha of .05.  However, a larger sample size of 100 was set as a goal and recruited in
anticipation of the possibility of the dependent variable not being normally distributed as
has been evidenced in research studies examining medication adherence in patients with
chronic illness (Ediger et al., 2007; Horne & Weinman, 2002; Senior, Marteau,
Weinman, & Genetic Risk Assessment for F.H.T.S.G., 2004). To complete the study
with 100 participants based on the power analysis and on sample recruitment in IR-
medication adherence studies (Barnes, Moss-Morris, & Kaufusi, 2004; Griva, Myers, &
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Newman, 2000; O'Connor et al., 2008), approximately 240 patients were to be invited to
participate in an attempt to secure 134 consented participants agreeing to complete the
questionnaires.  It was anticipated that approximately 25% of the participants would not
complete the questionnaires due to time constraints, change in health status, or simply
disinterest in participating in the study.
The inclusion criteria guiding selection of participants for the sample was:
1. Stage 3 CKD diagnosis (ICD-9 585-3 or eGFR 30-59 mL/min/1.73m2).
This information was obtained through chart review. Stage 3 CKD is an
early stage of kidney disease where efforts to prevent or slow the
progression has a higher success rate; also the stage often associated with
additional complications from the disease progression and patients are
being seen by nephrologists in renal clinics.
2. Prescribed an ACE-I in the 12 months preceding the study through the
VAMC pharmacy. This information was obtained through chart review.
An ACE-I is a medication that is shown to be renal protective.
All of the VAMC renal clinic patients are over the age of 18 and able to read and
speak English as a requirement of entering military service.
Protection of Participants’ Human Rights
Institutional Review Board approval as an expedited study (Appendix A) was
obtained from Indiana University and the VAMC Research and Development
department.  The purpose, risks, and benefits of the study were explained in
understandable written form for the VAMC population. Confidentiality, privacy of
patient information, and participants rights were addressed as well as contact information
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provided if participants had questions about their rights.  Voluntary participation and the
right to decline to participate were also addressed. Informed consent and authorization for
release of health information for research forms were obtained in writing before data
collection.  Participant’s personal private information was removed and anonymous
identification (ID) numbers were assigned to data from questionnaires and chart reviews.
Master files with participant private information was kept in a locked file cabinet in the
research office with access limited to the PI and research assistant.  Identifying
information and study data were kept separate at all times.
All data were kept confidential on secured, password protected computers.  Data
were entered into an SPSS database using assigned study ID numbers.  No personal
identifiers were entered into the database.  The data was reported as group data with no
individual identifying information.  All identifying information was destroyed as soon as
possible after data collection.
Study Procedures
Recruitment was carried out by the principal investigator (PI) who had staff
privileges in the VAMC renal clinic.  The PI was an authorized delegate of an attending
nephrologist in the renal clinic and the renal clinic medical director.  The renal clinic
medical director granted permission to the PI to screen medical records of clinic patients
in order to determine eligibility (Appendix B).
The medication records of 914 renal clinic patients were screened in order to
determine participant eligibility. Specific eligibility criteria confirmed via medical record
review included the patient being: 1) diagnosed with CKD stage 3, or had an estimated
Glomerular Filtration Rate (eGFR) of 30-59 mL/min/1); and 2) prescribed an ACE-I
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within 12 months before recruitment started. A total of 350 patients were seen in the renal
clinic who had stage 3 CKD of which 200 were prescribed an ACE-I.  As the PI had
authority to screen for eligibility status only, a chart review to investigate why only 200
patients met criteria was not possible.  A reasonable explanation would be that some of
the stage 3 CKD patients were unable to tolerate an ACE-I and some may have been
prescribed a non-formulary ARB.  A contact list of 200 eligible patients was created by
the PI that contained eligible patients’ names, addresses, and phone numbers only.
The initial contact with 200 eligible patients was made by mail.  Cover letters
(Appendix C) were mailed along with the self-administered survey, an informed consent
form (Appendix D), an authorization for release of health information for research form,
a stamped self-addressed return envelope, and $2.00 bill in appreciation and as an
incentive to complete the study.
One week after the survey packet was mailed, the PI or research assistant
followed-up with a telephone call to answer any questions the participants may have had
about participating in the study or completing the questionnaire, consent form, or
authorization form.  If a participant did not receive a survey packet, the PI or research
assistant confirmed name and address and mailed another packet, and then called one
week later to answer any questions.  Patients were informed that participation was
completely voluntary and that they were free to decline participation.
Approximately one week after the prospective participant received the packet and
was contacted by telephone, a reminder letter (Appendix E) was mailed to participants
who had not returned survey packets.
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At completion of the study period, a total of 200 survey packets were mailed out
to eligible participants.  During follow-up phone calls, 10 eligible participants indicated
that they had not received a packet and requested that another be sent.  The address was
confirmed and 10 packets were re-sent a second time.  A third packet was mailed to one
prospect who reported not having received the first or second packet and requested a third
packet be mailed.  A total of 92 participants returned signed informed consent,
authorization form and completed survey questionnaire.  A total of 33 subjects returned
blank survey packets as an indication that they did not wish to participate.  A total of 75
did not respond at all.  The final number of participants for this study is 92 which is a
46% response rate.  A delay in follow-up phone calls was encountered approximately
midway in the study due to changes in research assistants which may have contributed to
a less than desired response rate.
Information obtained by the PI from medical records after obtaining informed
consent included:
1. Individual and clinical characteristic information: age, co-morbid
conditions, and total number of prescribed medications.
2. Pharmacy records were also accessed by the PI to
measure participants’ refill rates of ACE-I using the Medication
Possession Ratio.
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Operational Definitions and Instruments
Individual and Clinical Characteristics
A demographic data sheet was used to collect self-reported: gender, race,
education, financial status, living with partner status, history of living with family
member with ESRD or dialysis, and length of time with CKD diagnosis (Appendix F).
A chart review was performed by the PI to collect: age, co-morbid conditions and
total number of medications prescribed. Age is defined as the number of years based on
documented age in the VAMC medical record at the time of chart review. The co-morbid
conditions are operationally defined as the presence of diabetes mellitus, hypertension,
and/or cardiovascular conditions.  Diabetes is operationally defined as a documented
diagnosis of type 1 or type 2 diabetes. Hypertension is operationally defined as a
documented diagnosis of hypertension. Cardiovascular co-morbid condition is
operationally defined as general cardiovascular disease (CVD) including documented
diagnosis of myocardial infarction, coronary insufficiency, angina, ischemic stroke,
hemorrhagic stroke, transient ischemic attack, peripheral artery disease, or heart failure
(D'Agostino et al., 2008). The total number of medications prescribed is defined as the
sum of medications prescribed for outpatient use and is listed as VAMC or non-VAMC
active medications in the patient’s electronic chart at the time of chart review.
Illness Representation
Illness Representation is conceptually defined as the CKD patient’s cognitive
perceptions of and emotional responses to their illness and treatment which determines
how they will respond to the threats imposed by CKD.  The cognitive perceptions, termed
cognitive representations, are composed of five dimensions:  identity, cause, timeline,
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control/cure, and consequences.  The emotional representation scale and the five
cognitive representation dimensions, identity, timeline, control/cure, consequences, and
cause, are operationalized independently and measured with the Revised Illness
Perception Questionnaire (IPQ-R).
The IPQ-R is a psychometrically enhanced version of the original Illness Perception
Questionnaire (IPQ) (Moss-Morris et al., 2002; O'Connor et al., 2008).  The developers
of the original IPQ, were also involved in the revision process (Moss-Morris et al., 2002;
Weinman, Petrie, Moss-Morris, & Horne, 1996).  The revised format of the scale was
improved by separating the causal and identity subscales from the rest of the scale.  The
causal scale range was extended suggesting that causes of many illnesses factor out into
psychological, risk factor, immune system and chance factors.  The changes made in the
identity scale separate the concept of illness identity from the somatization process.  The
original IPQ scale rates symptom severity, while the IPQ-R rates symptoms that the
patient identifies as related to their illness.  Whereas the original IPQ instrument
measured only the cognitive dimension of illness representation, the IPQ-R was extended
to include a subscale to measure the emotional dimension of illness representation.
The reliability of the IPQ-R has been supported in studies with variety of illnesses,
including chronic illnesses such as diabetes and hypertension, and with various racial and
ethnic populations (Broadbent, Petrie, Main, & Weinman, 2006; Hagger & Orbell, 2005;
Kaptein et al., 2007; Marcos, Cantero, Escobar, & Acosta, 2007; Searle, Norman,
Thompson, & Vedhara, 2007).  Moss-Morris et al. (2002) verified factorial structure of
the IPQ-R with principal components analysis in a sample of 711 patients from eight
different illness groups (asthma, n = 86; diabetes, n = 73; rheumatoid arthritis, n = 76;
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chronic pain n = 63; acute pain, n = 35; myocardial infarction, n = 47; multiple sclerosis,
n = 170; and HIV, n = 161).  Analysis also revealed evidence of good internal subscale
reliability with Cronbach’s alpha of:  .84 for timeline, .81 for control/cure, .84 for
consequences, and .88 for emotional responses).  The internal consistency of the identity
subscale was considered less important than the other subscales due to the disparate
symptoms among different illnesses.  However, the Cronbach’s alpha of .75 for the
identity subscale demonstrated a relatively high degree of internal reliability.  A separate
principal components analysis with varimax rotation was conducted on the causal items
and produced four factors which accounted for 57% of the total variance.  Psychological
attributions, the first factor, accounted for 33% of the total variance and had a Cronbach’s
alpha of .86.  The remaining factors, labeled risk factors, immunity, and accident or
chance had Cronbach’s alpha of .77, .67, and .23 respectively for the mixed illness
samples in the Moss-Morris et al. study.  Investigation of the test-retest reliability of the
IPQ-R was carried out with 76 rheumatoid arthritis (RA) patients over a long-term
interim of six-months and with 28 inpatient renal patients in a short-term interim of three
weeks.  Generally good stability was evidenced over both periods with Pearson’s
correlations ranging from .46 to.88 (the only correlation less than .5 was personal
control) for the short-term renal patients and from .35 to .82 (the only correlation less
than .5 was timeline, cyclical) for the long-term RA sample.
For this study, the Illness Representation is measured with the IPQ-R instrument
which has been adapted to reflect items specific to chronic kidney disease patients (see
Appendix F).  The word “illness” has been changed to kidney disease throughout the
instrument.  Additional items were added to the Identity subscale and were tested for
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content validity by five expert reviewers (discussed in more detail below in Identity
section). The authors of the IPQ-R encourage researchers to use the questionnaire, adapt
it to particular illnesses and research settings and share the results with others through the
IPQ website: http://www.uib.no/ipq/ (Moss-Morris et al., 2002).
Discussion of the IPQ-R is divided into three sections, covering the identity and
causal subscales separately from timeline, control/cure, consequences and emotion
response subscales. It is important to note that the Illness Representation construct in this
study is the unique and dynamic perceptions specific to CKD stage 3 patients in the renal
clinics of a VAMC.  There is no overall Illness Representation score, rather the Illness
Representation is described by the scoring of the subscales: identity, cause, timeline,
control/cure, consequences, and emotional response.  Thus, the relationships between the
Illness Representation and medication adherence is drawn from analyses of these same
subscales.
Identity. Identity is conceptually defined as the label assigned to the illness by
the patient, often associated with symptoms they perceive to be related to their illness.
The identity subscale consists of 14 commonly experienced symptoms: pain, sore throat,
nausea, breathlessness, weight loss, fatigue, stiff joints, sore eyes, wheeziness, headaches,
upset stomach, sleep difficulties, dizziness, and loss of strength.  In the IPQ-R
questionnaire for this study, eight items were added to the identity subscale to reflect
symptoms CKD patients may experience and/or associate with their kidney disease:
itching, back pain, problems with urinating, not hungry, bad taste in mouth, bad breath,
legs swelling, and puffy eyes. These symptoms, specific to CKD patients, have been
described by CKD patients in personal clinical encounters with the PI as well as
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described and reported in two recent studies (Agarwal, 2009; Harwood, Wilson, Locking,
Sontrop, & Spittal, 2009).
A panel of five expert clinical and research reviewers was chosen to examine the
content of the IPQ-R adapted identity subscale for evidence of content validity before
using the added items for data collection. These experts were chosen for their research
and clinical experience evidenced by published papers in refereed journals, papers
presented at professional meetings, research experience with the target population and
focus topic, as well as work with theoretical guided research and instrument construction.
Content validity was quantified by using a four-point scale index of content validity
(CVI) measurement tool that is included in Appendix G (DeVon et al., 2007; Grant &
Davis, 1997; Lynn, 1986; Waltz, Strickland, & Lenz, 2005). Newly added items were
rated as valid with a minimum score of .83 CVI (Lynn, 1986). After items were
considered for revision, elimination and addition according to CVI and expert reviewer
communications, three of the 8 proposed new items were retained and added to the
original scale.  Each item added, bad taste in mouth, legs/feet swelling, and puffy eyes,
had a CVI score of 1.  Item wording changes were made based on expert reviewer
recommendations: “breathlessness” was changed to “short of breath”; “wheeziness” to
“wheezing”; “sleep difficulties” to “problems sleeping”; “dizziness” to “dizzy”.  The
final identity subscale contains 17 symptoms.
The instructions for the Identity scale are congruent with the concept of illness
identity, rather than just reporting symptoms.  Theoretically individuals will attempt to
link symptoms to an illness label, therefore, after asking the participants to indicate
whether or not they have experienced a symptom, in a yes or no response, they are then
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asked to indicate, in a yes or no response, if they believe that symptom is related to CKD.
Only the data from the second part of this scale, symptoms related to CKD, are used in
analyses. Coding for the identity scale is: yes = 1; no = 0.  The yes-rated responses
indicate that the participant believes the symptom is CKD related.  Scores are summed to
indicate a heavier or lighter symptom burden relative to CKD, as perceived by the
participants.
Cause. Cause is conceptually defined as the patient’s ideas of CKD etiology.
Cause is operationalized with a subscale of 18 attribution items: stress or worry,
hereditary, germ or virus, diet, chance, poor medical care, pollution, own behavior,
mental attitude, family problems or worries, overwork, emotional state, aging, alcohol,
smoking, accident or injury, personality, and altered immunity. Participants were
instructed to share their own views about the causes of their illness rather than what
medical providers or family members may suggest as causes.  Participants were asked to
rate all 18 attribution items on a 5-point scale, where strongly disagree = 1, disagree = 2,
neither agree nor disagree = 3; agree = 4, and strongly agree = 5, the extent to which they
believe causes such as stress or worry, hereditary factors, germs or viruses, diet are
responsible for their CKD. Initial analysis for these items will start with separate items
grouped according to mean of scores rated for each of the 18 attribution items.  The
causal items are not independently used as a scale. With a sufficient sample size of 90
participants, groups of causal beliefs can be identified with factor analysis (e.g. stress,
lifestyle, environment).  The identified groups are then used as subscales and examined
as possible predictors of coping strategies, which in this study is medication adherence
(Moss-Morris et al., 2002).  The measure also includes a section for the participants to
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rank the top three causes perceived as most important in causing their illness.  They were
invited to choose from the list of 18 causes or list others that are not on the list.  This
information is not included in the analysis, but will be examined for future refinement of
the measurement instrument.
Timeline, control/cure, consequence, and emotion. The timeline, control/cure,
consequence, and emotion subscales include items soliciting patient responses on a
continuum scale from agreement to disagreement that reveal their perceptions of these
illness representation dimensions of CKD.  Their responses are coded as follows:
strongly disagree = 1, disagree = 2, neither agree nor disagree = 3; agree = 4, and strongly
agree = 5.  The mean scores, standard deviations, and ranges for each subscale are
calculated for analysis. For subscales with six items, a maximum of two missing items
are allowed and for the remainder, a maximum of one missing item per subscale are
allowed with the individual participant’s mean inserted for adjustment.
Timeline is conceptually defined as the patient’s perception of duration or pattern
of illness (i.e. acute, chronic, cyclical).  The timeline subscale consists of six items that
measure the patient’s perceived duration of CKD as acute or chronic, using the
aforementioned 5-point scale (i.e. I expect to have this illness for the rest of my life) and
four items that measure the patient’s perceived pattern of recurrence as cyclical (i.e. My
symptoms come and go in cycles).  Items are coded, with reverse coding appropriately so
that higher scores indicate the patient’s perception of CKD being more chronic and more
cyclical in nature and lower scores indicating a perception of CKD being more acute and
less cyclical in nature. Items 18, 21, and 35 are reverse scored.
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Control or cure is conceptually defined as the patient’s perception of how well he
or she can control or cure the illness and how well a treatment can control or cure their
condition.  The control or cure subscales consists of six items that measure the patient’s
perceived ability to personally control/cure their illness (i.e. What I do can determine
whether my chronic kidney disease gets better or worse) and five items that measure
beliefs that treatment can effectively control/cure their illness (i.e. My treatment can
control my chronic kidney disease).  Items are coded, with reverse coding appropriately
so that higher scores indicate the patient’s perception that control or cure is possible
through personal efforts or in response to treatment. Items 32, 34, 36, and 40 are reverse
scored.
Consequence is conceptually defined as the effects the patient associates with the
illness and aspects of life such as social and economical changes.  The consequence
subscale consists of six items that measures the perceived financial, social, family and
self-image impact of CKD on the patient’s life (i.e.  My chronic kidney disease has major
consequences on my life; and My chronic kidney disease has serious financial
consequences).  Items are coded, with reverse coding appropriately so that higher scores
indicate the patient’s perception that CKD carries serious consequences. Item 25 is
reverse scored.
Emotional representations are internal emotional responses to the mental image of
possible dangers imposed by the illness threat, such as depression, fear, anger, or anxiety.
The emotion subscale consists of six items measuring emotional distress specific to
illness (i.e. Having chronic kidney disease makes me feel anxious.) and also found to
predict health related responses (Cameron, Leventhal, & Leventhal, 1993).  Items are
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coded, with reverse coding appropriately so that higher scores indicate strong negative
feelings associated the illness.  Item 53 is reverse coded.
Medication Adherence
Medication adherence is conceptually defined as the patient’s decision to take his
medication as prescribed. An accurate assessment of adherence to medication is essential
to achieve valid, reliable, and generalizable research findings.  One of the greatest
challenges in medication adherence research is the lack of a gold standard measure.
Many years of adherence research producing hundreds of studies and thousands of papers
have yet to answer the question of how best to operationalize the concept of adherence
(DiMatteo, 2004; Garber, Nau, Erickson, Aikens, & Lawrence, 2004). The use of
multiple strategies (i.e. self-report, refill records, pill count, biological markers, electronic
monitoring) with a variety of advantages and disadvantages of each, adds to the challenge
(Balkrishnan & Jayawant, 2007; National Quality Forum, 2005; World Health
Organization, 2003).
Farmer (1999) recommends basing the choice of the method for measuring
adherence to medication “on the usefulness and reliability of the method in light of the
researcher’s or clinician’s goals.  He goes on to state that “specific methods may be more
applicable to certain situations, depending on the type of adherence being assessed, the
precision required, and the intended application of the results.” (p. 1074).  Using more
than one adherence measurement method is considered a more effective analysis of
medication adherence than reliance on one single method, with caution and
understanding of the limitations of each (Cook, Wade, Martin, & Perri, 2005; Farmer,
1999; Steiner, Koepsell, Fihn, & Inui, 1988).  Steiner et al. (1988) posited that pharmacy-
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based measurements of adherence should always be examined and explained taking into
account the patient’s self-reported adherence behavior.  With this in mind, medication
adherence of ACE-I is measured by a self-report questionnaire, the Medication
Adherence Report Scale (MARS) and by pharmacy refill records.
Self-report questionnaire. Using self-report measures of medication adherence is
appropriate, in light of the theoretical framework of the study examining medication
adherence from patient perspectives of their illness and treatment.  Although subjective,
self-report measures are more qualitatively informative than some more objective
adherence measures and can add insight into reasons for lack of therapeutic responses to
prescribed treatment (Choo et al., 1999). Self-report measures have been shown to
overestimate adherence and are more accurate in identifying nonadherence (Cook et al.,
2005; Farmer, 1999; R. E. Grymonpre, Didur, Montgomery, & Sitar, 1998).  In general,
the benefits of self-report questionnaires are that they are inexpensive, easy to use, can be
validated, and may explain patient behavior.  Limitations include being subject to
response bias, overestimate adherence, accuracy is instrument dependent and may lack
continuous data (Balkrishnan & Jayawant, 2007; Farmer, 1999; National Quality Forum,
2005; World Health Organization, 2003). Steps to minimize limitations were taken in the
study.
Several precautions were taken to minimize skewed data resulting from response bias
and overestimation of adherence, the tendency of participants to respond in a socially
desirable manner rather than report actual medication adherence behavior which may be
different than prescribed.  Research indicates response bias can often be found in self-
report studies and several instruments exits to measure social desirability in order to
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control for it.  However, even though the social desirability measures have been used and
published in respectable publications and institutions over the years, when subjected to
rigorous psychometric evaluation, they were found lacking and researchers are cautioned
about using scores from these scales to correct scores from other scales (Barger, 2002; T.
P. Johnson & Fendrich, 2002; Leite & Beretvas, 2005).  For this reason and to avoid
adding to participants’ questionnaire burden, rather than add a social desirability
questionnaire, strategies for reducing socially desirable responses were implemented.
Waltz, Strickland, and Lenz (2005), recommended several strategies for minimizing
socially desirable response:
1. Offering participants two socially desirable options rather than offering only the
extremes of one socially desirable and one socially undesirable option helps to
alleviate the judgmental dimension of the rating system. Avoid dichotomous
formats such as true/false, yes/no.  The five point MARS offers multiple options
with degrees of social desirability or social undesirability (i.e. never, rarely,
sometimes, often, and very often) rather than being dichotomous (i.e. yes, no) or
having one socially desirable option and one socially undesirable option (i.e.
always, never, not applicable).
2. The probability of socially desirable responses increases when respondents are
faced with repeated closely related items in a multi-item single dimension
measure. Using a measurement tool that assesses multiple dimensions of the
variable of interest helps reduce bias. The MARS is designed so that respondents
are not asked to respond to multiple closely related items on the medication
adherence scale.  The five items of the MARS assesses multiple dimensions
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(intentional, unintentional, timing, dosing) of medication non-adherence with
questions that are not closely related, (i.e. how often they forget to take it, take
less, stop taking, miss a dose, and alter their medication dose).
3. Caution must be taken when wording instructions or writing scenarios in order
not to induce a situation in which the information given leads respondents to
answer in a way that will put them in a more favorable light. Clear and concise
wording avoiding ambiguity helps reduce the potential for social desirable
responses. Word items with general rather than personal referents are preferable.
Avoid communicating that the responses will be positively or negatively valued
by the investigator. The MARS was designed to minimize socially desirable
response bias with item wording intentionally written to “diminish the social
pressure on patients to report high adherence…” (Horne & Weinman, 2002, p.
22). The items are written in a fashion validated by adherence researchers in the
early 1990s (Kravitz et al., 1993; Rand & Wise, 1994) that being to elicit reports
of non-adherence.  The scale is prefaced with instructions written in clear and
concise wording with general referents that avoids implications of responses
being judged positively or negatively by the investigator: “Many people find a
way of using their medicines which suits them.  This may differ from the
instructions on the label or from what their doctor has said.  Here are some ways
in which people have said they use their medicines.  For each statement please
check the box that best applies to you.” (Horne & Weinman, 2002, p. 22).
4. Multiple sources used to support the results of a single measure helps reduce
social desirability bias.  Multiple methods of measurement of a phenomena helps
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reduce social desirability bias.  Multiple measures are used to measure medication
adherence in this study, the self-report MARS and chart review Refill Records.
5. Anonymity decreased participants concern for having their responses judged for
social approval. Mailing the survey to the participant’s home to complete
encourages anonymity. The less identifying information, the less social
desirability bias is evidenced.  The participant’s name did not appear on the
questionnaire.  Each questionnaire was numbered and cross referenced with name
securely filed with investigator.  Multiple methods, written and verbal, served as
assurance of information confidentiality and responses not being shared with
patient providers.
To address the limitations of accuracy of self-report instruments and data type, the
self-report measurement instrument for the study was carefully chosen, with
understanding that the accuracy of self-report data is instrument dependent and
continuous is preferable to dichotomous data. The self-report instrument chosen is
congruent with the theoretical framework of the study and has been tested for reliability
and validity among participants with various illnesses, including chronic illness. The tool
is designed and has been implemented in studies with data analysis using both continuous
and dichotomous data.
The MARS self-report measure is also referred to as the MARS-5 in some studies.
This is a relatively new instrument (Horne & Weinman, 2002) and has not been used in
studies with CKD patients. The instrument was chosen for this study because of the close
theoretical underpinnings of patients’ illness representations and intentional decisions to
adhere or not adhere to prescribed medication regimen.  The MARS is written to provide
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an estimation of intentional non-adherence with only one question related to
unintentional non-adherence (how often they forget to take a medication dose) and four
questions focused on the extent that patients follow recommendations in a way they find
more suitable, but different from the way they perceived the provider recommended (how
often they take less, stop taking, miss, and alter their medication dose).  The MARS has
been used in studies of medication adherence among 1674 patients including those with
migraine headaches (Hedenrud, Jonsson, & Linde, 2008), chronic obstructive pulmonary
disease (COPD) (George, Kong, Thoman, & Stewart, 2005), inflammatory bowel disease
(IBD) (Ediger et al., 2007), familial hypercholesterolemia (Senior et al., 2004), chronic
pain (Kendrew, Ward, Buick, Wright, & Horne, 2001), asthma (Menckeberg et al., 2008)
and general pharmacy clients with prescribed medications (Mårdby, Åkerlind, &
Jörgensen, 2007).  Of these studies, internal reliability was reported with a Cronbach’s
alpha of 0.68 by Hedenrud et al. (2008), 0.73 by Mardby et al. (2007), and 0.81 by
Menckeberg et al. (2008).  The original MARS was developed as a nine item measure to
assess non-adherence to preventive asthma inhalants (Horne & Weinman, 2002) and was
utilized in a later asthma study by (Ohm & Aaronson, 2006), both with a Cronbach’s
alpha of 0.85. Barnes et al. (2004) adapted the MARS by adding two culturally
appropriate questions to the original nine item scale in their study of Tongan and
European diabetes patients, with a Chronbach’s alpha of 0.79.  The five-item MARS
excludes the asthma specific questions (i.e. I only use it [inhaler] when I feel breathless)
and in a non-threatening way asks the participant to rate how often they forget to take,
take less, stop taking, miss and alter their medication dose on a 5-point scale where 1 =
very often, 2 = often, 3 = sometimes, 4 = rarely, and 5 = never.  The responses are
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summed for each of the five items for a total range of 5 to 25.  Higher levels of self-
reported adherence are indicated with higher scores.
Previous studies have scored the MARS as a continuous or dichotomous variable.
Some studies reported the MARS scores to be skewed toward higher values and selected
to dichotomize the data with a priori cut-off points (Mårdby et al., 2007).  Others chose
cut-off points close to the mean value (Ediger et al., 2007).  The MARS items are
delivered in a manner in which the response options are congruent with a continuum of
adherence behavior rather than an explicit adherent or non-adherent label (Ediger et al.,
2007; Horne & Weinman 2002).  Subjects are able to describe their typical medication
adherence pattern even when they are not currently taking the medication rather than give
an account of their medication adherence behavior over a specific timeframe.
Pharmacy refill records. Findings from using pharmacy refill records are
encouraging in that there is consistency among studies using this method, and there are
useful associations with the results derived from these measures and clinical outcomes in
specific illnesses or medications (R. Grymonpre, Cheang, Fraser, Metge, & Sitar, 2006;
Steiner & Prochazka, 1997).  It is also generally acknowledged that measurement using
pharmacy records are measuring refill patterns and not actual drug-taking behaviors
(Christensen et al., 1997; Hess, Raebel, Conner, & Malone, 2006; Steiner & Prochazka,
1997).  However, R. Grymonpre et al. (2006), in their study of medication adherence in
older persons, found concordance between the rates with which patients refilled their
medications and the rate that they consumed them.  Refill records have been found to be
positively related with direct measurements such as serum (r = 0.42, p = 0.005) and urine
(r = 0.45, p<0.05) drug levels, self-reported medication consumption (r = 0.47, p <
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0.001), and pill counts (r = 0.68, p < 0.001) (Steiner and Prochazka, 1997; Choo et al.
1999).
In general, the benefits of using pharmacy refill records includes: records accurate
frequency and timeliness of refills; is inexpensive; avoids Hawthorne Effect; is non-
invasive; and provides long-term data for large populations.  Some of the limitations
include: lack of information on quantity taken or timing of intake; difficult to classify
unique refill patterns; problems with multiple pharmacies used; validity depends on
completeness of database; assumption that a filled prescription equates to a prescription
taken; and using electronic records requires database knowledge (Balkrishnan &
Jayawant, 2007; Farmer, 1999; Vermeire et al., 2001; World Health Organization, 2003).
Steps to minimize limitations have been used in this study.
The limitation of pharmacy refill records lacking information on quantity taken or
timing of intake is more applicable to medications with difficult to measure exact doses
(i.e. topical, drops, liquid) or when the timing of oral consumption is imperative (i.e.
asthma inhalants, seizure medications).  Pharmacy refill records are suitable for the
proposed study of ACE-I since they are in oral pill form, and the timing of medication
consumption is not a crucial factor. Unique refill patterns are problematic when using
refill records as a measurement of adherence.  Pharmacy refill records are appropriate for
this study, since ACE-I are prescribed on a structured, consistent pattern and not on an
“as needed” basis.
Multiple pharmacies used are not a limitation in this study. The participants in
the study are veterans most of whom receive their medications from the centralized
VAMC pharmacy.  The limitations of pharmacy refill records depending on the
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completeness of the database, is reduced by the Veteran’s Health Information System
Technology Architecture (VISTA) database,  the well established computerized medical
records system used by the VAMC (Morgan, 2005; Wannemacher, Schepers, &
Townsend, 2002).  The VAMC electronic pharmacy registry records the name of the
drug, the dosage of each pill, the date of issue of the prescription, dosage instruction (i.e.
pills per dose per times a day) and the quantity of pills released for a specified number of
days.
The assumption that a filled prescription equates to a prescription taken is a well
known limitation of pharmacy refill records.  This limitation is also recognized in pill
count and electronic monitoring devices, where the absence of a pill or the opening of the
electronic pill bottle cap is assumed to equate consumption of the medication. Although
this limitation can not be eliminated, there are studies with findings suggesting
concordance between filled prescriptions and consumed medications (R. Grymonpre et
al., 2006; Steiner & Prochazka, 1997) and with direct measurements such as serum (r =
0.42, p = 0.005) and urine (r = 0.45, p <0.05) drug levels (Steiner and Prochazka, 1997).
The limitation of electronic records requiring knowledge of database is reduced in the
study because the PI has a working knowledge of the VAMC electronic records and
database needed to successfully acquire pharmacy refill information for the proposed
study.
Prescription refill records are used in conjunction with patient self-report to
measure medication adherence.  Medication adherence using pharmacy refill records
have become more prominent with growth in computerized records systems (Christensen
et al., 1997; Farmer, 1999; Karve et al., 2008).  Even though pharmacy refill records have
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been validated using biochemical assays, pill counts, and patient reports, there is no gold
standard refill adherence measurement.
The Medication Possession Ratio (MPR) derived from VAMC electronic
pharmacy records data will be used as a medication adherence measure in the proposed
study. This measurement method reveals both length of therapy and gaps in therapy over
a specified period of time in continuous measurement form.  The MPR was chosen after
reviewing the literature on pharmacy refill record medication adherence measures,
especially with samples drawn from renal disease, diabetes, and hypertensive
populations.  The review of literature on pharmacy refill records was complicated by the
inconsistent terminology used where a common term may have different definitions or
mathematical expressions.  On the other hand, there were also common definitions or
mathematical expressions used for different terms.
Validity testing of pharmacy refill records suggests that the MPR is a valid
adherence measure and that it is the term that should be applied across medication
adherence studies using the formula:  Number of days supply in index period divided by
number of days in the study period (Cooper, Hall, Penland, Krueger, & May, 2009; Hess
et al., 2006; Karve et al., 2008).  MPR (or the same formula with a different term) is
widely used in medication adherence studies using pharmacy records, and more
important to the proposed study, is used in many of the studies examining medication
adherence with ACE-I, and in studies with samples drawn from renal disease, diabetes,
and hypertension patient populations (Cooke & Fatodu, 2006; R. Grymonpre et al., 2006;
Hess et al., 2006; Karve et al., 2008; Mattke et al., 2007; Roe et al., 2000; Steiner &
Prochazka, 1997).  The MPR is operationally practical for research and for clinical
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purposes in the VAMC and using the MPR term and formula in this study will contribute
to the standardization of medication adherence terminology thus contributing to
comparability and combining of research results (Cooper et al., 2009; Cramer, Benedict,
Muszbek, Keskinaslan, & Khan, 2007).
Pharmacy records were examined for cohort dates of ACE-I starting 12
months or earliest date less than 12 months before study participation date as suggested
by Karve et al. (2008).  Participant adherence with ACE-I therapy was measured using
the MPR formula: Number of days supply in index period divided by number of days in
the study period. The MPR is truncated at 100% to prevent overestimation of MPR that
does not equate with non-adherence behaviour (i.e. lost medication replacement, change
in prescription, vacation extras). A one month run-out (grace) period is allowed for
pharmacy record entry lag; therefore, the measure is calculated one month after the last
refill record for each patient. In the case of hospitalization, it is assumed that the patient
was perfectly adherent during hospitalizations in the index period. For the purposes of
this study, MPR = Released / Issued.  Released = Number of days ACE-I was supplied to
patient in index period (filled within 12 months from start of study).  Issued = days within
12 months of start of study in which the ACE-I was available by prescription to the
patient.  The number of issued days is calculated by subtracting the time between date the
prescription was issued and the date of cancellation or index date if prescription is not
canceled before then.  The index date is the date of the start of study (initial survey
packets mailed), August 10, 2010, therefore, the index period would be 365 days before,
August 11, 2009.  Allowing a grace period of 31 days is common in medication refill
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literature and is allowed in this study.  The end date for the grace period for this study is
September 10, 2010.
The MPR results are reported as a percentage on a continuum from 0% to 100%
adherence rather than the often used cut-offs of 80% or greater equating to adherence and
20% or less equating to non-adherence.  When there is no scientific justification for cut-
off points, using continuous rather than categorical data is preferable (Cramer et al.,
2007; Steiner & Prochazka, 1997).
Preliminary Analysis
Quantitative data were collected, coded, entered into a database and analyzed
using the Statistical Package for Social Sciences (SPSS) version 18.0 (SPSS Inc.,
Chicago, IL).  Data were screened for errors prior to analysis. Identified errors were
linked to appropriate data files, corrected then screened again in attempt to obtain error
free data. Descriptive statistics, mean, median, standard deviation, and range for all
continuous variables and subscale items were examined with raw data before reversal or
recoding (Table 1); multi-item questionnaires, IPQ-R and MARS, were tested for internal
consistency reliability using Cronbach’s coefficient alpha.
Reliability
Support for internal consistency is recognized with a Cronbach’s alpha of 0.70 or
greater (Netemeyer, Bearden, & Sharma, 2003). If Cronbach’s alpha is less than 0.70,
item deletion was considered as well as Corrected Item-Total Correlation, especially for
scales with a small number of items.  As shown in Table 1, the Cronbach’s alpha for the
IPQ-R of 0.85 with subscales ranging from 0.76 to 0.86, before factoring the cause
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subscale, indicates adequate internal consistency.  The IPQ-R Cause subscale was
examined before and after factor analysis.
Table 1
IPQ-R Subscale Item Statistics and Chronbach's Alpha
Scale (# of Items)
Possible
Range Mean SD Alpha
IPQ-R Questionnaire 0.85
Timeline acute - chronic (6) 0.86
short time 1 - 5 2.16 1.11
permanent 1 - 5 3.73 1.17
long time 1 - 5 3.69 1.16
pass quickly 1 - 5 2.02 1.03
rest of life 1 - 5 3.78 1.16
improve in time 1 - 5 2.50 0.94
Consequences (6) 0.81
Serious condition 1 - 5 3.72 1.14
Major consequences 1 - 5 3.54 1.17
Not much effect on life 1 - 5 2.46 1.24
Affects how others see me 1 - 5 2.34 0.96
Financial 1 - 5 2.91 1.13
Difficulties for those close to me 1 - 5 2.63 1.05
Personal Control (6) 0.86
A lot I can do 1 - 5 3.36 0.98
I determine 1 - 5 3.64 0.85
Course depends on me 1 - 5 3.46 1.06
Nothing I do affects my disease 1 - 5 2.21 0.97
I have power to influence disease 1 - 5 3.21 1.04
My actions have no affect 1 - 5 2.34 0.97
Treatment Control (5) 0.76
Little can be done 1 - 5 2.81 0.97
Treatment effective in curing 1 - 5 2.83 0.97
Negative affects can be avoided 1 - 5 3.22 0.87
Medications can control 1 - 5 3.24 0.86
No treatment can help 1 - 5 2.58 0.96
Possible Range 1 = Strongly disagree to 5 = Strongly agree
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Table 1 continued
IPQ-R Subscale Item Statistics and Chronbach's Alpha
Scale (# of Items)
Possible
Range Mean SD Alpha
IPQ-R Questionnaire
Timeline cyclical (4) 0.83
Change day-to-day 1 - 5 2.41 0.81
Comes and go in cycles 1 - 5 2.62 0.89
Unpredictable 1 - 5 2.82 0.95
Gets better and worse 1 - 5 2.80 0.89
Emotional Representation (6) 0.76
Depressed 1 - 5 2.76 0.99
Upset 1 - 5 2.49 0.92
Angry 1 - 5 2.46 0.83
Does not worry 1 - 5 2.68 0.98
Anxious 1 - 5 2.83 0.91
Afraid 1 - 5 2.78 0.86
Cause 0.81
Stress/Worry 1 - 5 2.94 1.05
Heredity 1 - 5 2.63 1.13
Germ or virus 1 - 5 2.62 3.00
Diet or eating habits 1 - 5 3.32 0.98
Chance or bad luck 1 - 5 2.49 0.93
Poor medical care in past 1 - 5 2.83 1.07
Pollution or environment 1 - 5 2.69 0.91
Own behavior 1 - 5 2.97 0.98
Negative mental attitude 1 - 5 2.37 0.82
Family problems and worries 1 - 5 2.52 0.92
Overwork 1 - 5 2.53 0.91
Emotional state 1 - 5 2.48 0.90
Aging 1 - 5 3.39 0.99
Alcohol 1 - 5 2.36 1.12
Smoking 1 - 5 2.49 1.13
Accident or injury 1 - 5 2.41 0.97
Personality 1 - 5 2.25 0.80
Altered immune system 1 - 5 2.77 1.00
Identity:
Symptoms related to kidney disease N/A N/A 0.84
Possible Range 1 = Strongly disagree to 5 = Strongly agree
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Table 1 continued
IPQ-R Subscale Item Statistics and Chronbach’s Alpha
Scale (# of Items)
Possible
Range Mean SD Alpha
Cause Subscale Factors
Psychological (7) 1 - 5 2.55 0.92 0.84
Lifesyle (3) 1 - 5 2.55 1.14 0.73
Environmental (4) 1 - 5 2.65 0.97 0.60
Behavioral (2) 1 - 5 3.15 0.97 0.63
Destiny (2) 1 - 5 2.95 0.90 0.50
Study participants responded to the 18 item Cause subscale regarding their beliefs
of the cause of their kidney disease.  A separate principal components analysis (PCA)
with varimax rotation was conducted on the causal items and produced five components
with eigen values greater than 1 (Table 2) which accounted for 63% of the total variance.
Nunnally and Bernstein (1994) recommend checking the data to make sure it warrants
factoring.  Sample size and strength of relationship among items are important
considerations.  Although there is disagreement in the literature about the appropriate
sample size for factoring, the general consensus is the larger the better.  The goal of the
current study was to have a minimum of 90 responses to the cause subscale which would
equal five responses per item.  The actual response rate for the cause subscale was 88
slightly below the goal of 90.  As recommended by Nunnally and Bernsetin, prior to
performing PCA, the data was assessed for suitability for factor analysis.  The correlation
matrix revealed many coefficients of 0.3 or above.  The Kaiser-Meyer-Oklin value was
0.71, exceeding the recommended value of 0.6, and the Barlett’s Test of Sphericity
reached statistical significance.  These results indicated that the Cause subscale was
suitable for factoring. Five factors were produced and labelled as Psychological,
Lifestyle, Environment, Behavioral, and Destiny. Psychological causes, the first factor,
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accounted for 27.87% of the total variance and had a Cronbach’s alpha of 0.84 (Table 1).
Lifestyle causes, the second factor, accounted for 10.95% of the total variance and had a
Cronbach’s alpha of 0.73.  The remaining factors labelled environmental, behavioural,
and destiny had a Cronbach’s alpha of 0.60, 0.63, and 0.50 respectively for this study
sample. Based on recommendations by Netemeyer et al. (2003), further investigation
was performed on the factors with Cronbach’s alpha less than 0.70.  The Environmental
factor had a Cronbach’s alpha based on standardized items of 0.60 with only one item-
total correlation below 0.3 (altered immune system 0.28) and the mean inter-item
correlation of 0.27. The behavioural and destiny factors each had only two loadings and
also had Cronbach’s alphas based on standardized items of less than 0.70; all corrected
item-total correlations were less than 0.30; and the mean inter-item correlation was 0.17.
Three factors, psychological, lifestyle, and environment were retained for further
analysis.  Two factors, behavioural, and destiny were not used in further analyses.
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Table 2
IPQ-R Cause Subscale Factor Loadings
The Cronbach’s alpha coefficient for the MARS scale was 0.64 which is below
the recommended 0.70 (Table 3). Investigation of items revealed an increase in the alpha
coefficient to 0.68 if item number 77 (I forget to take it) was deleted.  This is
understandable since this is a small scale of five items and the item in question is the only
item of the five items that refers to unintentional nonadherence, whereas the other four
Item
# Original Item Name
Cause Factors
1 2 3 4 5
50 Cause - emotional state .815
48 Cause - family problems and worries .805
47 Cause - negative mental attitude .785
39 Cause - stress/worry .661
55 Cause - personality .647
49 Cause - overwork .539
44 Cause - poor medical care in past .462
52 Cause - alcohol .873
53 Cause - smoking .803
40 Cause - heredity .608
41 Cause - germ or virus .676
45 Cause - pollution or environment .648
56 Cause - altered immune system .637
54 Cause - accident or injury .621
42 Cause - diet or eating habits .824
46 Cause - own behavior .658
43 Cause - chance or bad luck .790
53 Cause – aging .664
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items refer to intentional nonadherence.  Based on recommendations by Netemeyer et al.
(2003), further investigation was performed and revealed a Cronbach’s alpha based on
standardized items of 0.73; all corrected item-total correlations were greater than 0.30;
and the mean  inter-item correlation was 0.35.  Based on these findings, and theoretical
and clinical importance of all five items in examination of medication adherence with
ACE-I in this study population, it was decided that the MARS with all five questions
would be used for analyses.
Table 3
MARS Subscale Item Statistics and Chronbach's Alpha
Scale (# of Items)
Possible
Range Mean SD
Mean
inter-item
correlation Alpha
Alpha on
Standardized
Items
MARS (5) 0.35 0.64 0.73
Forget 1 - 5 4.39 0.90
Change dose 1 - 5 4.88 0.54
Take less 1 - 5 4.85 0.67
Stop taking 1 - 5 4.93 0.25
Miss a dose 1 - 5 4.87 0.48
Possible Range 1 = Strongly disagree to 5 = Strongly agree
Missing Values
Missing values were examined to understand the type of missing data and, if
needed, the appropriate adjustment made. As seen in Table 4, only two Individual and
Clinical Characteristic variables had greater than 5% missing data, ethnic origin (10.9%)
and time since diagnosed with kidney disease (12%).
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Table 4
Missing Data on Individual and Clinical Characteristics (Total N = 92)
Variables Valid N % Missing N %
Age 92 100 0 0
Gender 92 100 0 0
Race 90 97.8 2 2.2
Ethnic origin 82 89.1 10 10.9
Education 89 96.7 3 3.3
Financial status 89 96.7 3 3.3
Live with partner 90 97.8 2 2.2
Live with relative with ESRD/dialysis 90 97.2 2 2.2
Co-morbid conditions 92 100 0 0
Time since diagnosed with kidney disease 81 88 11 12
Number of prescribed medications 92 100 0 0
All IPQ-R subscale items had less than 5% missing values except for the Cause
and Identity subscales.  Missing values in the Cause subscale items ranged from 3.3 to
8.7%. With the exception of the identity subscale, there was acceptable missing data in
the IPQ-R questionnaire (Table 5).
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Table 5
Missing Values on IPQ-R Subscales (Total N = 92)
Subscale/Items Valid N % Missing N %
Timeline acute/chronic
Short time 89 96.7 3 3.3
Permanent 91 98.9 1 1.1
Long time 89 96.7 3 3.3
Pass quickly 89 96.7 3 3.3
Rest of life 90 97.8 2 2.2
Improve in time 90 97.8 2 2.2
Consequences
Serious condition 89 96.7 3 3.3
Major consequences 89 96.7 3 3.3
Not much effect 90 97.8 2 2.2
Affect how others see me 90 97.8 2 2.2
Financial 91 98.9 1 1.1
Difficulties for those close to me 91 98.9 1 1.1
Personal Control
A lot I can do 90 97.8 2 2.2
I determine 91 98.9 1 1.1
Course depends on me 92 100 0 0
Nothing I can do 90 97.8 2 2.2
Power to influence disease 89 96.7 3 3.3
My actions have no affect 90 97.8 2 2.2
Treatment Control
Little can be done 91 98.9 1 1.1
Treatment effective cure 90 97.8 2 2.2
Negative effects can be avoided 91 98.9 1 1.1
Medications can control 91 98.9 1 1.1
No treatment can help 90 97.8 2 2.2
Timeline Cyclical
Change day-to-day 90 97.8 2 2.2
Comes and goes in cycles 89 96.7 3 3.3
Disease unpredictable 91 98.9 1 1.1
Gets better and worse 92 100 2 2.2
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Table 5 continued
Missing Values on IPQ-R subscales  (Total N = 92)
There was a marked difference of missing values on the Identity subscale with
more respondents answering “yes” or “no” to experiencing a symptom as opposed to
answering whether or not they perceived that symptom being related to kidney disease
(Tables 6 and 7). Initial analysis of the identity scale revealed a large range of non-
random missing responses to the section asking the participants to indicate if they
perceived the symptom to be related to kidney disease.  This was an important finding
since that is the section of the identity subscale that is used for analyses.  An investigation
Subscale/Items Valid N % Missing N %
Emotional Representation
Depressed 91 98.9 1 1.1
Upset 89 96.7 3 3.3
Angry 89 96.7 3 3.3
Does not worry 88 95.7 4 4.3
Anxious 88 95.7 4 4.3
Afraid 88 95.7 4 4.3
Cause 85 92.4 7 7.6
Stress/worry 88 95.7 4 4.3
Heredity 85 92.4 7 7.6
Germ or virus 85 92.4 7 7.6
Diet or eating habits 84 91.3 8 8.7
Chance or bad luck 87 94.6 5 5.4
Poor medical care in past 88 95.7 4 4.3
Pollution or environment 88 95.7 4 4.3
Own behavior 87 94.6 5 5.4
Negative mental attitude 88 95.7 4 4.3
Family problems and worries 85 92.4 7 7.6
Overwork 86 93.5 6 6.5
Emotional state 87 94.6 5 5.4
Aging 89 96.7 3 3.3
Alcohol 87 94.6 5 5.4
Smoking 87 94.6 5 5.4
Accident or injury 89 96.7 3 3.3
Personality 86 93.5 6 6.5
Altered immune system 85 92.4 7 7.6
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of responses to the identity scale often revealed that if an individual had not experienced
the symptom, they did not answer the second part of the item, asking if the symptom they
experienced was believed to be related to their kidney disease.  It is understandable that
they may have believed that since they did not have the symptom, it was not necessary to
address the second statement.  Since the intent of the identity subscale is to evaluate the
perceptions of participants’ contribution of an experienced symptom to their kidney
disease, further exploration was required.  Post hoc analysis was performed to filter only
those participants who answered “Yes” they had experienced a symptom since knowing
they had kidney disease, and then frequency statistics was run on the filtered data to
investigate if they answered whether or not they believed the symptom was related to
their kidney disease.  As Table 7 indicates, there are fewer missed responses with the
filtered data; however the valid number of cases is reduced substantially. The Identity
subscale will be used for descriptive purposes only and will be deleted from further
analysis.
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Table 6
Missing Values of Identity Subscale:  Symptoms Experienced (N = 92)
Symptoms Experienced Valid N % Missing N %
Pain 85 92.4 7 7.6
Sore throat 83 90.2 9 9.8
Nausea 82 89.1 10 10.9
Short of breath 86 93.5 6 6.5
Weight loss 83 90.2 9 9.8
Fatigue 85 92.4 7 7.6
Stiff joints 85 92.4 7 7.6
Sore eyes 83 90.2 9 9.8
Wheezing 82 89.1 10 10.9
Headaches 84 91.3 8 8.7
Upset stomach 83 90.2 9 9.8
Problem sleeping 86 93.5 6 6.5
Dizzy 83 90.2 9 9.8
Loss of strength 86 93.5 6 6.5
Bad taste in mouth 84 91.3 8 8.7
Legs/feet swelling 85 92.4 7 7.6
Puffy eyes 81 88 11 12
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Table 7
Missing Values on IPQ-R Identity Subscale (Total N = 92)
UNFILTERED* FILTERED*
Symptoms related
to kidney disease
Valid
N %
Missing
N %
Valid
N %
Missing
N %
Pain 54 58.7 38 41.3 31 91.1 3 8.8
Sore throat 49 53.3 43 46.7 17 100 0 0
Nausea 44 47.8 48 52.2 17 85 3 15
Short of breath 38 41.3 38 41.3 15 65.2 8 34.8
Weight loss 47 51.1 45 48.3 46 97.9 1 2.1
Fatigue 57 62 35 38 56 82.3 12 17.6
Stiff joints 59 64.1 33 35.9 53 85.5 9 14.5
Sore eyes 48 52.2 44 47.8 18 81.8 4 18.2
Wheezing 47 51.1 45 48.9 21 87.5 3 12.5
Headaches 48 52.2 44 47.8 27 81.8 6 18.2
Upset stomach 50 54.3 42 45.7 25 83.3 5 16.7
Problem sleeping 57 62 35 38 46 85.2 8 14.8
Dizzy 49 53.3 43 46.7 32 78 9 22
Loss of strength 56 60.9 36 39.1 51 83.6 10 16.4
Bad taste in mouth 46 50 46 50 19 86.4 3 13.6
Legs/feet swelling 59 64.1 33 35.9 47 90.4 5 9.6
Puffy eyes 47 51.5 45 48.9 16 88.9 2 11.1
*Only computed among patients who answered “Yes” to having experienced the
symptom
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Examination of the values missing for the MARS items (Table 8) revealed less
than desirable results with a range from 16 - 18 (17.4 - 19.6 %). Further analysis was
employed to examine difference between observations.
Table 8
Missing Values on MARS (N = 92)
MARS Items Valid n % Missing n %
Forget 76 82.6 16 17.4
Change dose 75 81.5 17 18.5
Take less 75 81.5 17 18.5
Stop taking 74 80.4 18 19.6
Miss a dose 75 81.5 17 18.5
After examination of missing values from variables, further examination of the
number of missing observations was indicated to identify patterns of missing data. When
considering missing data, it must be determined if observations with missing values are
systematically different from observations with observed values.  If such a difference
exists, bias can be easily introduced. Therefore, an analysis was employed (through the
use of chi-squares and t-tests) in order to decipher if study participants that completed
and did not complete the MARS scale differed by individual and clinical characteristics,
as well as the cognitive representation and emotional response scales. This procedure
was not deemed necessary for missing values regarding the cognitive representation and
emotional response scales, due to the fact that only 2 - 4 (2% - 4%, respectively) study
participants failed to provide sufficient data for these scales, relative to 20 (21.7%) of
study participants on the MARS scale. For subscales with six items, a maximum of two
missing items were allowed and for the remainder, a maximum of one missing item per
subscale are allowed to be considered sufficient data. In these cases the missing values
are replaced by the individual participant’s mean score for that subscale.
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Tables 9 and 10 indicated study participant Response/Non-response on the MARS
did not vary significantly by the Individual Characteristics (Age, Education, Financial
Status, Race and Living with a Partner). However, Response/Non-response on the
MARS varied significantly by the clinical characteristic number of medications, t(90) =
2.85, p < .01. All other clinical characteristics were unrelated to response.
Table 9
T-test Analysis of Study Participant Response/Non-response on the MARS by the
Individual (Age, Education, and Financial Status) and Clinical Characteristics (Length of
Time Since CKD Diagnosis and Number of Medications)
Possible
Individual Characteristic n M (SD) Range t
Age
Responded 72 68.25 (8.62) NA -1.61
Did not respond 20 72.05 (11.68) NA
Education (years)
Responded 69 13.97 (3.02) 1.00 - 19.00 .29
Did not respond 20 13.75 (2.99) 1.00 - 19.00
Clinical Characteristic
Length of Time (months) since CKD Diagnosis
Responded 63 72.76 (86.57) 0 - 480 -.17
Did not respond 18 77.50 (109.37) 0 - 480
Number of Medications
Responded 72 12.86 (5.42) NA 2.85**
Did not respond 20 10.25 (2.94) NA
**p <.01
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Table 10
Chi-square Analysis Examining of Study Participant Response/Non-response on the
MARS by the Individual (Race and Living with a Partner) and Clinical (Co-morbidity
and Family history of ESRD/dialysis) Characteristics
Individual Characteristic n Responded Did Not Respond X2
Race
Caucasian/White 80 63 (78.8%) 17 (21.3%) .01
African-American/Other 10 8 (80.0%) 2 (20.0%)
Living with Partner
Yes 54 43 (79.6%) 11 (20.4%) .04
No 36 28 (77.8%) 8 (22.2%)
Financial Status
Not enough 23 17 (73.9%) 6 (26.1%) .46
Just enough 44 35 (79.5%) 9 (20.5%)
Comfortable level 22 18 (81.8%) 19 (21.3%)
Clinical Characteristic
Co-morbidity
DM, HTN, or CVD 11 10 (90.9%) 1 (9.1%) 1.86
Combination of two 49 36 (73.5%) 13 (26.5%)
Combination of three 32 26 (81.3%) 6 (18.8%)
Living with Partner
Yes 7 5 (71.4%) 2 (28.6%) .25
No 83 66 (79.5%) 17 (20.5%)
Table 11 indicated study participant Response/Non-response on the MARS varied
significantly by the cognitive representation personal control, t(89)=2.09, p<.05. All
other cognitive and emotional representation scale variables were unrelated to response.
Thus, analysis indicated a slight bias among study participants regarding Response/Non-
response on the MARS scales in terms of the number of medications and personal control
variables.
99
Table 11
T-test Analysis Examining of Study Participant Response/Non-response on the MARS by
the Cognitive and Emotional Representation Scales
Possible
Scale n M (SD) Range t
Timeline (acute/chronic)
Responded 72 3.78 (.84) 1.00-5.00 .70
Did not respond 19 3.62 (.84) 1.00-5.00
Consequences
Responded 72 3.18 (.78) 1.00-5.00 1.52
Did not respond 19 2.87 (.78) 1.00-5.00
Personal Control
Responded 72 3.59 (.80) 1.00-5.00 2.09*
Did not respond 19 3.17 (.66) 1.00-5.00
Treatment Control
Responded 72 3.19 (.62) 1.00-5.00 .23
Did not respond 19 3.15 (.86) 1.00-5.00
Timeline (cynical)
Responded 72 2.63 (.67) 1.00-5.00 -1.02
Did not respond 19 2.82 (.88) 1.00-5.00
Cause:  Psychological
Responded 70 2.57 (.63) 1.00-5.00 .51
Did not respond 19 2.48 (.72) 1.00-5.00
Cause:  Lifestyle
Responded 70 2.50 (.94) 1.00-5.00 .26
Did not respond 19 2.44 (.73) 1.00-5.00
Cause:  Environment
Responded 70 2.50 (.94) 1.00-5.00 1.32
Did not respond 19 2.44 (.79) 1.00-5.00
Emotional Response
Responded 72 2.80 (.60) 1.00-5.00 .52
Did not respond 18 2.71 (.70) 1.00-5.00
* p = <.05
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Normality of Variables
Independent variables. Prior to analysis, data were screened for the assumptions
of normality, homoscedasticity, linearity, and presence of outliers.  Each variable was
tested individually and multivariate normality was assumed with individual normality.
Individual and clinical characteristics. As seen in Table 12, normality of
individual and clinical characteristic variables were explored with descriptive statistics
and with visual examination of histograms, QQ Plots and Box Plots.  The results indicate
an acceptable degree of skewness and kurtosis for age, education, family income, live
with partner, time since diagnosed with kidney disease, co-morbid conditions and number
of prescribed medications for use in further analyses.
The subject’s responses on the original questionnaire were examined for subscales
with extreme outliers.  Outlier scores were checked for errors and if found, corrected.  If
Outlier scores were genuine, then the original mean was compared to the 5% trimmed
mean.  The trimmed mean is obtained by removing the top and bottom 5 percent of cases
and recalculated for a new mean value.  The original mean and the 5% trimmed mean
should be compared to evaluate whether the outliers have a large influence on the mean.
If the mean values are very different, the outliers have a large influence on the mean
(Duffy & Jacobsen, 2001).  As noted in Table 12, the mean and the 5% trimmed means in
the subscales were all very similar for age, education years, family income, lived with
partner, co-morbid conditions and number of prescribed medications indicating that the
outliers will not have a large influence on the mean.  These variables also have acceptable
skewness and kurtosis; therefore these cases will be retained for further analyses.
Gender and ethnic origin is not suitable for further analysis at this point.  The
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outliers indicated in the QQ and Box Plots greatly affect the mean so that if the outliers
are removed only one group is left in gender and ethnic origin (male, non-
Spanish/Hispanic).  These variables also exhibit extreme skewness or kurtosis.  The time
since being diagnosed with kidney disease variable has acceptable degrees of skewness
and kurtosis, however there is a large difference between the Mean and the 5% Trimmed
Mean, indicating that the outliers greatly affect the Mean and thus would pose problems
for further analysis. This is a theoretically and clinically important variable and was
adjusted by collapsing into percentiles around the median in order to be acceptable for
use in further analysis.
Table 12
Individual and Clinical Characteristics Tests for Normality
Variable Mean
5%TrimmedMean Skewness Kurtosis
Age 69.08 69.06 .235 -.697Gender N/A N/A 9.59 92
Ethnic Origin N/A N/A -1.59 25.75
Race N/A N/A -2.52 5.15
Education Years 13.92 13.89 .323 -1.10
Family Income N/A N/A .02 -1.01
Live with Partner N/A N/A .415 -1.87
Lived with ESRD relative N/A N/A -3.21 8.47
Diagnosed with kidney disease 73.81 61.85 .812 1.19
Co-morbid conditions 5.23 5.33 -.82 -.27
# prescribed medications 12.29 12.07 .812 1.19
Illness representation subscales. As seen in Table 13, normality of subscales
were explored with descriptive statistics and with visual examination of histograms, QQ
Plots and Box Plots. The results indicate an acceptable degree of skewness and kurtosis
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for use of these subscales for further analyses.  The original questionnaire responses were
examined for subscales with extreme outliers.  Outlier scores were checked for errors and
if found, corrected.  If Outlier scores were genuine, then the original mean was compared
to the 5% trimmed mean.  As noted in Table 13, the mean and the 5% trimmed means in
the subscales were all very similar, therefore all cases in the subscales will be retained for
further analyses.
Table 13
IPQ-R Summed Subscales Test for Normality
Subscale PossibleRange Mean
5%TrimmedMean Skewness Kurtosis
Timeline acute/chronic 6 - 30 22.69 22.98 -.61 .41
Consequences 6 - 30 18.66 18.76 -.22 -.45
Personal Control 6 - 30 21.13 21.17 -.18 -.51
Treatment Control 5 - 25 15.91 15.97 -.45 .90
Timeline Cyclical 4 - 20 10.68 10.75 -.39 .124
Emotion Representation 6 - 30 16.68 16.64 .25 .25
Total Cause 18 - 90 49.10 49.58 -.87 .62
Cause Factored
Psychological 7 - 35 17.95 18.10 -.625 .241
Lifestyle 3 - 15 7.49 7.40 .311 -.002
Environmental 4 - 20 10.62 10.55 .385 1.23
Behavioral 2 - 10 6.29 6.35 -.525 .516
Destiny 2 - 10 5.90 5.99 -.767 .512
Dependent variable. As seen in Table 14, normality of the MARS subscale was
explored with descriptive statistics and with visual examination of histograms, QQ Plots
and Box Plots. The results indicate a violation of the assumption of skewness. Five
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outliers were noted.  The original questionnaire responses were examined for extreme
outliers.  Outlier scores were checked for errors and if found, corrected.  The Total
MARS mean was compared to the 5% trimmed mean.  The MARS mean and the 5%
trimmed mean in the subscale were very similar, indicating that the outliers should not
have a major affect on further analyses.  The Normal Q-Q Plot of the MARS was
examined with some deviations from normality indicated (Figure 2). Transformation of
the distribution for the MARS variable was considered, however, criteria for a
problematic level of skewness is inconsistent in the literature (Norris & Aroian, 2004).
The effect of skew on the Cronbach alpha and correlation analyses have not been
substantive (Norris & Aroian, 2004; Greer, Dunlap, Hunter, & Berman, 2006), inferring
that transformation may not be necessary.  In addition, transformation often complicates
interpretation of data in relation to theoretical or clinical purposes; therefore,
transformations will not be used in this study.
Table 14
Summed MARS Tests for Normality
Scale Mean 5% TrimmedMean Skewness Kurtosis
MARS 24.07 24.34 2.93 .56
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Figure 2
Homogeneity and Linearity
Homogeneity of variance was evaluated as part of the t-test and analysis of
variances analyses (ANOVA). Levene’s test for equality of variances was used to test
the assumption of homogeneity when answering the research questions in Chapter 4.
When there were violations to the assumption of homogeneity in t-test analyses, Leven’s
test < .05, the Equal variances not assumed t-value was used.  There were no violations to
this assumption in the ANOVA analyses.  Linearity was evaluated using scatter plots and
correlation indicating no violation of this assumption.
Summary
This chapter provided information about the study design, procedure for data
collection, sample and setting, operational definitions and instruments.  Preliminary
analysis was conducted to examine means, standard deviations, and ranges of variables
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and subscales, reliability of instruments, effect of missing values, normality,
homogeneity, and linearity.
Descriptive means were within the possible ranges.  Chronbach’s alpha was found
to be in acceptable ranges except for two Cause Factors which were ultimately dropped
from further analyses.
Missing values was examined indicating acceptable levels for all of the IPQ-R
subscales except Identity, which is retained for descriptive purposes, but not for further
analyses.  The MARS was examined to determine if missing values were systematically
different from observed values.  Study participant Response/Non-response on the MARS
did not vary significantly by Individual and Clinical Characteristics or IPQ-R subscales
except in two cases.  This analysis indicated a slight bias among study participants
regarding Response/Non-response on the MARS in terms of number of medications and
personal control.
Normality tests indicated the presence of skewness and kurtosis which is noted as
limitations that might weaken the outcomes.  However, transformation will not be used
for analyses. Homogeneity and linearity were evaluated with no major violations of
assumption noted.
A description of study participants will be discussed and research questions
answered in Chapter 4. Descriptive statistics including frequency, mean, standard
deviation, median, and range will be used to describe study participants. Descriptive
statistics including frequency, mean, standard deviation, and range were used to answer
research questions 1 and 2.  Pearson’s correlation coefficients were used to answer
research questions 3, 5, and 8.  A series of correlations and t-tests were used to answer
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research question 4.  A series of correlations, t-tests, and ANOVA were used to answer
research question 6 and 7.
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CHAPTER 4
Results
In this chapter, the results of analyses are presented in two sections.  The first
section describes the participants in terms of individual and clinical characteristics.  The
second section focuses on analysis of the research questions.
Sample Characteristics
A total of 92 VAMC veterans diagnosed with stage 3 CKD and prescribed an
ACE-I agreed to participate in the study by returning completed or partially completed
survey questionnaires.  As shown in Table 15, the participants ranged in age from 50 to
89 years with a mean age of 69 (SD = 9.43) years.  The sample included 98.9% (n = 91)
males with 87% (n = 80) self-reporting race as Caucasian or White and 85.9% (n = 79)
reporting not being of Spanish or Hispanic origin. The majority reported having 12 years
or more education (77%), living with a partner (58.7%) and had enough or comfortable
family income (71.7%).  Only 7.6% (n = 7) of the respondents reported having lived with
a relative diagnosed with end stage renal disease. The gender and ethnic origin variables
will not be used in further analyses due to the extreme bias toward the male gender and
non-Hispanic ethnic origin, though they are representative of the VAMC patient
population. As illustrated in Table 16, the reported length of time, in months, since being
told they had kidney disease ranged from 0 to 480  ( Mean =  73.8, SD = 91.4;  median =
36) months.  The co-morbid conditions extracted from chart review indicated
approximately 84% (n = 81) of the participants were diagnosed with some combination
of DM, HTN, and general cardiovascular disease and were prescribed an average of 12.3
medications.
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Table 15
Frequencies and Percentages for Individual Characteristics of Participants (N = 92)
Variable n %
Age (n = 92) Range 50 - 89 years
M =  69.08 SD = 9.43
Gender (n = 92) Male 91 98.9
Female 1 1.1
Race* (n = 90) Caucasian/White 80 87.0
African American/Black 9 9.8
Other (not specified) 1 1.1
Ethnic origin - Yes 2 2.2
Spanish/Hispanic(n = 82) No 79 85.9
Education*  (n = 89) Range 8 – 19 years
M =  13.92 SD = 3.00
8-11 years 19 21.3
12 years 21 22.8
13 – 15 years Technical
and/or some college 25 28.1
17 years Completed
college 6 6.5
18 years Some graduate
school 10 10.9
19 years Completed
graduate school 8 8.7
Financial Status* (n = 89) Not enough 23 25.0
Just enough 44 47.8
Comfortable level 22 23.9
Living with Partner* (n = 90) Yes 54 58.7
No 36 39.1
Lived with relative with
ESRD* (n = 90) Yes 7 7.6
No 83 90.2
*Total does not equal to the total sample size due to missing values
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Table 16
Frequencies and Percentages for Clinical Characteristics of Participants (N = 92)
Variable n %
Co-morbid conditions DM 2 2.2
(n = 92) HTN 8 8.7
CVD 1 1.1
DM + HTN 23 25.0
DM + CVD 3 3.3
HTN + CVD 23 25.0
DM + HTN + CVD 32 34.8
Months since diagnosed Range 0 – 480 mos
with kidney disease M =  73.81 SD 91.40
(n = 81) Median 36
Less than 6 months 2 2.2
6-11 months 5 5.5
1 - 2 years 30 32.7
3 - 5 years 19 20.7
6 - 9 years 8 8.7
10 + years 17 18.6
Number of prescribed Range = 2 – 29
medications (n = 92) M = 12.3 SD 5.10
less than 5 3 3.3
5 to 8 17 18.4
9 to 10 17 18.5
11 to 12 17 18.5
13 to 15 16 17.4
16+ 22 23.9
* Total does not equal to the total sample size due to missing values
DM = diabetes mellitus, HTN = hypertension, CVD = General Cardiovascular Disease
Research Questions
Data analysis used to answer the research questions included descriptive statistics
(frequency, mean, standard deviation, median, and range) to describe the illness and
treatment perceptions of the participants.  Correlation analysis using Pearson’s
correlation coefficients, as well as independent sample t-tests and ANOVA, were used to
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describe variables, and relationships. To aid increasing the number of responses that
could be included in the analysis, mean subscale scores for individual participants have
been substituted for missing data on each of the subscales if less than 25% of the items
were missing data.  Gender and ethnic origin were eliminated from analysis as there was
not enough variance to compose more than one group. The significance level was set at
.05.
Research Question 1
What are the illness representations (cognitive representation [identity, cause,
timeline, control/cure, consequences] and emotional representation) of patients with CKD
stage 3?
The illness representations  as measured by the self-report IPQ-R is divided into
three sections, covering the identity and causal subscales separately from timeline,
control/cure, consequences and emotion response subscales.
Identity. The identity subscale is composed of 17 symptoms with two sections;
one section asks participants to answer “yes” or “no” to having experienced the
symptoms listed since having kidney disease.  The second section asks participants to
answer “yes” or “no” regarding their belief that the symptom is related to their kidney
disease. As seen in Table 17, all 17 symptoms were reported as having been experienced
by participants and all 17 symptoms reported as having been experienced were perceived
as related to CKD by at least one respondent with most reporting legs and feet swelling (n
= 31), followed by fatigue (n = 28).
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Table 17
IPQ-R Identity Subscale N = 92
Symptom AND
Related symptom to
kidney disease
Experienced n n %
Legs/feet swelling 42 30 71.4
Fatigue 44 28 63.6
Loss of strength 41 21 51.2
Problem sleeping 38 18 47.4
Pain 28 14 50
Stiff joints 44 14 31.8
Short of breath 38 13 34.2
Bad taste in mouth 16 11 68.8
Upset stomach 20 9 45
Nausea 14 8 57.1
Weight loss 14 7 50
Dizzy 23 7 30.4
Puffy eyes 14 7 50
Sore eyes 14 6 42.9
Wheezing 18 6 33.3
Headache 21 5 23.8
Sore throat 17 3 17.6
Cause. Cause is operationalized with a subscale of 18 attribution items (Table
18).  Participants were asked to rate the extent to which they believed the items were
causes of their kidney disease on a 5-point scale, where strongly disagree = 1, disagree =
2, neither agree nor disagree = 3; agree = 4, and strongly agree = 5. All 18 causes were
reported as being a cause of kidney disease with over half of the participants indicating
agreement or strong agreement that aging and diet or eating habits are a cause of kidney
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disease (n = 52 (59.8%) and n = 44 (51.8%) respectively).  There were even stronger
perceptions that personality and alcohol are not causes of kidney disease indicated by
disagree or strongly disagree ratings (n = 57 (64%) and n = 55 (61.8%) respectively).
The greatest ambivalence toward possible causes of kidney disease was indicated by 37
(42%) respondents answering “neither agree nor disagree” that pollution and environment
were causes of kidney disease (not reported in table). As noted in Table 19 the overall
mean for the cause subscale (M = 2.73, SD = 0.47) indicates general ambivalence or
disagreement that the list of causes from which they could choose from were perceived as
attributing to kidney disease.
Table 18
IPQ-R Cause Subscale Frequencies
Agree/Strongly
Agree
Disagree/Strongly
Disagree
Cause
Total
n Valid n % Valid n %
Aging 87 52 59.8 16 18.4
Diet or eating habits 85 44 51.8 18 21.2
Stress/worry 85 31 36.5 29 34.1
Own behavior 88 29 33 27 30.7
Poor medical care in past 87 22 25.2 37 42.5
Heredity 88 22 25 44 50
Smoking 87 18 20.7 48 55.2
Altered immune system 86 17 19.8 34 39.5
Alcohol 89 17 19.1 55 61.8
Accident or injury 87 13 14.9 53 60.9
Pollution or environment 88 13 14.7 38 43.2
Family problems/worries 88 13 14.7 45 51.1
Germ or virus 85 12 14.1 40 47.1
Overwork 85 12 14.1 40 47.1
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Chance or bad luck 84 11 13.1 40 47.6
Emotional state 86 10 11.7 44 51.2
Personality 89 5 5.6 57 64
Negative mental attitude 87 4 4.5 47 54
Timeline, Control, Consequences, and Emotion. IPQ-R items (Table 19) have
a possible range of 1 to 5 with higher scores indicating perceptions of higher personal and
treatment control of chronic, cyclical illness with serious consequences and negative
emotional reactions (Figure 3).
Figure 3
IPQ-R Scoring Indications
Higher Scores on subscale → indicates patients’ perception of:
Cognitive Representation
Timeline Acute/Chronic Kidney disease being more chronic, long-term condition
Timeline Cyclical Kidney disease being more cyclical in nature; symptoms
come and go
Consequences Higher burden on negative consequences resulting from
kidney disease
Personal Control Higher sense of personal control over kidney disease
Treatment control Higher sense of ability of treatment to control kidney
disease
Emotional Representation Higher negative emotional responses to having kidney
disease
As can be seen in Table 19, the CKD timeline was perceived as a long-term
chronic rather than short-term acute condition (M = 3.78, SD = 0.84), with minimal
cyclical exacerbations (M = 2.67, SD = 0.72), and moderate severity of consequences (M
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= 3.11, SD = 0.80).  Respondents perceived having both, but more personal control than
treatment control of CKD (M = 3.52, SD = 0.75 vs. M = 3.18, SD = 0.65).  Participants
did not perceive CKD as related to a great negative emotional response (M = 2.78, SD =
0.62).
Table 19
IPQ-R Subscales Descriptive Statistics
Subscale (# of Items)
Possible
Range Mean SD
Illness Representation
Subscales
Timeline acute - chronic (6) 1 - 5 3.78 0.84
Personal Control (6) 1 - 5 3.52 0.75
Treatment Control (5) 1 - 5 3.18 0.65
Consequences (6) 1 - 5 3.11 0.80
Emotional Representation (6) 1 - 5 2.78 0.62
Timeline cyclical (4) 1 - 5 2.67 0.72
Cause (18) 1 - 5 2.73 0.47
Research Question 2
What are the medication adherence levels of ACE-I among patients in CKD stage 3
as measured by self-report MARS?
Descriptive statistics (e.g., frequencies, means, standard deviations and ranges) were
used to examine the self-reported medication adherence patterns of the respondents.
Self-reported medication adherence with ACE-I is measured by the MARS self-report
instrument.  The MARS was written with a focus on an estimation of intentional non-
adherence with only one question related to unintentional non-adherence (how often they
forget to take a medication dose) and four questions focused on the extent that patients
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follow recommendations in a way they find more suitable, but different from the way
they perceived the provider recommended (how often they take less, stop taking, miss,
and alter their medication dose). Participants were asked to check the response that best
describe how they take their ACE-I. Responses were scored on a 5-point scale where 1 =
ery often, 2 = often, 3 = sometimes, 4 = rarely, and 5 = never. Higher scores indicate
higher levels of self-reported adherence patterns.
Table 20 presents descriptive data regarding the MARS items. Data indicated that
study participants reported a high frequency of adherent responses regarding MARS
variables. Specifically, regarding Forgetfulness, only 5.3% (n = 4) reported often/very
often forgetting to take their ACE-I. Regarding both Change Dose and Take Less, 4% (n
= 3) reported often/very often. For the variables Stop Taking and Miss a Dose, 0%
reported often/very often. Looking at the MARS scale as a whole, the mean value score
(M = 4.81, SD=.35) of this variable was very close to the highest scale value of 5.00.
Table 20
MARS Frequencies, Mean, and Standard Deviation (N = 92)
Often/Very
Often
Sometimes Rarely/Never
MARS Items Total n Valid n (%) Valid n (%) Valid n (5)
Forget 76 4 (5.3) 3 (3.9) 69 (90.8)
Change Dose 75 3 (4) 1 (1.3) 71 (94.7)
Take Less 75 3 (4) 0 72 (96)
Stop Taking 74 0 0 74 (93.2)
Miss a Dose 75 0 4 (5.3) 71 (94.7)
Total n Possible Range Mean SD
MARS Scale 72 1 - 5 4.81 0.35
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Research Question 3
Does illness representation (cognitive representation [identity, cause, timeline,
control/cure, consequences] and emotional representation) of patients with CKD stage 3
predict self-reported adherence to ACE-I?
Pearson correlation coefficients were used to examine strength and direction of
the linear relationship between cognitive and emotional illness representation dimensions
and medication adherence. The original intent of analysis was to use multiple regression
to test the predictability of illness representation dimensions that had statistically
significant r values indicating strong correlation to self-reported medication adherence.
However, correlations were so low that taking the next step to multiple regression
analysis was unwarranted, as prediction would not be found. Table 21 presents
correlations between the MARS and all Illness Representation variables. Data indicated
that the MARS was not significantly correlated with any of the variables reflecting Illness
Representation.
Table 21
Correlations Between MARS and Illness Representations
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MARS 0.13 -0.03 -0.05 0.10 -0.01 -0.16 -0.03 0.02 0.06
Research Question 4
What are the relationships among each of the Individual Characteristics (age,
gender, race, education, financial status, and living with a partner status) with the
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individual Cognitive Representation dimensions (identity, cause, timeline, control/cure,
consequences) and self-reported medication adherence with ACE-I?
A series of correlations and t-tests were used to examine research question 4.
Table 22 presents the correlations among age, years of education, financial status, and
illness representation dimensions. Correlations and t-tests examining relationship among
age, years of education, financial status, and MARS are also presented in Table 22.
Analysis indicated a negative correlation in which older age was significantly
related to lower levels of the cognitive representation dimension of Timeline -
acute/chronic, r = - 0.25, p < .05. Additionally, analysis indicated a negative correlation
in which older age was significantly related to lower levels of the cognitive
representation dimension of consequences, r = -0.25, p < .05 and personal control, r = -
0.29, p < .01. All other variables representing cognitive representation were not
significantly correlated to age.
Correlation analysis indicated that higher levels of education was significantly
correlated with higher levels of the cognitive representation dimension Timeline
acute/chronic, r = 0.31, p <.05. Analysis indicated that education was not significantly
correlated with other variables representing illness representation. Analysis indicated
that financial status was not significantly correlated with other variables representing
cognitive representations.
Correlation analysis indicated no statistically significant correlations between age,
education, financial status and MARS.
118
Table 22
Correlations Between Age, Education, and Financial Status with
Cognitive Representation and MARS
AGE
Years of
Education
Financial
Status
Timeline Acute/Chronic -0.25* 0.31** 0.07
Consequence -0.25* 0.09 -0.12
Personal Control -0.29** 0.09 -0.11
Treatment Control 0.05 -0.15 0.09
Timeline cyclical -0.14 -0.13 -0.08
Psychological Causes 0.06 -0.13 -0.13
Lifestyle Causes -0.19 -0.16 -0.01
Environmental Causes -0.03 0.13 -0.12
MARS -0.14 -0.04 0.01
* p = < .05 (2-tailed); **p = < .01 (2-tailed); MARS = Medication Adherence Report Scale
Table 23 presents t-test analysis examining mean value scores of cognitive
representation variables by race and living with a partner. Analysis indicated that
African-Americans/Others had significantly higher mean value scores regarding the
variable Treatment Control relative to Caucasian/White study participants, M = 3.61, SD
= 0.64 vs. M = 3.10, SD = 0.59, t(87) = 2.37, p < .05, respectively. Mean value scores
reflecting Personal Control were also significantly higher among African-
American/Black study participants, M = 3.99, SD = 0.52, relative to Caucasian/White
study participants, M = 3.44, SD = 0.81, t(87) = 2.09, p < .05.
Analysis also indicated that those living with a partner had a significantly lower
mean value regarding Lifestyle Causes, M = 2.31, SD = 0.82, relative to those that do not
live with a partner, M = 2.74, SD = 0.98, t(87) = -2.25, p < .05.
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Table 23
T-test Analysis Examining Mean Value Scores of Cognitive Representation Variables by
Race and Living with a Partner
Possible 95% CI
Cognitive Representation n M (SD) Range t Lower - Upper
Treatment Control
Race
Caucasian/White 79 3.10 (.59) 1.00-5.00 2.37* .08 - .93
African-American/Other 10 3.61 (.64)
Living with Partner
Yes 53 3.17 (.67) 1.00-5.00 .24 -.25 - .32
No 36 3.14 (.64)
Timeline (acute/chronic)
Race
Caucasian/White 79 3.83 (.78) 1.00-5.00 -1.82 -1.04 - .05
African-American/Other 10 3.33 (1.06)
Living with Partner
Yes 53 3.88 (.76) 1.00-5.00 1.51 -.08 - .62
No 36 3.61 (.90)
Timeline (cynical)
Race
Caucasian/White 79 2.68 (.68) 1.00-5.00 .85 -.26 -.65
African-American/Other 10 2.88 (.70)
Living with Partner
Yes 53 2.69 (.65) 1.00-5.00 -.26 -.33 - .25
No 36 2.73 (.72)
Personal Control
Race
Caucasian/White 79 3.44 (.81) 1.00-5.00 2.09* .03 – 1.07
African-American/Other 10 3.99 (.52)
Living with Partner
Yes 53 3.48 (.84) 1.00-5.00 -.29 -.39 - .30
No 36 3.53 (.76)
p = < .05; CI = Confidence Interval of the Difference
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Table 23 continued
T-test Analysis Examining Mean Value Scores of Cognitive Representation Variables by
Race and Living with a Partner
Possible 95% CI
Cognitive Representation n M (SD) Range t Lower - Upper
Consequences
Race
Caucasian/White 79 3.19 (.74) 1.00-5.00 -1.73 -.94 - .064
African-American/Other 10 2.75 (.87)
Living with Partner
Yes 53 3.26 (.78) 1.00-5.00 1.80 -.03 - .62
No 36 2.96 (.70)
Psychological Causes
Race
Caucasian/White 78 2.57 (.65) 1.00-5.00 -1.24 -.70 - .16
African-American/Other 10 2.30 (.62)
Living with Partner
Yes 53 2.53 (.72) 1.00-5.00 -.20 -.31 - .25
No 35 2.56 (.54)
Lifestyle Causes
Race
Caucasian/White 78 2.44 (.84) 1.00-5.00 1.18 -.25 - .96
African-American/Other 10 2.80 (1.34)
Living with Partner
Yes 53 2.31 (.82) 1.00-5.00 -2.25* -.82 - -.05
No 35 2.74 (.98)
Environmental Causes
Race
Caucasian/White 78 2.60 (.64) 1.00-5.00 .66 -.30 - .60
African-American/Other 10 2.75 (.95)
Living with Partner
Yes 53 2.55 (.58) 1.00-5.00 -1.12 -.46 - .13
No 35 2.72 (.79)
p = < .05; CI = Confidence Interval of the Difference
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Table 24 presents t-test analysis examining mean value scores of MARS by race
and living with a partner. Analysis indicated that mean value scores of MARS did not
vary at a statistically significant level by race and living with a partner.
Table 24
T-test Analysis Examining Mean Value Scores of MARS by Race and Living with a
Partner
Possible 95% CI
n M (SD) Range t Lower - Upper
MARS
Race
Caucasian/White 63 4.21 (.37) NA .30 -.23 - .31
African-American/Other 8 4.85 (.10)
Living with Partner
Yes 42 4.78 (.41) NA -1.10 -.27 - .08
No 27 4.87 (.26)
CI = Confidence Interval of the Difference
Research Question 5
What are the relationships among each of the Individual Characteristics (age,
gender, race, education, financial status, and living with a partner status) with the
Emotional Representation construct?
A series of correlations and t-tests were used to examine research question 5.
Table 25 presents the correlations between the age, years of education, financial status
and Emotional Representation. Analysis indicated that emotional response was not
significantly correlated with age, education or financial status.
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Table 25
Correlations Between Age, Education, Financial Status and Emotional
Representation
AGE
Years of
Education
Financial
Status
Emotional Representation -0.06 0.06 -0.18
Table 26 presents a t-test analysis examining mean value scores of emotional
response by race and living with a partner.  Analysis indicates that Caucasian/White
study participants evidenced a significantly higher mean values score regarding
Emotional Representation relative to African American/black study participants, M =
2.85, SD – 0.56 vs. M = 2.40, SD = 0.56, t(87) = -2.35, p < .05.  Emotional
Representation was not related to living with a partner.
Table 26
T-test Analysis Examining Mean Value Scores of Emotional Representation by Race and
Living with a Partner
Possible
n M (SD) Range t
Race
Caucasian/White 78 2.85 (.56) 1.00-5.00 -2.35*
African-American/Other 10 2.40 (.56)
Living with Partner
Yes 52 2.90 (.65) 1.00-5.00 .24
No 36 2.66 (.47)
* p < .05
Research Question 6
What are the relationships among clinical characteristics (Co-morbidity, Length
of time CKD diagnosis, Family history of ESRD/dialysis and Number of medications)
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with individual Cognitive Representation dimensions (identity, cause, timeline,
control/cure, consequences) and self-reported medication adherence with ACE-I?
A series of correlations, t-tests, and ANOVAs were used to examine research
question 6. Table 27 presents correlations between length of time since CKD diagnosis
and number of medications with cognitive representation. Correlations examining
relationships between length of time since CKD diagnosis and number of medications
with Mars are also presented in Table 27.
Analysis indicated that greater time since diagnosis was significantly correlated
with higher levels of timeline - acute/chronic, r = .23, p < .05, and lower levels of
Timeline cyclical, r = -.26, p < .05. All other cognitive representation variables were
unrelated to time since CKD diagnosis. Data indicated that greater time since CKD
diagnosis was significantly correlated with lower MARS scores (r = -.33, p < .01).  Data
indicated that number of medications was unrelated to all cognitive representation
variables and the MARS.
Table 27
Correlations Between Length of Time since CKD Diagnosis and
Number of Medications with Cognitive Representation and MARS
Length of Time
since CKD
Diagnosis
Number of
Medications
Timeline Acute/Chronic 0.23* -0.03
Consequence 0.17 0.10
Personal Control -0.01 0.02
Treatment Control -0.06 -0.04
Timeline cyclical -0.26* 0.04
Psychological Causes -0.11 0.07
Lifestyle Causes 0.06 0.12
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Environmental Causes 0.09 0.16
MARS -0.33** 0.02
* p = < .05 (2-tailed); **p = < .01 (2-tailed); MARS = Medication Adherence Report Scale
Table 28 presents t-test analysis examining differences in mean value scores of
cognitive representation variables by history of living with relative with ESRD/dialysis.
T-test analysis examining differences in mean MARS scores by history of living with
relative with ESRD/dialysis is also presented in Table 28.
Data indicated that study participants who lived with relative with ESRD/dialysis
had significantly higher mean scores on Timeline cynical relative to those that did not
report living with a relative with ESRD diagnosis, M = 3.21, SD = .27, vs. M = 2.67, SD
= .68, respectively, t(87) = 4.39, p < .001. Living with a relative with ESRD/dialysis was
unrelated to all other cognitive representation variables. Analysis indicated that mean
value scores of the MARS did not vary at a statistically significant level by family history
of ESRD/dialysis.
Table 28
T-test Analysis Examining Mean Value Scores of Cognitive Representation and MARS Variables
by Lived with relative with ESRD/dialysis
Possible
Cognitive Representation n M (SD) Range t
Timeline (acute/chronic)
Lived w/relative w/ESRD/dialysis
Yes 7 3.98 (.92) 1 – 5 .68
No 82 3.75 (.81)
Consequences
Lived w/relative w/ESRD/dialysis
Yes 7 3.22 (.78) 1 – 5 .30
No 82 3.13 (.76)
Personal Control
Lived w/relative w/ESRD/dialysis
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Yes 7 3.57 (.77) 1 – 5 .24
No 82 3.50 (.81)
Treatment Control
Lived w/relative w/ESRD/dialysis
Yes 7 3.09 (.68) 1 – 5 -.31
No 82 3.17 (.65)
Timeline (cyclical)
Lived w/relative w/ESRD/dialysis
Yes 7 3.21 (.27) 1 – 5 4.39***
No 82 2.67 (.68)
Psychological Causes
Lived w/relative w/ESRD/dialysis
Yes 7 2.29 (.67) 1 – 5 -1.10
No 81 2.57 (.65)
Lifestyle Causes
Lived w/relative w/ESRD/dialysis
Yes 7 2.14 (.72) 1 – 5 -1.03
No 81 2.51 (.92)
Environmental Causes
Lived w/relative w/ESRD/dialysis
Yes 7 2.68 (.49) 1 – 5 .25
No 81 2.61 (.69)
MARS
Lived w/relative w/ESRD/dialysis
Yes 5 4.72 (.52) 1 – 5 -.61
No 66 4.82 (.35)
***p < .001 MARS = Medication Adherence Report Scale
Table 29 presents an Analysis of Variance (ANOVA) examining mean value
scores of cognitive representation variables by co-morbidity. Analysis indicated that
mean value scores of all cognitive representation variables did not vary significantly
whether by a single co-morbid condition (DM, HTN, or CVD), a combination of two of
these conditions, or a combination of all three. Analysis also indicated that mean value
scores of the MARS did not vary at a statistically significant level by co-morbidity.
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Table 29
Analysis of Variance (ANOVA) Examining Mean Value Scores of Cognitive
Representation Variables and MARS by Co-morbidity
Possible
Cognitive Representation n M (SD) Range F
Timeline (acute/chronic)
DM, HTN, or CVD 10 4.00 (.68) NA .70
Combination of two 35 3.67 (.94)
Combination of three 25 3.84 (.84)
Consequences
DM, HTN, or CVD 10 3.43 (.58) NA .92
Combination of two 35 3.07 (.80)
Combination of three 25 3.22 (.83)
Personal Control
DM, HTN, or CVD 10 3.56 (1.03) NA .28
Combination of two 35 3.51 (.76)
Combination of three 25 3.67 (.77)
Treatment Control
DM, HTN, or CVD 10 3.00 (.65) NA 1.32
Combination of two 35 3.17 (.64)
Combination of three 25 3.35 (.54)
Timeline (cynical)
DM, HTN, or CVD 10 3.05 (.40) NA 2.34
Combination of two 35 2.57 (.70)
Combination of three 25 2.56 (.65)
Cause Factor 1
DM, HTN, or CVD 10 2.61 (.67) NA .03
Combination of two 35 2.55 (.68)
Combination of three 25 2.58 (.58)
Cause Factor 2
DM, HTN, or CVD 10 2.57 (.72) NA .15
Combination of two 35 2.43 (.93)
Combination of three 25 2.56 (1.04)
Cause Factor 3
DM, HTN, or CVD 10 2.83 (.56) NA .96
Combination of two 35 2.71 (.65)
Combination of three 25 2.52 (.72)
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MARS
DM, HTN, or CVD 10 4.76 (.36) NA .52
Combination of two 36 4.79 (.40)
Combination of three 26 4.87 (.28)
Research Question 7
What are the relationships among each of the clinical characteristics (Co-
morbidity, Length of time CKD diagnosis, Family history of ESRD/dialysis and Number of
medications) with the Emotional Representation construct?
A series of correlations, t-tests, and ANOVAs were used to examine research
question 7.
Table 30 presents correlations between length of time since CKD diagnosis,
number of medications, and emotional response. Data indicated that emotional
representation was not significantly related to time since diagnosis and number of
medications.
Table 30
Correlations Between Length of Time since CKD Diagnosis and Number of
Medications with Emotional Representation
Length of Time since
CKD Diagnosis
Number of
Medications
Emotional Representation -.14 0.09
Table 31 presents a t-test analysis examining mean value scores of emotional
representation by living with relative with ESRD/dialysis. Analysis indicated that
emotional representation was unrelated to whether or not participants had lived with a
relative with ESRD/dialysis.
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Table 31
T-test Analysis Examining Mean Value Scores of Emotional Representation by Lived
with relative with ESRD/dialysis
Possible
Emotional Representation n M (SD) Range t
Timeline acute/chronic
Lived w/relative w/ESRD/dialysis
Yes 7 3.05 (.70) 1 – 5 1.15
No 81 2.78 (.58)
Table 32 presents Analysis of Variance (ANOVA) examining mean value scores
of emotional representation variables by co-morbidity. Analysis indicated mean value
scores of emotional representation variables did vary significantly by a single co-morbid
condition (DM, HTN, or CVD), a combination of two of these conditions, or the
combination of all three, F(2,67)=5.62, p<.01. A Post-hoc Bonferroni Test of Multiple
Comparisons indicated that the mean value score of DM, HTN, or CVD, M = 3.31, SD =
.77, was significantly higher relative to the mean value of those respondents having a
Combination of two, M = 2.64, SD = .52.
Table 32
Analysis of Variance (ANOVA) Examining Mean Value Scores of Emotional
Representation Variables by Co-morbidity
Possible
Cognitive Representation n M (SD) Range F
DM, HTN, or CVD 10 3.31 (.77) NA 5.62 **
Combination of two 35 2.64 (.52)
Combination of three 25 2.82 (.52)
**p<.01.
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Research Question 8
What is the relationship between the Medication Adherence Report Scale
(MARS) and the Medication Possession Ratio (MPR)?
Correlation analysis was used to examine research question 8. Table 33 presents
correlations between MARS and MPR. Analysis indicated that higher levels of MPR
were correlated with higher levels of MARS, r = .35, p < .01, variables.
Table 33
Correlations between MARS and MPR Variables
MPR
MARS .35**
**p < .01 (2-tailed); MARS = Medication Adherence Report Scale; MPR = Medication Possession Ratio
Summary
In this chapter, the results of analyses were presented in two sections.  The first
section described the sample of VAMC renal clinic patients who were in stage 3 CKD
and were prescribed an ACE-I.  A cross sectional design was used in the second section
to answer the research questions.  Descriptive statistics, correlation, independent t-test,
and ANOVA were used to describe variables and relationships in answering the research
questions.  The findings are discussed in more detail in Chapter 5, along with the
limitations of the study and recommendations for future research.
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CHAPTER 5
Discussion
This chapter begins with a summary of the study, followed by a description of the
individual and clinical characteristics of the study sample. A discussion of results in
relation to the purposes, conceptual framework and research literature is presented next.
Along with this discussion, challenges encountered during the study are addressed.  At
the conclusion of the chapter, limitations of the study and recommendations for future
research are discussed.
Summary of the Study
Chronic kidney disease places a high personal and economic burden on
individuals, families, society, as well as national and international healthcare systems.
Research indicates that adherence to medications that can slow progression of CKD to
ESRD and help prevent cardiovascular events is suboptimal.  Patient perceptions about
illness and beliefs about treatment have been shown to be related with adherence (Haynes
et al., 1996; Wetzels et al., 2006).  The theoretical framework chosen to guide this study
is the Common Sense Model (Figure 1) which proposes that an individual is an active
participant with unique cognitive beliefs and emotional responses when faced with illness
threats such as kidney disease.  These beliefs and responses direct the individual to using
common-sense coping strategies, such as taking medications, to manage the life changing
challenges of CKD.  At the time of this study, studies could not be found examining
Illness Representations or predictors of adherence to ACE-I, renal protective medications,
in CKD stage 3 patients.  The current study contributed to this area of research by 1)
describing the illness and treatment beliefs of CKD patients in stage 3 guided by the
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CSM; 2) examining the relationship of those beliefs with adherence to renal protective
medications, ACE-I; 3) describing the adherence levels of ACE-I among patients with
CKD stage 3; 4) examining relationships between individual and clinical characteristics
with patient beliefs and with self-reported medication adherence with ACE-I; and 5)
examining the relationship between the self-report Medication Adherence Report Scale
(MARS) and the Medication Possession Ratio (MPR) extracted from pharmacy refill
data.
Individual and Clinical Characteristics
The findings in this study of the individual characteristics of patients seen in the
VAMC renal clinic, diagnosed with stage 3 CKD, and prescribed ACE-I are very similar
to the general population of patients with stage 3 CKD (USRDS, 2008a), with the
exception of a slightly higher education and financial status and the overwhelming
predominance of males.  This gender bias is to be expected in the veteran population
which has a history of and is still, at this time, predominantly male.  The profile of
participants in this study includes being an older (69+ years) white, non-Hispanic male
with 12 or more years of education, living with a partner, and a financial status that is
adequate or comfortable.
The clinical characteristics are also similar to the general population of patients
with stage 3 CKD.  Very few participants reported having lived with a family member
who had ESRD or had been on dialysis.  Having a predominantly White sample may be a
contributory factor since the adjusted incidence of ESRD among African American
individuals is almost four times that of White individuals (K. C. Norris, et al., 2006).  In a
study by Tan, Hoffman, and Rosa (2010) African American patients with CKD stages 3
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and 4 were six times more likely to report a family history of ESRD than Caucasian
patients.  A wide range of months since being diagnosed with kidney disease was
reported by the respondents (0 – 480 months), with a median of 36 months.  Even though
the study sample was drawn from CKD patients in stage 3 who were being seen in the
renal clinic, some still reported not being diagnosed, or told, that they had kidney disease.
The PI received several phone calls from eligible participants questioning why they had
been invited to participate in the study when they did not have kidney disease.  They
confirmed that they were seen in the renal clinic on a regular basis, but were not aware
that they had kidney disease, even when in stage 3 of the disease process.  This may seem
strange, however, there are several studies reporting this is not unusual and that there is a
low awareness of having kidney disease.  Plantinga, and colleagues (2008) found that
disease awareness among U.S. adults with CKD to be generally low, even into stage 4,
with fewer than half of the persons with CKD aware of their disease.  Plantinga reported
improvement in awareness among those with CKD has been noted in CKD stage 3, but
still with awareness among these persons fewer than 1 in 10.  Chart review of co-morbid
conditions, DM, HTN, and general CVD is congruent with literature findings of these
illnesses being often found in common with CKD (USRDS, 2008a; NKF, 2002).  The
majority of the study sample had a combination of two of more of these co-morbid
conditions.  Participants in this study, on average, were prescribed 12 medications.  A
complex medication regimen with several medications is not unexpected since CKD
patients often have multiple co-morbidities.  However, the finding of 12 prescribed
medications for patients in stage 3 CKD are higher than that found in the literature for
early CKD stage.  Bailie et al. (2005) examined patterns of medication use of 619
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patients in stages 2-5 CKD, of which 81% were in stages 2-4.  The average number of
prescribed medications for this cohort of CKD participants was eight.  Eight was also the
average number of prescribed medications for patients with stages 3-5 CKD in a study by
Rifkin et al. (2010).  In a pooled analysis of seven studies including 395 stage 5 CKD
hemodialysis patients, Manley, Cannella, Bailie, and St. Peter (2005), found the average
number of prescribed medications for this later stage of CKD patients was 12.  A larger
number of prescribed medications would be expected for patients in stage 5 CKD on
dialysis who have not only more advanced kidney disease, but usually more advanced co-
morbid conditions as well.  The higher of number of medications prescribed to the
participants in the current study may be because the VAMC medications are provided at a
low to no co-payment.  The findings may be related to the fact that VAMC patients are
seen regularly in specialty clinics for their multiple co-morbid conditions and their
providers may not feel hindered by the patient’s ability or inability to afford the needed
medications.  A comparative study of medication prescribing patterns among various
stages of CKD and different systems would help shed more light on this interesting
finding.
Primary Purposes
The primary purposes of this study were to: 1) describe the illness and treatment
beliefs of CKD patients in stage 3 guided by the CSM; and 2) examine the relationship of
those beliefs with adherence to renal protective medications, ACE-I.  Secondary purposes
of this study included determining adherence levels of ACE-I among patients with CKD
stage 3; examining relationships between individual and clinical characteristics with
patient beliefs and medication adherence with ACE-Is; and examining the relationship
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between the Medication Adherence Report Scale (MARS) and the Medication Possession
Ratio (MPR).
Description of Illness Representations
Findings of the illness representation dimensions will be described in sections.
Discussion of the cognitive and emotional representation dimensions are divided into
three sections Identity, Cause, and the remainder of the dimensions, Timeline, Control,
Consequences, and Emotion.
Identity. According to the theoretical framework for this study, when individuals
are faced with threats to their health, they build unique cognitive and emotional
representations that determine how they will respond to the threat.  The individual faced
with a health treat will use these representations to guide their choices of coping
strategies in attempt to reduce the threat of illness or symptoms (Leventhal et al., 1997,
Leventhal et al., 2003)
One of the reasons for choosing participants in stage 3 of CKD was because this
is the stage in which individuals begin to experience symptoms secondary to organ
dysfunction and decline in renal function leading to patient awareness of renal disease
(Garcia-Donaire, et.al, 2005; NKF, 2004).  According to the theoretical framework of
CSM, at this stage an individual will try to make sense of their illness by identifying
symptoms that they then label to define the disease.  The participants in this study labeled
their kidney disease with a wide range of symptoms some of which are not typically
associated with kidney disease at this stage by the medical community, such as sore
throat, weight loss, sore eyes, and being dizzy.  This finding supports the theoretical
construct of individuals’ illness representation being dynamic and are drawn from
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experiences and sociocultural environments that are unique to the individual and not
necessarily congruent with medical knowledge (Bauman, Cameron, Zimmerman, &
Leventhal, 2000; Velez & Ramasco, 2006). However, the two symptoms most reported
by participants as being related to their kidney disease, legs/feet swelling and fatigue are
found in the medical literature and are generally found true for this patient population
(Agarwal, 2009; Harwood et al. 2009).  Both findings, that patients identify their illness
by symptoms not supported with medical research and, most often, those symptoms that
are recognized by the medical community as related to kidney disease, have clinical and
research relevance.  Clinically, the findings alert health care providers to the fact that
patients develop their own mental model of their disease process which may not match
the medical model, even when they also recognize the accepted medical model.  Rather
than assuming that the patient understands or agrees with the description of kidney
disease offered by the health care community during visits and classes, it may be more
important to ask the patient to describe the symptoms they are experiencing that they
relate to their kidney disease.  Findings from this study suggest this method could help
educate the health care community of how patients identify and understand their illness.
Understanding how the patient perceives their illness may help establish a stronger
patient-provider partnership in which to discuss disease management.  The findings from
the responses on the Identity subscale are inviting to qualitatively research how and why
patients assign symptoms to their illness in order to identify their illness.  A well
designed qualitative study might strengthen the theoretical construct of the Illness
Representation and bring understanding of the origins of illness identity perceptions.
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The information gathered from the Identity subscale was valuable for descriptive
purposes, however, challenges were encountered with the number of results produced by
the subscale. The low response rate on the Identity subscale resulted in this variable
being dropped from further analysis.  On examination of the scale and individual
responses, a systematic pattern of missing values was identified.  The scale was divided
into two sections.  The items in the first section ask the participant to indicate if they had
experienced any of the symptoms that were listed since knowing that they had kidney
disease.  They were then instructed in the second section to report if they believe that this
symptom was related to their kidney disease.  Identifying the experienced symptoms as
related to their CKD was the intent of the IPQ-R Identity subscale, thus the findings from
the second section was to be used for further analysis.  The second section of the Identity
subscale had an unacceptable high level of missing values.  It appears that if the
participants answered “No” to the first part, many left the second part unanswered,
leaving items blank.  The unanswered items were treated as missing values which
decreased the number of responses for analysis.  In the future, it may be wise to redesign
the scale and instructions so that a “skipped pattern’  is planned and participants are
instructed to answer the second part of the question only if they answered “Yes” to the
first part of the question in order to eliminate missing responses.  Even in making these
changes to the subscale design, experience from this study would indicate that the sample
size would have to be increased to accommodate the variance of participant answers
among the 18 item Identity subscale.
Cause. Cause is conceptually defined as the patient’s ideas of the etiology of
their kidney disease and is operationalized with a subscale of 18 attribution items.  The
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cause items are intentionally broad in spectrum and not confined to kidney disease
etiology as defined in medicine.  The fact that every cause listed was reported as a
perceived cause of kidney disease by at least one respondent supports the theoretical
model of patient’s understanding their illness in a way that makes sense to them, not
necessarily how medical science views it.  Like the Identity subscale, participants
perceived causes of their kidney disease beyond those recognized by the medical
community, but the causes most often attributed to kidney disease were directly or
indirectly recognized by the medical community as causes of kidney disease.  Some
examples of perceived causes of kidney disease not consistent with the medical model
were negative mental attitude, personality, chance or bad luck and family problems and
worries.  The items most cited as causes of kidney disease were aging, which is supported
in the medical literature, and diet or eating habits, which is indirectly related to kidney
disease by way of contributing to DM and HTN which are the two main causes of kidney
disease (NKF, 2002; USRDS 2008b).
It is impossible to compare the specific causes attributed to early stage kidney
disease with other studies because there were no studies examining patient perceptions of
causes among stage 3 CKD patients.  Since each Cause item represents a specific causal
belief, the use of a single score for analysis would be meaningless.  As recommended by
the IPQ-R authors, Moss-Morris and colleagues (2002), a principal components analysis
was computed on the 18 causal items.  Varimax rotation produced five factors accounting
for 63% of the total variance.  The first factor was labeled Psychological causes and
accounted for 27.87 % of the total variance.  The remaining factors were labeled Lifestyle
causes, Environmental causes, Behavioral causes, and Destiny.  Psychological, Lifestyle,
138
and Environmental cause factors were entered into analyses.  Behavioral causes and
Destiny were dropped from further analysis secondary to having low internal consistency
scores and only two items each.  The Cause factors in this study are different, but similar
to other studies in the literature.  Whereas the current study produced five factors
accounting for 63% of the total variance, Moss-Morris et al. (2002) produced four factors
accounting for 57% of the total variance.  The Psychological factor in the present study
contained items similar to the Moss-Morris et al. factor labeled Psychological attributions
which accounted for 33% of the total variance.  The second factor in the Moss-Morris et
al. study, Risk Factors, contained all of the items in the Lifestyle cause factor in the
present study plus additional factors.  The Risk Factors item also loaded the items that are
in the Behavioral Cause factor in the current study.  The Environment Cause factor in the
present study was similar to the Immunity factor in the Moss-Morris et al. study.
A review of the literature revealed that some studies produced the same or similar
Cause factors to Moss-Morris et al. (2002) (Cherrington, Lawson, & Clark, 2006; Searle
et al., 2007; Vaughan, Morrison, & Miller, 2003). Rutter and Rutter, (2007) produced
two factors and labeled them Internal and External.  Some researchers using the IPQ-R
did not include the Cause subscale in their study (Covic et al., 2004; Fowler & Baas,
2006; Lau-Walker, 2004).
The similarity of the Cause subscale factors in this study to Moss-Morris et al.
(2002) and other studies may have been increased if the sample size of the current study
had been larger.  Sample size is an important consideration when assessing the suitability
of data for factor analysis, however there is little agreement on what that sample size
should be.  The proposed sample size of 100 for this study included having a minimum of
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five cases for each of the 18 causal items.  Although the actual sample size was 92
participants, only 88 subjects completed the Cause subscale in entirety, this small 4%
non-response affected the reliability of the factor structure.  Although the ratio of
respondents to items was lower than desired, the strength of the inter-correlations among
the items was tested and found suitable for factor analysis.  The coefficients were greater
than .3, the Bartlett’s test of sphericity was significant with p < .05, and Kaiser-Meyer-
Olkin index of 7.6 indicating a minimum value for a good factor analysis (Tabachnick &
Fidell, 2007).  Even so, a larger ratio of respondents to items should be proposed in future
studies to increase the reliability of the measure and the generalizability of the data.
Timeline, Control, Consequences, and Emotion. A brief review of the
construct definitions of each of the Illness Representation dimensions, Timeline, Control,
Consequences, and Emotion are provided, along with a description of the findings from
this study.
Timeline is conceptually defined as the patient’s perception of duration and
pattern of illness.  Two subscales were used to measure Timeline.  One subscale
measured Timeline as acute or chronic and the other subscale measured Timeline as
cyclical.
Regarding Timeline, the participants in this study had strong perceptions of their
kidney disease as being a chronic, long-term condition.  They also perceived a Timeline
with minimal cyclical exacerbations of their kidney disease.  These findings support the
chronic Timeline findings of research by O’Connor et al. (2008) with ESRD patients,
Searle et al. (2008) with DM patients, and Ross et al. (2004) with HTN patients.  Meyer
et al. (1985) found chronic Timeline perceptions among long term HTN patients, but a
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more acute Timeline perception among newly treated patients with HTN.  This implies
that a perception of chronicity may evolve over time as individuals live with kidney
disease, DM, and HTN.  The perception of a less cyclical nature of kidney disease in
current study was like findings with patients with HTN in the Meyer et al. study.  Patients
with HTN in the Ross et al. study, however, perceived HTN as cyclical, a condition that
comes and goes.  All studies included participants drawn from a specialty clinic setting;
however the methods used to collect the data were different.  The current study was a
mail-out design, Meyer et al. used face to face interview sessions, and Ross et al.
incorporated both face to face and mail-out methods to obtain completed questionnaires.
The difference in methods may have influenced responses.
Control or cure is conceptually defined as the patient’s perception of how well he
or she can control or cure the illness and how well a treatment can control or cure their
condition. Respondents in this study perceived having both, but more personal control
than treatment control over their kidney disease.  These findings are congruent with
findings in other studies, O’Connor et al. (2008) with ESRD participants, Searle et al.
(2008) with DM participants, and Ross et al (2004) and Meyers et al. (1985) with HTN
participants.  The finding that patients with stage 3 CKD and other chronic illness hold
beliefs of being able to personally affect the course of their disease is important to nurses
as clinicians and future interventional research.  A positive relationship between a
perception of personal and treatment control over the course of illness and/or symptoms
and self-efficacy was shown in a study of patients with coronary heart disease by Lau-
Walker, M. (2006).  Furthermore, personal and treatment control beliefs were
significantly related to and held constant with self-efficacy and they made significant
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contributions to exercise and diet over the long-term.  This would suggest that clinicians
should incorporate the patient’s perceptions of controllability in assessments and self-
management of chronic illness behavior education sessions.  Future longitudinal
interventional studies would be in order to examine Illness Representation dimensions
effects on health behaviors over time.
Consequence is conceptually defined as the effects the patient associates with the
illness and negative aspects of life such as social, family, self-image, and economical
changes. The participants in this study reported having a moderate level of negative
consequence burden as a result of having kidney disease.  This finding may be related to
being in the early stage 3 of kidney disease as exemplified in the perception of severe
consequences of later stage 5 ESRD participants in the O’Connor et al. (2008) study.
Several studies found that perceptions of lower consequence was related to higher
compliance with various health care behaviors (Barnes et al. 2004, Ross et al. 2004, and
Scollan-Kolipoulos et al. 2007), thus implying that supporting positive self-management
behaviors, such as medication adherence, and instilling the importance to maintain these
behaviors over the long run would be most effective starting in the early stages of CKD
when the consequence burden is relatively low.  Longitudinal studies examining the
perceptions of consequences of CKD throughout the stages of the illness in relation to
self-management behavior outcomes and maintenance would be beneficial for this patient
population.
Emotional representations are internal emotional responses to the mental image of
possible dangers imposed by the illness threat, such as depression, fear, anger, or anxiety.
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The participants in this study did not perceive their kidney disease to cause a great
negative emotional response.  This was consistent with Ross et al. (2004) study with
HTN patients, but in contrast to the O’Connor et al. (2008) study with ESRD patients.
Here again, the difference between early and late stage CKD might be explanatory.
Another contributing factor, in the current study, may be a gender and culture effect of
the male dominated sample of military veterans in the current study reporting minimal
emotional response to their kidney disease.  Future studies drawn from a more varied
population, might examine the relationship of gender and military culture on Emotional
Representation.  The level of emotional response to a disease threat has been found to
inhibit disease screening decisions and temporarily facilitate disease prevention behavior
(Decruyenaere, Evers-Kiebooms, Welkenhuysen, Denayer,  & Claes, 2000; Leventhal et
al. 2001), thus it is important to ask patients about their emotional perceptions of having
kidney disease to help understand how best to help them detect or manage the illness.
In summary, the current study found that patients with stage 3 CKD seen in the
VAMC renal clinic identifies their kidney disease with a wide variety of symptoms, but
most identified legs/feet swelling and fatigue as most symptomatic of their kidney
disease.  Most participants attributed the cause to aging and diet, but the Psychological
Cause factor accounted for almost 30% of the total variance.  The participants perceived
their illness to be long-term with few exacerbations.  They perceived that they had a
relatively high degree of personal control over their illness and also believed that the
treatments, including ACE-I medications, were able to control their kidney disease.  The
participants in this study reported perceptions of a moderate level of consequences and
low emotional distress caused by their kidney disease.
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The description of Illness Representations as perceived by CKD patients in this
study had both similarities and differences with other chronic illness conditions.  All
Illness Representation dimensions have been found in one or more studies to affect some
aspect of patients’ choices of coping strategies to manage the illness threat.  Therefore the
findings from this study and others are important for clinicians to consider when
assessing and partnering with patients in healthcare management of chronic illnesses.
The findings in this study also indicate a need for more research efforts to learn about
patient beliefs and perceptions about their kidney disease at initial stages, later stages and
along the continuum.
Illness Representations Prediction of Medication Adherence
In regards to the second primary purpose, the findings of correlation analysis of
illness representation dimensions and self-report medication adherence are discussed.
Patient perceptions about illness and beliefs about treatment have been shown to
be related with adherence (Haynes et al., 1996; Wetzels et al., 2006).  Unlike findings in
other studies that found significant relationships between and predictability of illness
representation and medication adherence (Horne et al., 2005; Peterson et al., 2003;
Vermeire et al., 2001), the findings in this study did not support the conceptual
framework that illness representation is related to or can predict patients’ medication
adherence behaviors.  The research question asked if illness representation could predict
the participants’ coping strategy, which in this study is medication adherence.  Multiple
regression analysis was originally intended to test the predictability of illness
representation dimensions that were significantly correlated with medication adherence.
However, the results of the Pearson’s correlation coefficients analysis revealed no
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statistically correlated illness representation dimensions with medication adherence,
therefore no variables were entered into multiple regression analysis.
Based on Tabachnick and Fidell (2007), there were some non-significant
correlations with small (r = .02) and medium (r = .15) effects.  The largest of which was
a medium effect negative correlation (r = - .16) between Emotional Representation and
self-reported medication adherence.  This indicates that participant’s who reported less
perceptions of emotional distress in relation to their kidney disease, reported higher
adherence with their ACE-I.  Several dimensions had non-significant correlations with
small effects:  Timeline acute/chronic (r = .13), Personal Control (r = - .05),
Consequence (r = - .03), and the Cause Factors (Environmental, r = .06; Psychological, r
= - .03; and Lifestyle, r = .02).  There are several reasons why the correlations may not
have maintained statistical significance.  An initial power analysis indicated that an
estimated sample size of 68 would provide 80% power to detect a medium effect size of
.15 of as many as 16 predictors on the value of ƒ to detect correlations at an alpha of .05.
There were 72 completed MARS measuring the outcome variable, self-reported
medication adherence scale.  Even though the sample size was greater than the power
analysis estimate, there was insufficient power to detect the small and medium effect
correlations.  The power may have been weakened by the violation of the normality
assumption of the outcome measure.  The skewed data of the MARS resulted in a lack of
variation in scores, reducing variability in data and thus decreasing the power to detect
corrections with small and medium effects.  When examining the skewed data of the
MARS, a high ceiling effect is noted, which makes discrimination among high score
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subjects impossible.  The bounded design of the Mars measurement instrument may have
contributed to the skewness and ceiling effect.
Another consideration to entertain is whether the Pearson’s correlation coefficient
test was the best approach for the study measurement design.  Arostegui, Nunez-Anton,
and Quintana (2010) propose that even though analyzing ranked order variables as
continuous values is accepted practice, it may affect the statistical validity of the study
findings.  Considering this, there may be more appropriate statistical methods to use for
ordinal scaled measures.  The nature of the outcome variable and the objectives of the
study should be given careful thought.  Arostegui et al. propose that a beta-binomial
regression approach may be more appropriate approach when using ordinal data than one
where it is assumed that the ranked variable represents a continuous latent variable.
The mail-out design of the study was designed to allow the optimal amount of
confidentiality and anonymity to the participants to encourage non-biased answers to the
questionnaires.  A different method of self-report questionnaire data collection or a
comparison of different methods might yield different findings in future studies.  A
qualitative designed study might yield more information about how safe patients felt to
answer medication adherence questions honestly.  There may be a distrust that the
information will be held permanently confidential which affected the way the participants
answered medication adherence questions.
Although no statistically significant relationships were found in the present study,
it is evident from the review of literature that patient perceptions and beliefs about their
chronic illness, as measured by self-report, are related to and can predict medication
adherence.  The theoretical framework of CSM is supported with studies that found
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statistical significance of the same variables that the present study found as non-
significant correlations.  A significant negative relationship between Emotional
Representation and medication adherence was found in studies by O’Connor et al. (2008)
and Ross et al. (2004).  A significant positive relationship was found between Timeline
acute/chronic and medication adherence in a study by O’Connor et al. (2008). A
significant negative relationship was found with Personal Control and medication
adherence by Scollan-Koliopoulos et al. (2007) and Ross et al. (2004).  A significant
negative relationship was found with Consequence and medication adherence by Barnes,
et al. (2004) and Scollan-Koliopoulos et al. (2007) and a significant negative relationship
was found with the Psychological Cause factor and medication adherence in a study by
Kart et al. (2007).
In summary, this study revealed small non-significant correlations, but did not
reveal statistically significant relationships with illness representation and self-reported
medications adherence.  Several possible reasons for not detecting significance in the
relationships were discussed, such as small sample size, skewed data, study design and
statistical choices.  Other studies found significant relationships with illness
representation dimensions and medications adherence.  The issues discussed should be
taken into consideration in future studies as there is sufficient evidence to support more
studies using the CSM to examine medication adherence coping strategies.
Secondary Purposes
Secondary purposes of this study included determining adherence levels of ACE-I
among patients with CKD stage 3; examining relationships between individual and
clinical characteristics with patient beliefs and medication adherence with ACE-Is; and
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examining the relationship between the Medication Adherence Report Scale (MARS) and
the Medication Possession Ratio (MPR).  The discussion of the secondary purposes will
include a section of the adherence levels of ACE-I using two measurement instruments
and the relationship between the two instruments.  Then the examination of relationships
of individual characteristics with illness representation dimensions and self-report
medication adherence will be discussed. Lastly, the examination of relationships of
clinical characteristics with illness representation dimensions and self-report medication
adherence will be discussed.
Medication Adherence Levels of ACE-I
Average medication adherence rates across chronic disease populations and
across medications are estimated to be 50% (Balkrishnan, 2005; Gossec et al., 2007).
Some studies have shown that adherence with ACE-I is even higher than average at 60 %
(Cooke & Fatodu, 2006) and 77% (Pladevall et al., 2004).  Using more than one method
for measuring adherence to medication is considered to be a more effective analysis
choice than relying on one single method.  However, there is no gold standard measure
when it comes to medication adherence and caution should be used when interpreting
results (Cook et al., 2005; Farmer, 1999; Steiner et al., 1988).  To add to the validity of
the medication adherence with ACE-I findings, medication adherence was measured by
self-report MARS and by MPR computed from pharmacy refill data.  Both methods
indicate high levels of medication adherence in this study sample.
MARS. Self-report measures have been shown to overestimate adherence (Cook
et al., 2005, R. E. Grymonpre et al., 1998).  Several precautions were taken to minimize
bias and overestimation of adherence in this study.  However, a very high level of
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medication adherence was reported by the study participants (M = 4.81 with perfect
adherence being 5).  Even though the participants were allowed to answer the survey in
the privacy of their own homes and were assured that their responses would not be shared
with their providers, they may have had reservations about trusting the system to keep
their responses confidential.  On the other hand, the high reported medication adherence
in this study may be correct and impacted by the VAMC pharmacy system, with patients
having no, or low copayments, and access to pharmacy personnel and education.
Previous studies have reported MARS scores to be skewed toward higher values and
selected to dichotomize the data with a priori cut-off points (Fialko et al., 2008; Mardby
et al., 2007).  Others chose cut-off points close to the mean value (Ediger et al., 2007).  A
level of adherence rather than a rate of adherence was desired in the current study,
therefore the data were not dichotomized and a cut-off point was not utilized.
Considering the skewed results in this study, it may be prudent to consider a
dichotomized or set cut-off point in future studies.
There was debate regarding whether to use the MARS instrument as a whole with
all 5 items as the internal consistency of the MARS was below the recommended
Chronbach’s alpha coefficient of .70 (alpha = .64).  A review of the literature indicated
the values produced in the current study are in line with other studies.  An alpha of .75
was produced during the original development of the scale (Thompson, Kulkarni, &
Sergejew, 2000), however this scale had 10 items.  Other studies using the 5 item MARS
have produced alpha values of .60 (Fialko et al., 2008) .73 (Mardby etl al., 2007) and .83
Ohm & Aaronson, (2006).  Since the MARS measurement tool has not been used with
CKD patients and since the internal consistency was less than desired, it should be
149
psychometrically tested in the future with CKD subjects to validate its usefulness with
this population.
MPR. Pharmacy refill data was used to compute the MPR as a measure of
medication adherence in this study.  The MPR has been validated using patient reports,
pill counts, and biological and chemical markers.  It is generally acknowledged that
measurement using pharmacy records are measuring refill patterns and not actual drug-
taking behaviors.  As with the self-reported medication adherence, the data indicated that
study participants’ medication adherence with 73.3% filling their ACE-I prescriptions, as
prescribed, 100% of the time.  MPR results are reported on a continuum rather than the
often used cut-off of 80% or greater equating to adherence and 20% or less equating to
non-adherence (Cramer et al., 2007; Steiner & Prochazka, 1997).
A process of automatic refills might have led to higher prescription refill rates,
however such a program is not offered at the VAMC.  Patients have to request refills.
Knowledge of medications and access to medications are predictive factors in medication
adherence (Their, et al., 2008) – both are supplied at the VAMC and may have
contributed to the high medication adherence levels found in the current study.  Another
consideration when looking at the pharmacy refill outcomes is that prescriptions
supplying medication for 90 days is very common at the VAMC.  The participant may
have filled the first prescription without having another fill date come due during the
research study period.  There was no stipulation that more than one fill date was required
to calculate the MPR.  This may have contributed to the high refill rate as some studies
have shown medication adherence persistence declines after six months (Benner et al.,
2002; Cramer et al., 2007).  On the other hand, it may not have contributed to the
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outcome, based on a study by Wannemacher et al. (2002) in which prescription refill
records of a large Veterans Affairs population revealed a  97.6% medication adherence
rate with ACE-I.  The congruence of a high level of medication adherence reported in the
self-report MARS and the pharmacy refill MPR adds to the validity of the measurement
of medication adherence in this study.  Pearson’s correlation coefficient was used to test
the relationship between the self-report MARS and pharmacy refill MPR for significance.
Relationship of MARS and MPR
A statistically significant relationship was found between the MARS and MPR (p
< .01).  This is not surprising as high scores of adherence in both instruments are evident
in all of the tests of analyses in this study.  There are many studies in the literature
comparing various methods of measuring medication adherence but no gold standard has
been developed. Pharmacy refill records have been positively related to self-reported
medication adherence (p < .001) (R. Grymonpre et al., 2006).  Results from many studies
include recommendations to use more than one method to measure medication adherence
(Cook et al., 2005; Farmer, 1999; Steiner et al., 1988).  It has been recognized that the
subjective self-report instrument can supply more qualitative information than the more
objective pharmacy refill record; therefore Steiner et al. (1988) posits that pharmacy-
based measurements of adherence should always be examined and explained taking into
account the patient’s self-reported adherence behavior.   Validity of the self-report
MARS measurement instrument is increased in this study with the finding of a positive
significant correlation between the two measurement instruments.
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Individual Characteristics Relationship with Illness Representation and MARS
In the current study, older age was significantly associated with a more acute
timeline, less consequences, and less personal control.  In general, literature findings
support that older patients perceive fewer symptoms related to their illness, less severe
consequences and emotional distress, and higher treatment control compared to younger
patients (Lawson et al., 2007; Heckler, 2008; Glasgow, 2997).  Ross et al., (2004)
examined age in relationship to both Illness Representation and medication adherence
finding older participants perceived less treatment control and reported higher medication
adherence rates that younger participants.  Unlike the current study, none of the studies
found a significant correlation between age and more acute timeline.  The current finding
that older patients perceive their kidney disease to be acute, rather than chronic is not
supported in the literature and is contrary to clinical experiences, thus is an area for
further investigation.  It may be that as patients with CKD get older, they see everything,
including life itself as being less long term, and thus view their illness in the same light.
Sacajiu et al. (2007) found this phenomenon in a study of HIV patients who perceived
their illness timeline as acute because they believed their life expectancy was short.
Other factors may be involved.  For example, Heijmans and de Ridder (1998) found that
patients with Chronic Fatigue Syndrome who had high perceptions of personal control
also perceived a more chronic timeline of their chronic illness.  In the current study, age
was correlated with a perception of less Personal Control, so therefore it may be this
perception that is associated with a more acute Timeline rather than age.  Future research
in which correlations of Illness Representation dimensions along with mediating and
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moderating effects are examined might give more insight about the direct relationships
between age and Illness Representation dimensions.
A higher education was significantly associated with the perception of a chronic
Timeline of their kidney disease.  Considering this finding, it may be that older
participants had less education and thus the relationship between age and acute Timeline,
was affected by education status.  As suggested in the previous paragraph, future research
should consider this. A higher level of education has been shown in the literature to be
significantly associated with lower symptom burden, less treatment control and higher
personal control than those with less education (Glasgow et al., 1997; Heckler et al.,
2008).  Education was not found to be associated with Illness Representation and or
medication adherence by Ross et al., (2004), Bame et al., (1993), and Curtin et al.,
(1999).
African Americans had a significantly higher sense of personal and treatment
control, and reported a lower emotional response to their kidney disease than their
Caucasians counterparts in this study.  Because of the small number of African
Americans in this study, caution should be followed when generalizing these results.
However, these findings are consistent with findings in studies by Glasgow et al. (1997)
and Kressin et al. (2007).
In the current study, participants living with partners were significantly less likely
to contribute Lifestyle causes, such as alcohol consumption and smoking, to the cause
their kidney disease, than those living with partners.  The review of the literature did not
reveal studies examining like variables.  It would be hard to offer possible explanations
for this finding without more information about individuals who have kidney disease and
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are living with partners.  Possible areas for inquiry for future research would be to ask if
the participants living with partners married, divorced, or widowed; if they are living in a
harmonious relationship; do they have children and the ages of their children?  There is
literature showing associations of lifestyle behaviors, like alcohol consumptions and
smoking, are related to home and family environments.  The answers to these questions
would serve as a guide to possibly answering why living with a partner might influence
individuals’ perceptions of Lifestyle causes of their kidney disease.
In this study financial status was not significantly related to any of the Cognitive
Illness dimensions, Emotional Representations or MARS.  Non-significant correlations
with small and medium effects were found with age, education, and financial status and
Cognitive and Emotional Representations.  Age was the only Individual characteristic
associated with self-report medication adherence with a small effect of r = - .14.  As
discussed earlier, stronger powered studies may identify significant relationships among
these variables.
This study partially supports the CSM that the patient, drawing from personal
background, knowledge, life events, experiences and familial experiences, develops a
cognitive and emotional illness representation of CKD and its treatments.  The
relationships of Individual Characteristics with Illness Representation and MARS in this
study of CKD patients indicate that age, race, and education were significantly associated
with cognitive and emotional representations.  All Individual Characteristics were non-
significantly related to at least one Illness Representation dimension and MARS.  Future
studies with more power may reveal more areas of significant relationships.
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Clinical Characteristics Relationship with Illness Representation and MARS
In the current study, a longer time span of being aware of having kidney disease
was significantly associated with a perception of their illness being more chronic and less
cyclical, and with being less adherent with medications.  Stage 3 CKD is a chronic
condition with few exacerbations at this stage.  The finding that the longer participants’
were aware of being diagnosed with CKD the closer their perceptions were in line with
medical findings is supported in the literature.  Studies have found that as patients have
lived with their chronic illness and treatments, their perceptions of their illness and
treatment evolved over time to be more in line with the medical model (Meyer et al.,
1985; Velez & Ramasco, 2006).  Horne, et al. (2010) found that participants’ perceptions
that were more congruent with the medical model of their HTN reported higher rates of
medication adherence.  These findings should encourage integrating patient perceptions
of their illness and treatments into the design of CKD patient education programs,
especially when discussing the importance of kidney protection with medication
adherence.
Participants who reported having lived with a relative diagnosed with ESRD or
being on dialysis were significantly more likely to perceive a more cyclical nature of their
kidney disease than those not having lived with relatives with ESRD or on dialysis.  The
sample size of participants reporting having lived with a relative diagnosed with ESRD or
being on dialysis was too small to allow generalization.  These results may be expected in
this study with a small sample and with a high ratio of Caucasian to African American as
African American renal patients are more likely to progress to ESRD than Caucasians
and in a shorter time period after diagnosis with CKD (USRDS, 2008).  Illness
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Representation and medication adherence have been evaluated among people living with
family members with chronic illness.  Lawson et al., (2007) found participants living with
family member with DM had a significantly higher perception of emotional stress (p <
.01) than those without family member with DM. Godoy-Izquierdo et al., (2007) found
participants with family members having high blood pressure perceived HTN to be less
chronic, more cyclical, have more personal control and with less serious consequences
than those without family members with HTN.  Considering this fact, whether or not a
participant lived with a family member with ESRD/dialysis may be an important variable
to consider in future studies.
In this study, a significantly higher perception of emotional distress was found in
participants diagnosed with DM, HTN, or CVD as opposed to those diagnosed with a
combination of two of those co-morbid conditions.  It may be that participants diagnosed
with just one of these conditions, in addition to their CKD, have lived longer without
knowing that they had other medical conditions and are having a more difficult time
adjusting.  However, there was no statistically significant difference between Emotional
Representation means between those with one co-morbid condition and those with three
co-morbid conditions.  This is an interesting finding that requires more research to arrive
at an explanation.
Number of medications was not significantly associated with any of the illness
representation dimensions or the MARS, although there were non-significant correlations
with small and medium effects. A review of the literature did not reveal studies
examining associating the number of medications with Illness Representation.  There
were many studies that investigated medication adherence with the number of prescribed
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medications; however the results were conflicting and without consensus.  Medication
adherence was not significantly associated with participants having lived with a relative
with ESRD/dialysis or co-morbidity status.
As with Individual Characteristics, the findings from the Clinical Characteristics
relationships partially supports the CSM that the patient, drawing from personal
background, knowledge, life events, experiences and familial experiences, develops a
cognitive and emotional illness representation of CKD and its treatments.  The
relationships of Clinical Characteristics with Illness Representation and MARS in this
study of CKD patients indicate that length of time since diagnosis, number of co-
morbidity conditions and whether or not a participant lived with a family member with
ESRD/dialysis were significantly associated with cognitive and emotional representations
and with self-reported medication adherence.  All Clinical Characteristics were non-
significantly related to at least one Illness Representation dimension and MARS.  Future
studies with more power may reveal more areas of significant relationships.
Limitations
Several limitations exist in the study.  First, the data for the study were obtained
from a non-random sample from one site which affects the ability to generalize findings,
especially to non-VAMC patients.  The sample characteristics, primarily White males
with 12 or more years of education and comfortable financial status infer that sample
selection bias may influence the results and should be taken into account when
interpreting the results.  Also noted, is that the patients in this study were being seen in a
military-academic healthcare setting by specialized providers making it difficult to
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generalize findings to other settings or even patients with stage 3 CKD who are not
followed by specialists in the same setting.
The sample size was relatively small (N = 92), consequently there was little
statistical power to demonstrate relationships between Illness Perceptions and medication
adherence. The small sample was complicated by a high level of missing values on some
subscales, especially the MARS with skewed data, thus decreasing the power. Future
research in this area with larger samples should consider comparing outcomes with this
study. Impetus for further research in the area of Illness Representation and medication
adherence is given considering significant relationships found in other studies.
The response rate in this study was 46%. Survey questionnaires were mailed out
and telephone calls made to eligible participants over a period of five months. Although
the response rate was higher during the first three months, a delay in follow-up phone
calls was encountered approximately midway in the study when changes in study
personnel occurred decreasing the overall response rate. There is the possibility that
those individuals who opted to participate were different in some indefinable way that
may have affected study results. The ability to recruit and retain study personnel may
help improve the response rate in future mailed surveys. An alternative method of data
collection, such as in person interviews, may help increase participation rates.
The current study had a cross-sectional design therefore no conclusions could be
drawn regarding causality of observed relationships.  It also does not allow exploration of
the full theoretical framework of the CSM.  The CSM construct proposes a dynamic state
in which illness representations influence coping mechanisms that are appraised in a
feedback loop that affects the original illness representation and coping decisions.  Future
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research should be designed using prospective longitudinal study designs to capture the
nature of this dynamic model.
The decision to use a mail out study design aided in decreasing social bias and
offered patient confidentiality benefits, however this type of design limited information
about individuals who did not respond to the invitation to participate.  No comparisons
could be made between study responders and non-responders.
Finally, although the measurement instruments used in the study have been
psychometrically tested for validity and reliability among patients with chronic illnesses,
they had not previously been applied to the stage 3 CKD patient population.  Based on
the high level of internal consistency found in the IPQ-R and moderate level found in the
MARS in this study, the instruments were considered suitable for use with CKD patients.
Revision of some of the subscales may be needed.  As discussed previously, the
directions and design of the Identity subscale may need revision to address the skipped
pattern of answering the second part of a question only if the first part was answered in
the affirmative.  Revision of the MARS scale might be in order for future studies aimed
at intentional adherence as opposed to unintentional adherence.  If the outcome is
intentional adherence, deleting the unintentional item of forgetting to take medication
may be of benefit.
Conclusion and Recommendations for Future Research
Despite its limitations, the present study revealed important information that has
helped fill the knowledge gap concerning patient perceptions and medication adherence
among patients with stage 3 CKD.  This study described the Illness Representations and
renal protective medication level of patients with stage 3 CKD.  Then the two constructs
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were examined to test the relationships of Illness Representations, as measured by the
IPQ-R on self-reported medication adherence, as measured by the MARS.  In addition,
the relationship between the two medication adherence tools, self-report as measured by
the MARS and prescription refill rate by MPR were explored. Lastly, relationships of the
individual and clinical characteristics of the study sample with the Illness Representation
dimensions and self-reported medication adherence were examined.
As there have been no studies on the Illness Representations of early stage CKD
patients or renal protective medication adherence studies, the results from this
descriptive, cross sectional research help advance the state of science by building a base
to support more robust longitudinal and interventional studies.
Recommendations for future studies include design of longitudinal studies to test
the whole CSM construct with feedback that purports that illness representations direct
the individual’s adherence behavior, the individual appraises the results of his or her
decisions and either continues the behavior, or alters the illness representations and the
loop begins again.  Other longitudinal studies of importance might be to examine the
change in illness perceptions over the years through the various stages of CKD in order to
detect differences that might be significant indicators of coping strategies that lead to
kidney preservation.  Based on understanding of patient perceptions of their kidney
disease, intervention studies to test differences between provider patient encounters
addressing Illness Representations and usual care would be valuable.  Intervention studies
to test effects of including Illness Representations in nurse led CKD patient education
clinics on patient self-management and kidney preservation outcomes would be
beneficial.
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The long term intent of this research effort is to discover ways to help patients
preserve kidney function and avoid dialysis or premature death from cardiovascular
disease. Focusing on the patient as the driving force and partnering patients with the
medical community is an important step in searching for solutions.  The findings from
this study and future studies will be beneficial in both the research and clinical arena.
Nephrology nurses and providers will be better equipped to provide care to CKD patients
by understanding patients’ Illness Representations.
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To: M. Sue McManus, PhD(c) Date:
Nephrology Nurse Practitioner
Richard L. Roudebush VAMC
1481 W. 10th Street  (111N)
Indianapolis, IN  46202
From:  Asif Sharfuddin, MD
Nephrologist
Medical Director, Renal Clinic
Richard L. Roudebush VAMC
1481 W. 10th Street  (111N)
Indianapolis, IN  46202
It is my understanding that you will be pursuing data collection for your doctoral
dissertation.  It is also my understanding that you will be screening, recruiting, and
enrolling patients seen in the renal clinic at RLR VAMC.  As a researcher who is also
part of the renal department at RLR VAMC, you are considered an Authorized Delegate
and have approval to act as a representative of the renal clinic patients’ treatment
providers to personally screen for eligibility and contact patients regarding participation
in your research.
You are already aware of the value we place on preserving kidney function in
patients being seen in the renal clinic.  This study is concordant with those values.
Sincerely,
Asif Sharfuddin, MD
Nephrologist
Medical Director, Renal Clinic
Richard L. Roudebush VAMC
Department of Richard L. Roudebush
Veterans Affairs
VA Medical Center
1481 West 10th Street
Indianapolis, IN 46202
(317) 988-4273
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Recipient address Date
Dear
We are inviting you to take part in an important research study of people with kidney
disease who are patients in the renal clinic at the Veterans Administration Medical Center
in Indianapolis, Indiana. We are interested in learning more about your thoughts and
opinions about your illness and treatment.
Enclosed is an:
1. Informed Consent form (yellow)
2. Authorization for the Release of Health Information for Research form (green)
3. Survey that includes questions about your thoughts and opinions about your
illness and treatment.
4. Self-addressed stamped envelope for returning completed survey packet
5. $2.00 as a thank you for joining the study
Please read and sign the Informed Consent (yellow) and Authorization forms (green), and
answer the questions on the survey form. A research assistant will follow the mailing
with a telephone call to answer any questions that you might have.   When completed,
place the forms in the self-addressed stamped envelope and mail.
Completing the survey is completely voluntary and your answers will remain
confidential. If you prefer not to participate, please let us know by returning the blank
questionnaire in the enclosed stamped envelope. You keep the $2.00.
This study will help doctors and nurses understand how patients with kidney disease
manage their illness and treatments.
Thank you for your time and consideration. Our research can only be successful with the
help of people like you. If you have any questions or comments about the informed
consent, authorization for release of information, or the survey please call Ms. McManus,
the nurse researcher at 317-988-4273 or toll free at 1-888-878-6889 and ask for extension
84273.
Sincerely,
Dr. Asif Sharfuddin Sue McManus, PhD candidate
Medical Director Indiana University School of
Nursing
Renal Clinic Nephrology Nurse Practitioner
Richard L. Roudebush VAMC Richard L. Roudebush VAMC
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IU and Department of Veterans Affairs Consent Form
Illness Representations Among Patients with Chronic Kidney Disease
Purpose of study and how long it will last:
You are being asked to be in this research study because you are currently receiving
treatment for chronic kidney disease in the renal clinic at the VA in Indianapolis.  The
study will last 10 months.
Description of the study including procedures to be used:
If you agree to participate, you will be one of 100 subjects who will be participating inthis research
If you agree to be in the study, you will do the following things:
1. Your first step will be to read and sign this Informed Consent form (Yellow).  By
signing the Informed Consent form, you are stating that you understand what
participating in the study means and are agreeing to participate.  Please call Sue
McManus at 317-988-4273 or toll free 888-878-6889 with any questions.
2. Next, read and sign the Authorization for the release of Health Information for
Research form (Green).  Signing this form gives us permission to obtain your
medical records for information about your illness and treatment.
3. You will receive a telephone call from a research associate to confirm that you did
receive the study packet and to answer any questions you might have about the
study.
4. Then, you will be asked to complete the survey questions (White) asking about
your thoughts and opinions about your kidney disease and treatment. This form is
numbered and does not have your name on it.  Please do NOT sign it.
5. When you have read and signed the forms and completed the survey questions,
place the signed forms and the completed survey questions in the self-addressed,
stamped envelope provided, and mail to the nurse researcher.  We would like for
you to complete and mail them back within two weeks of receiving them.
Risks:
There are no physical risks to being in the study.  One risk of taking part in a study
involves a possible loss of confidentiality since members of our research team will know
who you are and the information that you will share with us in answering the questions
about your illness and treatment.  Your information will be kept confidential and only the
nurse researcher and research assistant will know your identity.  Unless we are required
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by law, we will not share the information with anyone.  Your identifying information
(name and address) will be kept in a locked file cabinet in the nurse researcher’s private
office.  Any information you share with us will be confidential and kept in a secure
database.  The database will be password protected so that only members of the research
team will have access to the information.  Your name and other identifying information
will NOT be included on the survey questions.
Answering questions about kidney disease and treatment may make some people feel
uncomfortable.  You can refuse to answer any questions that make you uncomfortable.  If
you feel uncomfortable, we encourage you to talk about these feelings with the nurse
researcher.  You may call Sue McManus, nurse researcher, at 317-988-4273 or toll free
888-878-6889, ext 4273.
Not all of these things may happen.  None of them may happen.
Benefits:
Sometimes good things happen to people who are in research studies.  These good things
are called “benefits.”  We don’t know for sure if you will have any benefits.  Some
people benefit by knowing that their participation in this study may help others in the
future.  By joining this study, you may help improve the care for patients with kidney
disease.
Alternate Courses of Action or treatment:
Taking part in this study is voluntary. You may choose to complete part or none of the
survey questions.  If you do not wish to participate you may mail the blank survey to the
nurse researcher in the stamped self-addressed envelope.   Choosing not to take part in
the study will not affect the care you receive from your doctor or the VA in any way.
Statement of Use of Research Results:
The results of this study may be published, but your records or identity will not be
revealed unless required by law.
Confidentiality:Efforts will be made to keep your personal information confidential.  We cannotguarantee absolute confidentiality.  Your personal information may be disclosed ifrequired by law.  Your identity will be held in confidence in reports in which the studymay be published.
Organizations that may inspect and/or copy your research records for quality assuranceand data analysis include groups such as the investigator and his/her research associates,the IUPUI/Clarian Institutional Review Board or its designees and the VA Research andDevelopment Committee’s designees.
Research Subject Costs:
1. There will be no cost(s) to you for any of the treatment or testing done as part of
this research study.  Eligibility for medical care at a VA Medical Center is based
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upon the usual VA eligibility policy and is not guaranteed by participation in a
research study.
2. You will not be required to pay for medical care or services received as a
participant in a VA research project except as follows:
a. Some veterans are required to pay co-payments for medical care and
services provided by the VA.  These co-payment requirements will
continue to apply to medical care and services provided by VA that are
not part of this study.
Compensation:
1. You will receive $2.00 as a thank you for completing and returning thesurvey in the mail.
2. The VA Medical facilities shall provide necessary medical treatment to a
research subject injured as a result of participation in a research project
approved by a VA Research and Development Committee and conducted
under the supervision of one or more VA employees.  This does not apply to:
(1) treatment for injuries due to noncompliance by a subject with study
procedures; or (2) research conducted for VA under a contract with an
individual or a non-VA institution.
3. Financial compensation for research-related injuries is not available.
However, by signing this form, you do not give up your legal rights to seek
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RESEARCH SUBJECT’S RIGHTS:
Participation in this study is entirely voluntary.  You may refuse to participate.  Refusal to
participate will involve no penalty or loss of rights to which individuals are entitled.  You
may withdraw from this study at any time without penalty or loss of VA or other benefits.
You will receive a copy of this signed consent form.
In case there are questions, Ms. McManus, research investigator can be contacted at
(317) 988-4273 or toll free 888-878-6889 Monday through Friday between 7:00 am and 4:00
pm.  Her research office does not have a 24-hour emergency number.  If any medical
problems occur in connection with this study, the VA will provide emergency care.
Please direct questions about the consent process and the rights of research subjects to the VA
Customer Service Office at (317) 988-2602.  For questions about your rights as a research
participant or complaints about a research study, contact the IUPUI/Clarian Research
Compliance Administration office at 317/278-3458 or 800/696-2949.  If you have any
questions about the research study or want to check the validity, discuss problems, concerns
or obtain information or offer input, please call the Research Office at 317-988-3032.
I understand what participating in this study means and agree to participate.  The risks or
discomforts and possible benefits of the study have been described.
__________________________________ _________________________   ____________
Subject’s  Signature Printed Name of Subject                 Date
__________________________________ _________________________ ____________
Signature of Witness to above signature (may be
any adult who witnessed you signing this form)
If there is no one to witness your signature,
please call VA research office at 317-988-3032
Printed Name of Witness Date
__________________________________ __________________________________   ______
Signature of Person Obtaining Consent Printed Name of Person Obtaining Consent    Date
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Recipient address Date:
Dear
A survey asking for your thoughts and opinions about kidney disease and treatments was
mailed to you recently.
If you have already completed and returned the survey to us, please accept our sincere
thanks.  If not, please do so today.  We appreciate your help with this important topic.
If you did not receive a survey packet, or if it was misplaced, please call 317-988-4273 or
toll free at 1-888-878-6889 and ask for extension 84273, and we will get another one in
the mail to you.
Sincerely,
M. Sue McManus
Nurse Researcher, IUPUI School of Nursing
RLR VAMC Research Office
Indianapolis, IN 46202
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Kidney Patient Perception Questionnaire
Your views of
Kidney disease and treatments
We are interested in your personal views about kidney
disease and treatments.
Thank you for sharing your views about kidney
disease and treatments
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SYMPTOMS AND KIDNEY DISEASE
Listed below are a number of symptoms that you may or may not have had since having
kidney disease.  Please circle “Yes” or  “No” , whether you have had any of these
symptoms since you were told that you have kidney disease.  Then, please say if you
believe that these symptoms are related to your kidney disease.
Symptom
I have had this symptom
since knowing that I had
kidney disease 
This symptom is related to
my kidney disease
▼ ▼ ▼
1a Pain Yes No → Yes No 1b
2a Sore Throat Yes No → Yes No 2b
3a Nausea Yes No → Yes No 3b
4a Short of breath Yes No → Yes No 4b
5a Weight Loss Yes No → Yes No 5b
6a Fatigue Yes No → Yes No 6b
7a Stiff Joints Yes No → Yes No 7b
8a Sore Eyes Yes No → Yes No 8b
9a Wheezing Yes No → Yes No 9b
10a Headaches Yes No → Yes No 10b
11a Upset Stomach Yes No → Yes No 11b
12a
Problems sleeping Yes No → Yes No
12b
13a Dizzy Yes No → Yes No 13b
14a
Loss of Strength Yes No → Yes No
14b
15a Bad taste in mouth Yes No → Yes No 15b
16a Legs/feet swelling Yes No → Yes No 16b
17a Puffy eyes Yes No → Yes No 17b
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 We are interested in your personal views about your kidney disease
 Please show how much you agree or disagree with each of the following
statements about your kidney disease by checking one of the boxes.  There
are no right or wrong answers.
I believe that Strongly
Disagree Disagree
Neither
Agree
Nor
Disagree
Agree
Strong
ly
Agree
#
My kidney disease will last a
short time 18
My kidney disease is likely to
be permanent rather than
temporary
19
My kidney disease will last for
a long time 20
My kidney disease will pass
quickly 21
I expect to have kidney
disease for the rest of my life 22
My kidney disease is a
serious condition 23
My kidney disease has major
consequences on my life 24
My kidney disease does not
have much effect on my life 25
My kidney disease strongly
affects the way others see me 26
My kidney disease has
serious financial
consequences
27
My kidney disease causes
difficulties for those who are
close to me
28
There is a lot which I can do
to control my kidney disease
symptoms
29
YOUR PERSONAL VIEWS ABOUT YOUR
KIDNEY DISEASE
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What I do can determine
whether my kidney disease
gets better or worse
30
The course of my kidney
disease depends on me 31
Nothing I do will affect my
kidney disease 32
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I believe that Strongly
Disagree Disagree
Neither
Agree
Nor
Disagree
Agree
Strongly
Agree
#
My kidney disease will last a
short time 18
My kidney disease is likely to
be permanent rather than
temporary
19
My kidney disease will last for
a long time 20
My kidney disease will pass
quickly 21
I expect to have kidney
disease for the rest of my life 22
My kidney disease is a
serious condition 23
My kidney disease has major
consequences on my life 24
My kidney disease does not
have much effect on my life 25
My kidney disease strongly
affects the way others see me 26
My kidney disease has
serious financial
consequences
27
My kidney disease causes
difficulties for those who are
close to me
28
There is a lot which I can do
to control my kidney disease
symptoms
29
What I do can determine
whether my kidney disease
gets better or worse
30
The course of my kidney
disease depends on me 31
Nothing I do will affect my
kidney disease 32
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I believe that Strongly
Disagree Disagree
Neither
Agree
Nor
Disagree
Agree
Strongly
Agree
#
I have the power to influence
my kidney disease 33
My actions will have no affect
on the outcome of my kidney
disease
34
My kidney disease will
improve in time 35
There is very little that can be
done to improve my kidney
disease
36
The treatments that my doctor
orders for my kidney disease
will be effective in curing it
37
The negative effects of my
kidney disease can be
prevented (avoided) by my
medications
38
My medications can control
my kidney disease 39
There is no treatment which
can help my kidney disease 40
The Symptoms of my kidney
disease are puzzling to me 41
My kidney disease is a
mystery to me 42
I don’t understand my kidney
disease 43
My kidney disease doesn’t
make any sense to me 44
I have a clear picture or
understanding of my kidney
disease
45
The symptoms of my kidney
disease change a great deal
from day to day
46
My kidney disease symptoms
come and go in cycles 47
My kidney disease is very
unpredictable 48
I go through cycles in which 49
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my kidney disease gets better
and worse
I get depressed when I think
about my kidney disease 50
I believe that
Strongly
Disagree Disagree
Neither
Agree
Nor
Disagree
Agree
Strongly
Agree
#
When I think about my kidney
disease I get upset 51
My kidney disease makes me
feel angry 52
My kidney disease does not
worry me 53
Having kidney disease makes
me feel anxious 54
My kidney disease makes me
feel afraid 55
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CAUSES OF YOUR KIDNEY DISEASE
People are very different.  They report different causes of their kidney disease.  We are
most interested in your own views about the causes of your kidney disease.  Please say
what you believe, rather than what others, including doctors or family/friends have said
to you.
Below is a list of possible causes for your kidney disease.  Please show how strongly
you agree or disagree that they are causes of your kidney disease and check one of the
boxes on each line.  There are no right or wrong answers.
POSSIBLE CAUSES Strongly
Disagree Disagree
Neither
Agree Nor
Disagree Agree
Strongly
Agree
#
Stress or worry 56
Hereditary – it runs in my
family 57
A Germ or virus 58
Diet or eating habits 59
Chance or bad luck 60
Poor medical care in my
past 61
Pollution in the
environment 62
My own behavior 63
My mental attitude like
thinking about life
negatively
64
Family problems or worries 65
Over work 66
My emotional state e.g.
feeling down, lonely,
anxious, empty
67
Aging 68
Alcohol 69
Smoking 70
Accident or injury 71
My personality 72
Altered immune system 73
Please list the three most important causes that you believe caused your kidney
disease.  You may use any of the items from the box above, or add other causes that
were not listed above.  There are no right or wrong answers
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74 Most important cause ________________________________
75 Second most important cause    ________________________________
76 Third most important cause ________________________________
Medication Experience
We are interested in how you take certain medications.  Many people have
reasons for taking their medications in ways that are different from the instructions on
the label or different from the way they were instructed by their provider.  Below are
some ways in which others have said they use their medications.  For each statement,
please check the box that best applies to how you take your LISINOPRIL.
Your answers about how you actually take your medications will be confidential,
and will not be shared with your provider.  The results of this questionnaire will add to
the understanding of how medications are actually being used by individuals with chronic
kidney disease.
Adapted from Medication Adherence Report Scale with permission from the journal article publisher
(Appendix H). See reference: Horne and Weinman (2002)
How I take my:
LISINOPRIL
Very
Often Often Sometimes Rarely Never #
I forget to take it 77
I change the dose 78
I take less than
instructed 79
I stop taking it for a while 80
I decide to miss a dose 81
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Just a few more questions about you:
82. What is your sex?
Male ………………………….1                 (Circle one number)
Female ………………………2
83. Are you of Spanish or Hispanic origin, such as Mexican American,
Chicano, Puerto Rican, or
Cuban?
Yes …………………………..1
No…………………………….2 (Circle one number)
Don’t know/Refused ……….3
84. What is your race?
African American or Black .....................1
Native American or Alaska Native……...2 (Circle one number)
Caucasian or White…………………...….3
Other Race (Specify ____________) ….4
85.  What is the highest grade or year of school you have finished?
Circle year:
1 2 3 4 5 6 7 8 9 10 11 12
Technical/secretarial/business ………………………………………………….13
1 year of college …………………………………………………………………..14
2 years of college………………………………………………………………….15
3 years of college………………………………………………………………….16
Graduated from college………………………………………………………….. 17
At least some graduate school…………………………………………………...18
Completed graduate degree……………………………………………………...19
86.   Which of the following best describes your family income? (Circle one
number)
Family income is not enough to make ends meet ………………………1
Family income is just enough to make ends meet……………………….2
Family income is at a comfortable level…………………………………..3
87.   Do you live with a partner? (Circle one number)
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Yes …………………………………………………………………………….1
No……………………………………………………………………………...2
88. Have you lived in the same household for one year or longer with a relative
who was
diagnosed with ESRD or received dialysis treatments? (Circle one number)
Yes …………………………………………………………………………….1
No………………………………………………………………………………2
89.   Approximately how many months and/or years since you were told that you
had kidney disease?
_____________Years               ____________Months
90.   Approximately how long did it take you to complete this survey?
____________Minutes
91.  Please indicate how difficult it was for you to answer these survey questions.
Not at all difficult …………………….1
A little difficult ………………………..2
Moderately difficult…………………..3
Quite difficult…………………………4
Extremely difficult……………………5
This is the end of the survey.  Thank you for taking the time to
complete it.
Please place the:
1) completed survey,
2) the signed consent form (yellow) and
3) the signed authorization for release of information form
(green)
in the stamped return envelope and place it in the mail.
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If you have any questions before returning the packet by mail,
please feel free to call Ms McManus, nurse researcher, at 317-
988-4273.
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Dear Expert Reviewer,
Thank you for agreeing to review the Illness Perception Questionnaire – Revised
(IPQ-R) Identity subscale.  Your professional expertise as a nurse researcher with clinical
experience working with nephrology patients is of great value in determining content
validity of this instrument subscale for chronic kidney disease patients.
Chronic kidney disease (CKD) is estimated to affect 16 percent of the American
population, an estimated 31 million U.S. citizens (USRDS 2008).  Unless measures are
taken to delay progression, CKD leads to kidney failure requiring life sustaining
treatments.  Both treatment options, dialysis and transplantation, carry a high burden for
the patient, families, communities and society as a whole (Centers for Disease Control
and Prevention, 2007b; Coresh et al., 2007).
There are kidney protective medications such as Angiotensin Converting Enzyme
Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARBs).  These renoprotective
medications are proven to reduce the risk of renal disease progression, yet the overall
estimated prevalence rate of CKD is still increasing at an alarming rate.  Examination of
CKD patient’s medication adherence behaviors may reveal if patients are adherent with
renoprotective medications and reasons related to adherence or non-adherence (de Zeeuw
et al., 2006; Kopyt, 2005).
The theory of self-regulation provides a sound basis for the study of health
behaviors of CKD patients. According to Leventhal’s theory of self-regulation’s common
sense model (CSM), when individuals are faced with threats to their health, they build a
cognitive and emotional representation (mental model) and this representation determines
how they will respond to the threat (H. Leventhal et al., 1997; H. Leventhal, Brissette, &
Leventhal, 2003).  These representations of illness, unique to the individual, are based on
the individual’s sociocultural demographics, knowledge and personal and familial
experiences (Petrie & Weinman, 2006).  The illness representation leads the patient to
reduce the threat of illness or symptoms by guiding their choices of coping strategies
(e.g., to stop smoking, take medication, lose weight) directed at reducing the threat.  The
patient then analyzes the outcomes of his coping actions.  If the patient deems them
satisfactory, he will continue the action, if less than satisfactory a feedback loop is
redirected back to revisit representations and coping strategies (Leventhal et al., 2003).
The measurement instrument subscale being reviewed focuses on the CKD patient’s
perceptions and labeling of symptoms to their chronic kidney disease.
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Figure 1
Conceptual Definitions
Illness Representation:  The cognitive and emotional mental model individuals
make of their illness (Leventhal et al., 2003; Petrie & Weinman, 2006).  A parallel
cognitive and emotional representation is developed by a person to adapt to and manage
their illness (Howard Leventhal, Leventhal, & Cameron, 2001; H. Leventhal & Mora,
2005). Identity is one of the six components of the cognitive representation of the health
threat included in the model and is conceptually defined as: the patient assigned label to
the illness, associated with symptoms they perceive to be related to their illness.  It may
not be concurrent with the medical model of illness labels or symptoms.
Operational Definitions
 Illness Representation: cognitive and emotional representations
Revised Illness Perception Questionnaire (IPQ-R): The IPQ-R is a quantitative
measure of the five components of illness representation in Leventhal’s Common
Sense Model, developed by Moss-Morris et al. (2002).  The tool is composed of 19
yes/no questions and 56 Likert style items rated on a five point response scale. There
are nine subscales, one of which can be modified to reflect symptoms associated with
individuals living with CKD.  The subscales represent the dimensions of cognitive
Illness Representation
Cognitive Emotional
Identity Depression
Cause Fear
Timeline                    Anger
Control Anxiety
Consequences
Cohesiveness
Coping
Strategies chosen
to reduce illness
threats
Analysis
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and emotional illness representations theorized by Leventhal et al. (2001, 2003).  The
higher the score, the stronger is the belief (Llewellyn, McGurk, & Weinman, 2007).
For the purposes of the proposed study, the IPQ-R has been adapted to reflect items
specific to chronic kidney disease patients.  The word “illness” was changed to either
chronic kidney disease or kidney disease throughout the instrument.  Items were
added to the Identity subscale to reflect symptoms perceived by chronic kidney
disease patients to be associated with their kidney disease.
Aim
The aim is to elicit expert input in order to validate the content of the Identity
subscale, adapted from the IPQ-R. The CKD adapted IPQ-R instrument can then be used
to describe the Illness Representation of CKD patients and examine the relationship
between the CSM domains and the medication adherence coping strategies chosen by the
patient.
The following pages include all items related to Identity subscale with the conceptual
definition.  Please read the instructions and definition and rate each item.
Identity Scale
Instructions: Below are items designed to represent the concept of Identity.  These
items will be rated, by the participant, on a dichotomous scale as 0 = No or 1 = Yes as
symptom experienced and then as 0 = No or 1 = Yes as belief that the symptom is
associated with chronic kidney disease.
Please read the conceptual definition below, then rate each of the items for the degree of
relevance to the conceptual definition, using the response scale below.
In the comments box, please add any comments or edits that might improve the item.
In the empty rows below, please add additional items or areas of the conceptual definition
that are not represented by the items.
Conceptual definition of Identity: the patient assigned label to the illness, associated
with symptoms they perceive to be related to their illness
1=  NR = Not Relevant
2 = SR = Slightly Relevant
3 = MR = Moderately Relevant
4 = VR = Very Relevant and succinct
Item NR SR MR VR Comments
Pain 1 2 3 4
Sore Throat 1 2 3 4
Nausea 1 2 3 4
Breathlessness 1 2 3 4
Weight Loss 1 2 3 4
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Fatigue 1 2 3 4
Stiff Joints 1 2 3 4
Sore Eyes 1 2 3 4
Wheeziness 1 2 3 4
Headaches 1 2 3 4
Upset Stomach 1 2 3 4
Sleep Difficulties 1 2 3 4
Dizziness 1 2 3 4
Loss of Strength 1 2 3 4
Itching 1 2 3 4
Back pain 1 2 3 4
Problems urinating 1 2 3 4
Not hungry 1 2 3 4
Bad Breath 1 2 3 4
Bad taste in mouth 1 2 3 4
Legs/feet swelling 1 2 3 4
Puffy eyes 1 2 3 4
Additional Identity areas or
items not represented
1 2 3 4
1 2 3 4
1 2 3 4
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Content Validity Index Scoring Sheet
Identity Scale
Expert Reviewer Ratings
Item scoring:  proportion of experts who rated item as 3 or 4 divided by the number of experts (5)
Total subscale scoring:  proportion of the total number of items considered content valid (> .83
CVI item score) divided by the number of items (22):
Item ER 1 ER 2 ER 3 ER 4 ER 5 Item
proportion
CVI
item
Score
Pain /5
Sore Throat /5
Nausea /5
Breathlessness /5
Weight Loss /5
Fatigue /5
Stiff Joints /5
Sore Eyes /5
Wheeziness /5
Headaches /5
Upset Stomach /5
Sleep Difficulties /5
Dizziness /5
Loss of Strength /5
Itching /5
Back pain /5
Problems urinating /5
Not hungry /5
Bad Breath /5
Bad taste in mouth /5
Legs/feet swelling /5
Puffy eyes /5
Total:          Items 22
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Corp - ECC-SNF-ID Unit
Eunice, LA
Our Lady of Lourdes Regional Staff RN June 1996 to October 1996
Medical Center Full time
Lafayette, LA
PROFESSIONAL SOCIETIES:
National Kidney Foundation 2009 - present
Veterans Administration Advance Practice Nurse Group 2007 - present
Midwest Nursing Research Society 2007 - present
American Nurses’ Association 2004 - 2006
Louisiana State Nurses’ Association 2004 - 2006
Louisiana Association of Nurse Practitioners 2000 - 2007
Sigma Theta Tau International Honor Society of Nursing 2000 - present
American Nephrology Nurses’ Association 1998 - present
Louisiana Organization of Associate Degree Nursing (L-OADN) 1994 – 1996
HONORS:
Student Awards and Honors
Janel Parker Career Mobility Scholarship 2010
Alcavis International Career Mobility Scholarship 2009
Florence Nightingale Scholarship 2008
Watson Pharma Career Mobility Scholarship 2008
University of Louisiana Graduate Nursing Fellowship 2003
Featured in Louisiana Public Facilities Authority and
Entergy Louisiana Outstanding Graduates publication 2003
L-OADN Outstanding Associate Degree Alumnus 2003
Lettie Pate Whitehead Nursing Scholarship 1997
Louisiana State University at Eunice
Chancellor’s List of Academic Achievers 1994 – 1996
Outstanding LSUE Sophomore 1995
Outstanding LSUE Unclassified Student 1996
Outstanding LSUE Nursing Graduate 1996
Professional Honors
Profile Feature American Journal of Nursing November 2006 Issue
American Nephrology Nurses’ Association
Board of Directors Award 2006
TEACHING ASSIGNMENTS:
Clinical Nursing Instructor Term
Louisiana State University at Eunice
School of Nursing
General Medicine Floor Fall 2005
Spring 2006
Fall 2006
COMMUNITY SERVICE:
United Way Community Health Clinic
provided health services at free health clinic 2006
Volunteered for public health screening programs 2000 – 2006
Volunteered as counselor for National Kidney Foundation
Kidney Early Evaluation Program (KEEP) 2003 – 2005
Local Emergency Disaster volunteer for kidney patients
after Hurricanes Katrina and Rita 2005
PROFESSIONAL ACTIVITIES:
Committee Service
RLR VAMC – Dialysis Project Committee
Evaluate feasibility of fee base dialysis versus in-center dialysis 2010 - present
RLR VAMC -Diabetes Mellitus Performance
Improvement Work Group – Rapid Cycle Coach 2008 - present
Louisiana Association of Nurse Practitioners
Public Policy Committee – Political Action
Committee Chair 2002
American Nephrology Nurses’ Association – Regional
Officer - State Officer - Committee and task force work 2000 - present
LSUE Student Nurse Association
Chaired Incoming Student Committee 1996
LSUE Nursing Dept. Curriculum and By-Laws Committee 1995
Presentations/Posters:
McManus, M.S. and Sandine, J., VA APN Group Continuing
Education Presentation, Kidney Disease:  Stop the Trend on the
Front End 2010
Russ AL, Saleem JJ,McManus MS, Zillich AJ. “Medication
Order Checks: Design Implications for Prescriber Workflow.”
Poster to be presented at the Veterans Affairs HSRD/VERC
National Field-based Conference, Indianapolis, IN,
July 14, 2010 2010
Russ AL, Saleem JJ,McManus MS, Zillich AJ. “Medication
Order Checks: Design Implications for Prescriber Workflow.”
Poster presented at the Veterans Affairs Pharmacy Benefits
Management (VA PBM) Pharmacy Medication Reconciliation
Initiative and Workgroup, Salt Lake City, UT, May 18-20, 2010
McManus, M.S.,Welch, J.L., Rawl, S.M., Sloan, R.S.,
Halstead, J., Weaver, M.T. (2010). Illness Representations
and Medication Adherence Among Patients with Chronic
Kidney Disease.  Presented at 2010 Midwest Nursing Research
Society Conference, Nursing Research:  Bench to Bedside,
Kansas City, MO, April 2010 2010
Welch, J.L., Connelly, K., Siek, K.A., Jones, J., Perkins,
S.M., Chaudry, B., Kain, J., Scott, L., Astroth, K., Heo, S.,
McManus, S., Mooney, J. T., & Johnson, C. (2009). Merging
literacy with computer technology for self-managing diet and
fluid intake. Presented at Sigma Theta Tau International 20th
International Nursing Research Congress Focusing on Evidence-
Based Practice, July 2009, Vancouver, Canada. 2009
McManus, M. S., American Nephrology Nurses’ Association
expert panel continuing education program presenter on New
Science and Evidence for the Utilization of Vitamin D for today’s
Kidney Patients. 2009 – 2010
McManus, M.S. guest lecturer Indiana University School of
Nursing: Chronic Kidney Disease: Why is it important? 2009
McManus, M.S. and Porter, B. to V.A. APN Clinical Lunch
Conference Diabetes and Kidney Disease:
What is the Question? 2008
McManus, M. S. presented to V.A. APN Journal Club:
CKD guideline use by Primary Care 2008
McManus, M.S. to United Way Community
Diabetes Education Class, Preventing Kidney Disease
Progression Through Self-management 2006
McManus, M.S. to AD nursing renal system guest lecturer,
Hemodialysis and Peritoneal Dialysis – What’s It All About? 2005
McManus, M.S. to American Nephrology Nurses’ Association
Fleur de Lis Chapter Annual Conference, Understanding
New Hypertension Guidelines 2004
McManus, M.S., to Medical Center Southwest Louisiana
CEU presentation, Pathophysiology of Acute Kidney
Failure 2002
McManus, M.S., to Medical Center Southwest Louisiana
CEU presentation, Chronic Kidney Failure Patients in the
Acute Care setting, 2001
McManus, M.S.to AD and BSN senior nursing clinical
groups, Caring for End Stage Renal Disease Patients in
Non-Dialysis settings 2000, 2001, 2003
McManus, M.S., in-service presentations to Eunice Community
Nursing Home staff, Providing Care to End Stage Renal
Disease and Hemodialysis Residents in the Long Term
Care Setting. 1998, 2000
Reviewer
Registered Nurses’ Association of Ontario. (2010)
Strategies to Support Self-Management in Chronic Conditions:
Collaboration with Clients. Toronto, Canada.  Registered Nurses
Association of Ontario 2010
McMaster Online Rating of Evidence (MORE) for nurses 2008 - present
Chapter reviewer Core Curriculum for Nephrology
Nursing(2008).  5th Ed. C.S. Counts Ed. 2007
PUBLICATION:
Russ AL, Saleem JJ,McManus MS, Frankel, RM, Zillich AJ.
"The Workflow of Computerized Medication Ordering in Primary
Care is Not Prescriptive",  Proceedings of the Human Factors
and Ergonomics Society, 54th Annual Meeting, San Francisco,
CA, (In Press) 2010
Zillich AJ, Saleem JJ, McManus MS, Russ AL. A Qualitative
Study of Medication Alerts and Computerized Prescriber Order
Entry (CPOE):  Opportunities for Pharmacist Consultation at the
Point of Prescribing.(Abstract). Journal of the American
Pharmacists Association 2010;50(2):284-285. 2010
Welch, J.L., Siek, K.A., Connelly, K. H., Astroth, K.S., McManus,
M. S., Scott, L., Heo, S., & Kraus, M.A. (2010),  Merging health
literacy with computer technology: Self-managing diet and fluid
intake among adult hemodialysis patients.
Patient Education and Counseling (79), pp192-198 2010
Russ, A. L., Saleem, J. J.,McManus, M.S., Zillich, A.J.,
and Doebbeling, B. N. Computerized Medication Alerts
and Mental Models: Observing Routine Patient Care,
In Proceedings of the Human Factors and Ergonomics Society
53rd Annual Meeting. 2009
Russ AL, Zillich AJ,McManus MS, Doebbeling BN, Saleem JJ.
“A Human Factors Investigation of Medication Alerts: Barriers to
Prescriber Decision-Making and Clinical Workflow.” In Proceedings
of the American Medical Informatics Association (AMIA)
Symposium, 2009, AMIA Annu Symp Proc. 2009: 548–552.
Published online 2009 November 14. 2009
Welch, J. L., Burrows-Hudson, S., Hull, M. A., Kurt, M. J.,
Mapes, D., Mathers, T. R.,McManus, M. S., and
Thomas-Hawkins, C.. (2008).  Evidence-Based Practice.
In C. S. Counts (Ed.), Core Curriculum for Nephrology
Nursing (Fifth ed., pp. 461-498). Pitman, New Jersey:
American Nephrology Nurses' Association. 2008
RESEARCH RELATED ACTIVITIES
McManus, M.S. Immunization:  Primary Prevention
Efforts to Strengthen the End Stage Renal Disease Patient’s
Flexible Line of Defense. University of Louisiana at Lafayette, 2003
Grant Funded Projects:
Granting Agency Project Title Amount Dates
Indiana University Illness Representation of $3000 2009-2010
School of Nursing Patients with Chronic Kidney
Graduate Nursing Disease and Medication
Research Funding Adherence with Renal Protective
Medications
PI:  Janet L. Welch
Co-Investigator: M. Sue McManus
VA HSR&D Pilot Redesigning Medication $100,000 2010 - 2011
Alerts to Support Prescriber
Workflow
PI: Alissa L. Russ
Co-Investigators:  Jason Saleem,
Jeffrey R. Spina, Alan J. Zillich,
M. Sue McManus, David Haggstrom,
and Brad Doebbeling
National Institute of Self Monitoring of Dietary and $416,625 2006-2009
Biomedical Imaging Fluid Intake Using a PDA
and Bioengineering PI:  Janet L. Welch
Co-Investigators:  Josette Jones
Kay Connelly, Susan Perkins,
Laurie Trevino.
Collaborator:  M. Sue McManus
Co-Investigator through employment with Northwest
Louisiana Nephrology,   Shreveport, LA 2003 – 2004:
 A Randomized, Open Label, Parallel Design Study of Renagel Phosphate Binder Versus
Calcium-Based Phosphate Binders in Hemodialysis; Protocol GTC-68-401; GelTex
Pharmaceuticals, Inc; 3 Year Study
 Correction of Hemoglobin and Outcomes in Renal Insufficiency “CHOIR”; Protocol PR00-
06-014; Ortho Biotech Products, L.P.; 3 Year Study
 A Randomized, Controlled, Open Label Study of the Safety and Efficacy of Ferrlecit vs. Oral
Iron in Iron Deficient Patients with Chronic Kidney Disease Being Treated with
Erythropoietic Therapy; Protocol FER0201; Watson Laboratories, Inc.; 10 Week Study
 A Randomized, Controlled, Open Label Study of the Safety and Efficacy of Ferrlecit vs. Oral
Iron in Iron Deficient Patients with Chronic Kidney Disease; Protocol FER0202; Watson
Laboratories, Inc.; 10 Week Study
 A Prospective, Randomized, Double-Blind, Double-Dummy, Forced-titration, Multicenter,
Parallel Group, One Year Treatment Trial to Compare MICARDIS (telmisartan) 80 mg vs.
COZAAR (losartin) 100mg in Hypertensive Type 2 Diabetic Patients with Overt
Nephropathy (AMADEO Study); Protocol 502.397; Boehringer Ingelheim; 58 Week Study
